<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="b">
		<monograph id="1" status="active">
			<mono_name>bacitracin topical</mono_name>
			<section type="none" id="sidelem4x19">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>baclofen (Rx)</mono_name>
			<info>
				<pronunciation>(bak′loe-fen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x281">Gablofen</tradename>
					<tradename id="tnidelem4x280">Lioresal Intrathecal</tradename>
				</tradenames>
				<class type="func"> Skeletal muscle relaxant, central acting</class>
				<class type="chem"> GABA chlorophenyl derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x38">
				<para>
					<confusion>
						<tradename id="tnidelem4x380">Lioresal</tradename>
						<drug type="generic" refid="idelem4x380">Lotensin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x45">
				<sec_title>Action:</sec_title>
				<para>Inhibits synaptic responses in CNS by stimulating GABAb receptor subtype, which decreases neurotransmitter function; decreases frequency, severity of muscle spasms</para>
			</section>
			<section type="uses" id="sidelem4x50">
				<sec_title>Uses:</sec_title>
				<para>Spasticity with spinal cord injury, multiple sclerosis</para>
				<section type="none" id="sidelem4x55">
					<section type="none" id="sidelem4x56">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Neuropathic pain, hiccups, trigeminal neuralgia/nystagmus, recurrent priapism</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x61">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x66">
					<section type="none" id="sidelem4x67">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, peptic ulcer disease, renal/hepatic disease, stroke, seizure disorder, diabetes mellitus, psychosis</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x82">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x90">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x90">
							<item>
								<label>•</label>
								<para> 5 mg tid × 3 days, then 10 mg tid × 3 days, then 15 mg tid × 3 days, then 20 mg tid × 3 days, then titrated to response, max 80 mg/day;  use implantable intrathecal infusion pump, use screening trial of 3 separate bol doses if needed 24 hr apart (50 mcg, 75 mcg, 100 mcg); patients who do not respond to 100 mcg should not be considered for chronic IT therapy; maintenance: spinal origin spasticity 12-2003 mcg/day, cerebral origin spasticity 22-1400 mcg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x100">
					<label>•</label>
					<sec_title>Child &gt;2-7 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x100">
							<item>
								<label>•</label>
								<para> 10-15 mg/day divided q8hr; titrate q3days by 5-15 mg/day to max 40 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x107">
					<label>•</label>
					<sec_title>Child ≥8 yr</sec_title>
					<para>
						<list id="lidelem4x107">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Child ≥8 yr:</emphasis> As above; max 60 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x114">
					<label>•</label>
					<sec_title>Child<route> INTRATHECAL</route></sec_title>
					<para>
						<list id="lidelem4x114">
							<item>
								<label>•</label>
								<para> initial test dose same as adult; for small children, initial dose of 25 mcg/dose may be used; 25-1200 mcg/day infusion titrated to response in screening phase</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x118">
					<section type="none" id="sidelem4x119">
						<sec_title>Neuropathic pain including trigeminal neuralgia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x127">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x127">
									<item>
										<label>•</label>
										<para> 10 mg tid, may increase by 10 mg every other day; max 80 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x131">
						<sec_title>Hiccups (unlabeled)</sec_title>
						<section type="none" id="sidelem4x139">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x139">
									<item>
										<label>•</label>
										<para> 10 mg qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x143">
						<sec_title>Stuttering/recurrent priapism (unlabeled)</sec_title>
						<section type="none" id="sidelem4x151">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x151">
									<item>
										<label>•</label>
										<para> 40 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x155">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20 mg; IT inj 10,000 mcg/20 ml, 20,000 mcg/20 ml, 40,000 mcg/20 ml; 50 mcg/ml, 0.5 mg/ml, 10 mg/20 ml, 10 mg/5 ml, 40 mg/20 ml; pharmacy can prepare extemperaneous liquid preparations</para>
					</section>
					<section type="none" id="sidelem4x160">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x163">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x167">
									<item>
										<label>•</label>
										<para>With meals for GI symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in a tight container at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x178">
							<sec_title>IT route</sec_title>
							<section type="none" id="sidelem4x186">
								<label>•</label>
								<sec_title>
									<route>For screening,</route>
								</sec_title>
								<para>
									<list id="lidelem4x186">
										<item>
											<label>•</label>
											<para> dilute to a concentration of 50 mcg/ml with NaCl for inj (preservative free); give test dose over 1 min; watch for decreasing muscle tone, frequency of spasm; if inadequate, use 2 more test doses q24hr;  via implantable pump of 500-2000 mcg/ml because individual titration is required</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x193">
									<item>
										<label>•</label>
										<para>Do not give IT dose by inj, IV, IM, SUBCUT, epidural</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> CloNIDine, morphine, ziconotide</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x202">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x205">
					<section type="none" id="sidelem4x206">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, weakness, fatigue, drowsiness,</emphasis> headache, <emphasis style="italic">disorientation,</emphasis> insomnia, paresthesias, tremors; <emphasis style="bold">seizures, life-threatening CNS depression, coma; CNS infection , impaired cognition memory loss, insomnia, somnolence (IT)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x220">
						<sec_title>CV:</sec_title>
						<para> Hypotension, bradycardia, flushing, orthostatic hypotension, chest pain, palpitations, edema; <emphasis style="bold">cardiovascular collapse (IT)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x227">
						<sec_title>EENT:</sec_title>
						<para> Nasal congestion, blurred vision, mydriasis, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x232">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> constipation, <emphasis style="italic">vomiting,</emphasis> abdominal pain, dry mouth, anorexia, weight gain</para>
					</section>
					<section type="none" id="sidelem4x243">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, hematuria</para>
					</section>
					<section type="none" id="sidelem4x248">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x253">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea; <emphasis style="bold">respiratory failure (IT)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x260">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x263">
					<section type="none" id="sidelem4x264">
						<sec_title>PO:</sec_title>
						<para> Peak 2-3 hr, duration &gt;8 hr, half-life 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 hr, partially metabolized in liver, excreted in urine (unchanged)</para>
					</section>
					<section type="none" id="sidelem4x275">
						<sec_title>INTRATHECAL:</sec_title>
						<para> CSF levels with plasma levels 100 × that of the oral route, peak 4 hr, duration 4-8 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x280">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, tricyclics, opiates, barbiturates, sedatives, hypnotics, MAOIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives</para>
				<section type="none" id="sidelem4x291">
					<section type="none" id="sidelem4x292">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x299">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, blood glucose, CK</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x306">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x309">
					<section type="none" id="sidelem4x310">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Abrupt discontinuation;</emphasis> serious adverse reactions may occur</bbw>
						</para>
						<section type="none" id="sidelem4x330">
							<label>•</label>
							<sec_title>Multiple sclerosis</sec_title>
							<para>
								<list id="lidelem4x330">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Multiple sclerosis:</emphasis> spasms, spasticity, ataxia; improvement should occur with product</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x334">
								<item>
									<label>•</label>
									<para>B/P, weight, blood glucose, hepatic function periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x341">
								<item>
									<para>
										<emphasis alert="nurse">Seizures: for increased seizure activity with seizure disorders; product decreases seizure threshold; EEG in epileptic patients</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x346">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for urinary frequency</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x351">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, fever, respiratory distress</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x356">
								<item>
									<label>•</label>
									<para>Severe weakness, numbness in extremities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x361">
								<item>
									<label>•</label>
									<para>Tolerance: increased need for medication, more frequent requests for medication, increased pain</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x369">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x369">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> CNS depression, dizziness, drowsiness, psychiatric symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x376">
							<label>•</label>
							<sec_title>Intrathecal</sec_title>
							<para>
								<list id="lidelem4x376">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Intrathecal:</emphasis> have emergency equipment nearby; assess test dose and titration; if no response, check pump, catheter for proper functioning</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x380">
								<item>
									<label>•</label>
									<para>Assistance with ambulation if dizziness, drowsiness occurs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x385">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x389">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, spasticity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x395">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x403">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication quickly; hallucinations, spasticity, tachycardia will occur; product should be tapered off over 1-2 wk</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x406">
								<item>
									<label>•</label>
									<para>Not to take with alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x411">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsiness, dizziness occurs; to rise slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x416">
								<item>
									<label>•</label>
									<para>To avoid using OTC medications; not to take cough preparations, antihistamines unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x421">
								<item>
									<label>•</label>
									<para>To notify prescriber if nausea, headache, tinnitus, insomnia, confusion, constipation, inadequate or painful urination continues</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x429">
							<label>•</label>
							<sec_title>MS</sec_title>
							<para>
								<list id="lidelem4x429">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">MS:</emphasis> may require 1-2 mo for full response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x433">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Induce emesis in conscious patient, activated charcoal, dialysis, physostigmine to reduce life-threatening CNS side effects</para>
			</section>
		</monograph>
<monograph id="3" status="active" ha="yes">
			<mono_name> basiliximab (Rx)</mono_name>
			<info>
				<pronunciation>(bas-ih-liks′ih-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x4450">Simulect</tradename>
				</tradenames>
				<class type="func"> Immunosuppressant</class>
				<class type="chem"> Murine/human monoclonal antibody (interleukin-2) receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x455">
				<sec_title>Action:</sec_title>
				<para>Binds to and blocks the IL-2 receptor, which is selectively expressed on the surface of activated T lymphocytes; impairs the immune system to antigenic challenges</para>
			</section>
			<section type="uses" id="sidelem4x460">
				<sec_title>Uses:</sec_title>
				<para>Acute allograft rejection in renal transplant patients when used with cycloSPORINE and corticosteroids</para>
				<section type="none" id="sidelem4x465">
					<section type="none" id="sidelem4x466">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Liver transplant rejection prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x471">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding</para>
				<section type="none" id="sidelem4x476">
					<section type="none" id="sidelem4x477">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), children, geriatric patients, human anti-murine antibody, hypersensitivity to mannitol/murine, exposure to viral infections</para>
						<para>
							<bbw>Infections</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x492">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x500">
					<label>•</label>
					<sec_title>Adult/child ≥35 kg<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x500">
							<item>
								<label>•</label>
								<para> 20 mg × 2 doses; 1st dose within 2 hr before transplant surgery; 2nd dose 4 days after transplantation</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x507">
					<label>•</label>
					<sec_title>Child/adolescent &lt;35 kg<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x507">
							<item>
								<label>•</label>
								<para> 10 mg × 2 doses; 1st dose within 2 hr before transplant surgery; 2nd dose 4 days after transplantation</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<emphasis style="bold">Available forms:</emphasis> Powder for inj 10, 20 mg</para>
				<section type="none" id="sidelem4x515">
					<section type="none" id="sidelem4x516">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x519">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x527">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x527">
										<item>
											<label>•</label>
											<para> 10-mg vial/2.5 ml or 20-mg vial in 5 ml sterile water for inj; shake gently to dissolve;  reconstituted sol in 25 ml (10-mg vial) or 50 ml (20-mg vial) with 0.9% NaCl or D<emphasis style="inf">5</emphasis>W; gently invert bag, do not shake;  over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, do not admix</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x546">
									<item>
										<label>•</label>
										<para>Store reconstituted sol refrigerated for up to 24 hr or at room temperature for 4 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x551">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x554">
					<section type="none" id="sidelem4x555">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Pyrexia, chills, tremors, headache, insomnia, weakness, dizziness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x562">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Chest pain,</emphasis> angina, <emphasis style="bold">cardiac failure,</emphasis> hypotension, <emphasis style="italic">hypertension, edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x575">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Vomiting, nausea, diarrhea, constipation, abdominal pain,</emphasis><emphasis style="bold">GI bleeding,</emphasis><emphasis style="italic">gingival hyperplasia, stomatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x586">
						<sec_title>GU:</sec_title>
						<para> Urinary retention/frequency</para>
					</section>
					<section type="none" id="sidelem4x591">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Acne,</emphasis> pruritus, impaired wound healing</para>
					</section>
					<section type="none" id="sidelem4x599">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Acidosis, hypercholesterolemia, hyperuricemia, hypo/hyperkalemia, hypocalcemia, hypophosphatemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x606">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Infection, moniliasis,</emphasis><emphasis style="bold">anaphylaxis,</emphasis> anemia, allergic reaction, dysuria, CMV infection, candidiasis, abnormal vision</para>
					</section>
					<section type="none" id="sidelem4x616">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Arthralgia, myalgia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x623">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Dyspnea, wheezing,</emphasis><emphasis style="bold">pulmonary edema,</emphasis><emphasis style="italic">cough</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x634">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr (adults); terminal half-life 7 days (adult), 9<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> days (children)</para>
			</section>
			<section type="interactions" id="sidelem4x651">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> immunosuppression—other immunosuppressants</para>
				<section type="none" id="sidelem4x658">
					<section type="none" id="sidelem4x659">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> St. John’s wort, turmeric</para>
					</section>
					<section type="none" id="sidelem4x666">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, BUN, uric acid, creatinine, potassium, calcium blood glucose, Hgb, Hct</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, Hct, platelets, magnesium, phosphate</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x677">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x680">
					<section type="none" id="sidelem4x681">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>For infection: increased temperature, WBC, sputum, urine; may be fatal (bacterial, protozoal, fungal)</bbw>
						</para>
						<para>
							<list id="lidelem4x696">
								<item>
									<label>•</label>
									<para>Blood studies: Hgb, WBC, platelets during treatment monthly; if leukocytes are &lt;3000/mm<emphasis style="sup">3</emphasis>, product should be discontinued; electrolytes, B/P, edema assessment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x706">
								<item>
									<label>•</label>
									<para>Hepatic studies: alk phos, AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x712">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis, hypersensitivity: dyspnea, wheezing, rash, pruritus, hypotension, tachycardia; if severe hypersensitivity reactions occur, product should not be used again</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x717">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x721">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of graft rejection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x727">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To report fever, chills, sore throat, fatigue; serious infection may occur</bbw>
						</para>
						<para>
							<list id="lidelem4x741">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known upper respiratory tract infections</para>
								</item>
								<item>
									<label>•</label>
									<para>To use contraception during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To report GI symptoms, bleeding, allergic reactions</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>beclomethasone (Rx)</mono_name>
			<info>
				<pronunciation>(be-kloe-meth′a-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7620">QVAR</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, synthetic</class>
				<class type="chem"> Glucocorticoid​</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x772">
				<para>
					<confusion>
						<tradename id="tnidelem4x7720">beclomethasone</tradename>
						<drug type="generic" refid="idelem4x7720">betamethasone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x776">
				<sec_title>Action:</sec_title>
				<para>Prevents inflammation by suppression of the migration of polymorphonuclear leukocytes, fibroblasts and the reversal of increased capillary permeability and lysosomal stabilization; does not suppress hypothalamus and pituitary function</para>
			</section>
			<section type="uses" id="sidelem4x781">
				<sec_title>Uses:</sec_title>
				<para>Chronic asthma, allergic/vasomotor rhinitis, nasal polyps</para>
			</section>
			<section type="contra" id="sidelem4x786">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, status asthmaticus (primary treatment)</para>
				<section type="none" id="sidelem4x791">
					<section type="none" id="sidelem4x792">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr, nasal disease/surgery, nonasthmatic bronchial disease; bacterial, fungal, viral infections of mouth, throat, lungs; HPA suppression, osteoporosis, Cushing’s syndrome, diabetes mellitus, measles, cataracts, corticosteroid hypersensitivity, glaucoma, herpes infection​</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x797">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x805">
					<label>•</label>
					<sec_title>Adult and child &gt;12 yr<route> INH</route></sec_title>
					<para>
						<list id="lidelem4x805">
							<item>
								<label>•</label>
								<para> 40-80 mcg bid (alone) or 40-160 mcg bid (previous inhaled corticosteroids); max 320 mcg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x812">
					<label>•</label>
					<sec_title>Child 5-11 yr<route> INH</route></sec_title>
					<para>
						<list id="lidelem4x812">
							<item>
								<label>•</label>
								<para> 40 mcg bid; max 80 mcg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x816">
					<section type="none" id="sidelem4x817">
						<sec_title>Available forms:</sec_title>
						<para> Oral inh 40, 80, 250 <country code="CAN">FIX_STRUCTURE Oral inh 40, 80, 250 </country> mcg/metered spray</para>
					</section>
					<section type="none" id="sidelem4x825">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x830">
								<item>
									<label>•</label>
									<para>Bronchodilator inhaler; if used, should be used 1st, then wait a few minutes, then use beclomethasone</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x835">
								<item>
									<label>•</label>
									<para>Prime before 1st use or if not used for 7-10 days; prime by spraying 2 actuations into the air, away from the face; do not share inhaler</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x843">
							<label>•</label>
							<sec_title>
								<route>Oral inhalation</route>
							</sec_title>
							<para>
								<list id="lidelem4x843">
									<item>
										<label>•</label>
										<para> (metered-dose non-CFC aerosol); shake well, use spacer; after using, rinse mouth, gargle if possible; clean weekly with dry cloth/tissue; do not wash inhaler</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x847">
								<item>
									<label>•</label>
									<para>Titrated dose, use lowest effective dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x852">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x855">
					<section type="none" id="sidelem4x856">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> psychiatric/behavioral changes (child)</para>
					</section>
					<section type="none" id="sidelem4x864">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Hoarseness, candidal infection of oral cavity, sore throat,</emphasis> loss of taste/smell, dysgeusia, pharyngitis, rhinitis, sinusitis, cataracts, fungal infections, epistaxis</para>
					</section>
					<section type="none" id="sidelem4x872">
						<sec_title>ENDO:</sec_title>
						<para> HPA suppression</para>
					</section>
					<section type="none" id="sidelem4x877">
						<sec_title>GI:</sec_title>
						<para> Dry mouth, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x882">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Angioedema, adrenal insufficiency,</emphasis> facial edema, Churg-Strauss syndrome (rare)</para>
					</section>
					<section type="none" id="sidelem4x890">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> wheezing, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x898">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x901">
					<section type="none" id="sidelem4x902">
						<sec_title>INH:</sec_title>
						<para> Onset 1-4 wk; excreted in feces, urine (metabolites); half-life 2.8 hr; crosses placenta; metabolized in lungs, liver (by CYP3A)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x908">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x911">
					<section type="none" id="sidelem4x912">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x916">
								<item>
									<label>•</label>
									<para>For fungal infection in mucous membranes</para>
								</item>
								<item>
									<label>•</label>
									<para>Adrenal function periodically for HPA axis suppression during prolonged therapy, monitor growth/development</para>
								</item>
								<item>
									<label>•</label>
									<para>Gum, rinsing of mouth for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x932">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x936">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dyspnea, wheezing, dry crackles</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x942">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x947">
								<item>
									<label>•</label>
									<para>To gargle/rinse mouth after each use to prevent oral fungal infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x952">
								<item>
									<label>•</label>
									<para>That during times of stress, systemic corticosteroids may be needed to prevent adrenal insufficiency; not to discontinue oral product abruptly, to taper slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x957">
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases; dosage adjustment may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x962">
								<item>
									<label>•</label>
									<para>Proper administration technique and cleaning technique, need for spacer or face mask</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x967">
								<item>
									<label>•</label>
									<para>About all aspects of product usage, including cushingoid symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x975">
							<label>•</label>
							<sec_title>adrenal insufficiency symptoms</sec_title>
							<para>
								<list id="lidelem4x975">
									<item>
										<label>•</label>
										<para>About <emphasis style="bold">adrenal insufficiency symptoms:</emphasis> nausea, anorexia, fatigue, dizziness, dyspnea, weakness, joint pain, depression</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>beclomethasone (nasal)</mono_name>
			<info>
				<pronunciation>(be-kloe-meth′a-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x9852">Beconase AQ</tradename>
					<tradename id="tnidelem4x9851">Qnasl</tradename>
					<tradename id="tnidelem4x9850">
						<country code="CAN">Rivanase</country>
					</tradename>
				</tradenames>
				<class type="func"> Nasal corticosteroid</class>
			</info>
			<section type="actions" id="sidelem4x993">
				<sec_title>Action:</sec_title>
				<para>Readily crosses cell membranes and binds with high affinity to specific cytoplasmic receptors; inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, and suppression of humoral immune responses</para>
			</section>
			<section type="uses" id="sidelem4x998">
				<sec_title>Uses:</sec_title>
				<para>To relieve symptoms of seasonal/perennial rhinitis, postsurgical nasal polyps prophylaxis</para>
			</section>
			<section type="contra" id="sidelem4x1003">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1008">
					<section type="none" id="sidelem4x1009">
						<sec_title>Precautions:</sec_title>
						<para> Child &lt;6 yr, untreated fungal infections, glaucoma and/or cataracts, nasal septum ulcers/surgery/trauma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1014">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1022">
					<label>•</label>
					<sec_title>Adult/child ≥12 yr</sec_title>
					<para>
						<list id="lidelem4x1022">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult/child ≥12 yr:</emphasis> Nasal 1-2 sprays in each nostril bid (42 mcg/spray); 2 sprays in each nostril every day (80 mcg/actuation)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1029">
					<label>•</label>
					<sec_title>Child 6-12 yr</sec_title>
					<para>
						<list id="lidelem4x1029">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Child 6-12 yr:</emphasis> Nasal 1 spray (42 mcg) in each nostril bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1033">
					<section type="none" id="sidelem4x1034">
						<sec_title>Available forms:</sec_title>
						<para> Nasal spray 42 mcg/metered spray; nasal aerosol 40, 80 mcg/actuation</para>
					</section>
					<section type="none" id="sidelem4x1039">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1043">
								<item>
									<label>•</label>
									<para>Products are not always interchangeable owing to differences in route of administration and in the amount of active drug released per spray</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid the spread of infection, do not use the container for more than one person</para>
								</item>
								<item>
									<label>•</label>
									<para>Product’s effectiveness depends on regular use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1059">
							<sec_title>Nasal inhalation (metered-dose aerosol) (Qnasal):</sec_title>
							<para>
								<list id="lidelem4x1063">
									<item>
										<label>•</label>
										<para>Instruct patient to shake the canister well before administering</para>
									</item>
									<item>
										<label>•</label>
										<para>Before first use, instruct the patient to prime the pump by actuating 4 times; after the initial priming, the dose-counter should read 120</para>
									</item>
									<item>
										<label>•</label>
										<para>If the canister is not used for 7 consecutive days, instruct the patient to prime by actuating 2 times</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient on proper administration technique</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1084">
							<sec_title>Nasal inhalation (pump spray) (Beconase AQ):</sec_title>
							<para>
								<list id="lidelem4x1088">
									<item>
										<label>•</label>
										<para>Instruct patient to shake the nasal sprayer well before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Before first use, instruct the patient to prime the pump by actuating 6 times</para>
									</item>
									<item>
										<label>•</label>
										<para>If the pump is not used for 7 days, prime until a fine spray appears</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient on proper administration technique</para>
									</item>
									<item>
										<label>•</label>
										<para>After use, rinse the tip of the bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue; replace the cap</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1116">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1119">
					<section type="none" id="sidelem4x1120">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria</para>
					</section>
					<section type="none" id="sidelem4x1125">
						<sec_title>SYST:</sec_title>
						<para> Decreased growth, HPA suppression</para>
					</section>
					<section type="none" id="sidelem4x1130">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x1135">
						<sec_title>EENT:</sec_title>
						<para> Nasal burning, epistaxis, nasal fungal infections, nasal congestion, sneezing, irritation, loss of smell/taste, cataracts</para>
					</section>
					<section type="none" id="sidelem4x1140">
						<sec_title>GI:</sec_title>
						<para> Nausea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1145">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 5-7 days, peak 21 days, half-life 15 hr</para>
			</section>
			<section type="considerations" id="sidelem4x1150">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1153">
					<section type="none" id="sidelem4x1154">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1158">
								<item>
									<label>•</label>
									<para>Nasal symptoms: assess for sneezing, running of nose before and after use; avoid use longer than 3 wk; check for fungal infections, changes in vision</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1164">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1168">
								<item>
									<label>•</label>
									<para>Decrease nasal running, sneezing, other symptoms of seasonal/perennial rhinitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1174">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1178">
								<item>
									<label>•</label>
									<para>That products are not always interchangeable owing to differences in route of administration and in the amount of active drug released per spray</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use the container for more than one person, to avoid the spread of infection</para>
								</item>
								<item>
									<label>•</label>
									<para>That product effectiveness depends on regular use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1194">
							<sec_title>Nasal inhalation (metered-dose aerosol) (Qnasal):</sec_title>
							<para>
								<list id="lidelem4x1198">
									<item>
										<label>•</label>
										<para>Instruct patient to shake the canister well before administering</para>
									</item>
									<item>
										<label>•</label>
										<para>Before first use, instruct the patient to prime the pump by actuating 4 times; after the initial priming, the dose-counter should read 120</para>
									</item>
									<item>
										<label>•</label>
										<para>If the canister is not used for 7 consecutive days, instruct the patient to prime by actuating 2 times</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient on proper administration technique</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1219">
							<sec_title>Nasal inhalation (pump spray) (Beconase AQ):</sec_title>
							<para>
								<list id="lidelem4x1223">
									<item>
										<label>•</label>
										<para>Instruct patient to shake the nasal sprayer well before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Before first use, instruct the patient to prime the pump by actuating 6 times</para>
									</item>
									<item>
										<label>•</label>
										<para>If the pump is not used for 7 days, prime until a fine spray appears</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient on proper administration technique</para>
									</item>
									<item>
										<label>•</label>
										<para>After use, rinse the tip of the bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue; replace the cap</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>bedaquiline</mono_name>
			<info>
				<pronunciation>(bed-ak’-wi-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x12540">Sirturo</tradename>
				</tradenames>
				<class type="func"> Antiinfective/antituberculotic</class>
				<class type="chem"> Diarylquinoline</class>
			</info>
			<section type="actions" id="sidelem4x1264">
				<sec_title>Action:</sec_title>
				<para>Inhibits an enzyme that binds to adenosine 5’-triphosphate (ATP) synthase and prevents ATP synthase from using the energy from hydrogen and/or sodium</para>
			</section>
			<section type="uses" id="sidelem4x1269">
				<sec_title>Uses:</sec_title>
				<para>For use as part of a combination regimen to treat pulmonary multidrug-resistant tuberculosis infection (MDR-TB) when other effective treatment regimens are not available</para>
			</section>
			<section type="contra" id="sidelem4x1274">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1279">
					<section type="none" id="sidelem4x1280">
						<sec_title>Precautions: </sec_title>
						<para>Alcoholism, bradycardia, breastfeeding, arrhythmias, cardiac disease, children, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, MI, pregnancy (B), syncope, thyroid disease</para>
						<para>
							<bbw>QT prolongation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1294">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1302">
					<label>•</label>
					<sec_title>Adults</sec_title>
					<para>
						<list id="lidelem4x1302">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adults:</emphasis> PO 400 mg daily × 2 wk, then reduce dose to 200 mg 3×/wk with food (≥48 hr between doses). Total duration is 24 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1306">
					<section type="none" id="sidelem4x1307">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100 mg</para>
					</section>
					<section type="none" id="sidelem4x1313">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1318">
								<item>
									<label>•</label>
									<para>If a dose is missed during the first 2 wk of treatment, instruct patient not to make up the missed dose but to continue with the usual dosing schedule. If a dose is missed during treatment wk 3-24, the missed dose should be taken as soon as possible and then resume 3×/wk regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1323">
								<item>
									<label>•</label>
									<para>Give in combination with at least 3 other drugs proven to be or at least 4 other drugs suspected of being effective against the patient’s <emphasis style="italic">Mycobacterium tuberculosis</emphasis> isolate</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1334">
							<label>•</label>
							<sec_title>
								<route>Give with food, give with water, use whole, do not break, crush, chew</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1340">
							<label>•</label>
							<sec_title>
								<route>Store at room temperature in light-resistant container</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1343">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1346">
					<section type="none" id="sidelem4x1347">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1354">
						<sec_title>CV:</sec_title>
						<para> QT-C prolongation, chest pain</para>
					</section>
					<section type="none" id="sidelem4x1359">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia</para>
					</section>
					<section type="none" id="sidelem4x1364">
						<sec_title>MISC:</sec_title>
						<para> Arthralgia, rash, hemoptysis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1369">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 5 mo, peak 5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1374">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—other drugs that prolong QT (class IA/III antidysrhythmics, some phenothiazines, beta agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin); CYP3A4 substrates (methadone, pimozide, quetiapine, quinidine, risperidone, ziprasidone)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—lopinavir/ritonavir</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bedaquiline effect—strong CYP3A4 inhibitors, avoid use over 14 days</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> bedaquiline effect—strong CYP3A4 inducers, avoid concurrent use</para>
				<section type="none" id="sidelem4x1392">
					<section type="none" id="sidelem4x1393">
						<sec_title>Drug/Lab Test:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hepatic enzymes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1400">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1403">
					<section type="none" id="sidelem4x1404">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1412">
							<label>•</label>
							<sec_title>Acute TB<route> chest x-ray, sputum culture, blood culture</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1418">
							<label>•</label>
							<sec_title>Liver function</sec_title>
							<para>
								<list id="lidelem4x1418">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Liver function:</emphasis> monitor LFTs baseline and monthly if needed, repeat if &gt;3 × ULN, test for viral hepatitis before use; monitor for dark urine, anorexia, jaundice, nausea, fatigue, hepatomegaly
<bbw>
												<emphasis alert="lifethreat">QT Prolongation:</emphasis> monitor ECG baseline, at 2, 12 and 24 wk or more often if QT prolongation is suspected; close monitoring of the ECG is needed in those with QT prolonging risk factors; if prolongation of the QT interval is detected, electrolyte monitoring and frequent ECG (to ensure QTc interval return to baseline) are recommended; those developing a clinically significant ventricular arrhythmia or a QTcF interval &gt;500 ms (confirmed by repeat ECG) discontinue this product and all other QT prolonging products</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1433">
								<item>
									<label>•</label>
									<para>Monitor Ca, magnesium, K baseline and periodically, correct imbalances</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1438">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1442">
								<item>
									<label>•</label>
									<para>Positive therapeutic outcome: negative culture</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1448">
						<sec_title>Teach Patient/Family:</sec_title>
						<para>
							<list id="lidelem4x1452">
								<item>
									<label>•</label>
									<para>The importance of compliance with the entire course of therapy, that tabs should be swallowed whole, take with water and food and used as part of a multidrug regimen</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid breastfeeding, to notify prescriber if pregnancy is planned or suspected (B)</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use of alcohol, and all medications, herbs unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That scheduled appointments must be kept because relapse may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>belatacept</mono_name>
			<info>
				<pronunciation>(bel-a-ta′sept)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x14780">Nulojix</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier</class>
				<class type="chem"> Fusion protein</class>
			</info>
			<section type="actions" id="sidelem4x1488">
				<sec_title>Action:</sec_title>
				<para>Activated T-lymphocytes are the mediators of immunologic rejection. This product is a selective T-cell costimulation blocker; blocks the CD28 mediated costimulation of T-lymphocytes by binding to CD80 and CD86 on antigen-presenting cells; inhibits T-lymphocyte proliferation and the production of the cytokines interleukin-2, interferon-gamma, interleukin-4, and TNF-alpha.</para>
			</section>
			<section type="uses" id="sidelem4x1495">
				<sec_title>Uses:</sec_title>
				<para>Kidney transplant rejection prophylaxis given with basiliximab induction, mycophenolate mofetil, corticosteroids</para>
			</section>
			<section type="contra" id="sidelem4x1500">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, EBV seronegative, EBV status unknown</para>
				<section type="none" id="sidelem4x1505">
					<section type="none" id="sidelem4x1506">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, child/infant/neonate, pregnancy (C), diabetes mellitus, progressive multifocal leukoencephalopathy, immunosuppression, sunlight exposure, TB</para>
						<para>
							<bbw>Infection, organ transplant, requires an experienced clinician, secondary malignancy, posttransplant lymphoproliferation disorder</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1521">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1529">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x1529">
							<item>
								<label>•</label>
								<para> 10 mg/kg rounded to the nearest 12.5-mg increment; give over 30 min the day of transplantation (day 1) but before transplantation, on day 5 approximately 96 hours after the day 1 dose 1, at the end of wk 2, at the end of wk 4, at the end of wk 8, and at the end of wk 12; maintenance dosage is 5 mg/kg rounded to the nearest 12.5-mg increment; give over 30 min at the end of wk 16 and every 4 wk ± 3 days thereafter; doses should be calculated on actual body weight on the transplantation day unless the patient’s weight varies by &gt;10%</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1533">
					<section type="none" id="sidelem4x1534">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 250 mg</para>
					</section>
					<section type="none" id="sidelem4x1539">
						<sec_title>Administer:</sec_title>
						<para>
							<bbw>Only providers skilled in the use of immunosuppressant and management of transplant should use these products</bbw>
						</para>
						<section type="none" id="sidelem4x1552">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x1556">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter, discoloration; discard if present</para>
									</item>
									<item>
										<label>•</label>
										<para>Calculate the number of drug vials required to provide total infusion dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute each vial/10.5 ml of sterile water for injection, 0.9% sodium chloride, D<emphasis style="inf">5</emphasis>W, using the silicone-free disposable syringe provided with each vial and an 18-21G needle; if silicone-free disposable syringe is dropped or becomes contaminated, use a new silicone-free disposable syringe; if you need additional silicone-free disposable syringes, call 1-888-685-6549; if the powder is accidentally reconstituted using a different syringe than the one provided, the sol may develop a few translucent particles; discard any sol prepared using siliconized syringes</para>
									</item>
									<item>
										<label>•</label>
										<para>Using aseptic technique, inject the diluent into the vial and direct the stream of diluent to the glass wall of the vial; to minimize foaming, rotate the vial and invert with gentle swirling until the contents are dissolved; do not shake when reconstituted (25 mg/ml), should be clear to slightly opalescent and colorless to pale yellow; do not use if opaque particles, discoloration, or other foreign particles are present</para>
									</item>
									<item>
										<label>•</label>
										<para>Calculate the total volume of the reconstituted 25 mg/ml sol required to provide the total infusion dose; further dilute this volume with a volume of infusion fluid equal to the volume of the reconstituted drug sol required; use either NS or D<emphasis style="inf">5</emphasis>W if drug was reconstituted with SWFI; use NS if drug was reconstituted with NS; use D<emphasis style="inf">5</emphasis>W if drug was reconstituted with D<emphasis style="inf">5</emphasis>W; with the same silicone-free disposable syringe used for reconstitution, withdraw the required amount of belatacept sol from the vial, inject it into the infusion container, gently rotate; final concentrations in infusion container should range 2-10 mg/ml; volume of 100 ml will be appropriate for most doses, but total infusion volumes ranging from 50-250 ml may be used; discard any unused sol; after reconstitution, immediately transfer the reconstituted sol from the vial to the infusion bag or bottle; complete within 24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1596">
							<sec_title>IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1600">
									<item>
										<label>•</label>
										<para>Give over 30 min, use an infusion set and a sterile, nonpyrogenic, low-protein-binding filter (0.2-1.2 mm), use a separate line</para>
									</item>
									<item>
										<label>•</label>
										<para>Store refrigerated, protected from light ≤24 hr; max 4 hr of the total 24 hr can be at room temperature and room light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1611">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1614">
					<section type="none" id="sidelem4x1615">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x1620">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Guillain-Barré syndrome,</emphasis> anxiety, dizziness, headache, fever, insomnia, tremors</para>
					</section>
					<section type="none" id="sidelem4x1628">
						<sec_title>EENT:</sec_title>
						<para> Pharyngitis, stomatitis</para>
					</section>
					<section type="none" id="sidelem4x1633">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, constipation, diarrhea, nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x1638">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal tubular necrosis, renal failure,</emphasis> proteinuria, urinary incontinence, dysuria, UTI</para>
					</section>
					<section type="none" id="sidelem4x1646">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, neutropenia, leucopenia, leukoencephalopathy</para>
					</section>
					<section type="none" id="sidelem4x1651">
						<sec_title>INTEG:</sec_title>
						<para> Acne, alopecia, infusion reaction</para>
					</section>
					<section type="none" id="sidelem4x1656">
						<sec_title>META:</sec_title>
						<para> Hypercholesterolemia, hyperglycemia, hyper/hypokalemia, hypocalcemia, hypophosphatemia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x1661">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
					<section type="none" id="sidelem4x1666">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignancy, posttransplant lymphoproliferation disorder, wound dehiscence, BK-virus-associated neuropathy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1673">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life, 6.1-15.1 days during receipt of 10 mg/kg IV doses; during receipt of 5 mg/kg IV doses, terminal half-life 3.1-11.9; steady state by wk 8 after transplantation and by mo 6 during maintenance phase</para>
			</section>
			<section type="interactions" id="sidelem4x1678">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x1683">
						<item>
							<label>•</label>
							<para>Do not use 30 days before or with this product: live virus vaccines</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x1691">
					<label>•</label>
					<sec_title>
						<route>Do not use with cyclophosphamide IV</route>
					</sec_title>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1694">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1697">
					<section type="none" id="sidelem4x1698">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Transplant rejection:</emphasis> flulike symptoms, decreasing urinary output, malaise; some may experience pain in area (rare; monitor BUN/creatinine)</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Infection:</emphasis> monitor for fever, chills, increased WBC, <emphasis alert="lifethreat">wound dehiscences</emphasis></bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Posttransplant lymphoproliferation disorder:</emphasis> may lead to secondary malignancy (lymphoma) or infectious mononucleosis-like lesions; may be treated with antivirals or immunosuppressant; product may need to be discontinued</bbw>
						</para>
						<para>
							<list id="lidelem4x1740">
								<item>
									<label>•</label>
									<para>Hyperlipidemia: monitor cholesterol, triglycerides; an antilipidemic may be needed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1746">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1750">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of renal transplant rejection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1756">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1761">
								<item>
									<label>•</label>
									<para>Reason for product and expected result, use REMS guidelines</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1769">
							<label>•</label>
							<sec_title>
								<route>To avoid exposure to sunlight, tanning beds, risk of secondary malignancy</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1772">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1777">
								<item>
									<label>•</label>
									<para>That repeated lab test will be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1782">
								<item>
									<label>•</label>
									<para>To avoid with vaccines</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1787">
								<item>
									<label>•</label>
									<para>That immunosuppressants will be needed for life to prevent rejection; symptoms of rejection/infection and to call provider immediately</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>belimumab</mono_name>
			<info>
				<pronunciation>(be-lim′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x17970">Benlysta</tradename>
				</tradenames>
				<class type="func"> Monoclonal antibody</class>
				<class type="chem"> Disease-modifying antirheumatic drugs (DMARDs)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1807">
				<sec_title>Action:</sec_title>
				<para>Inhibits B-lymphocyte stimulator (BLyS), needed for B-cell survival; normally, soluble BLyS binds to its receptors on B cells and allows B-cell survival; binds BLyS and prevents binding to its receptors on B-cells</para>
			</section>
			<section type="uses" id="sidelem4x1814">
				<sec_title>Uses:</sec_title>
				<para>Active, autoantibody-positive, systemic lupus erythematosus (SLE) in combination with standard therapy</para>
			</section>
			<section type="contra" id="sidelem4x1819">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1824">
					<section type="none" id="sidelem4x1825">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children/infants, geriatric patients, African descent patients, depression, immunosuppression, infection, suicidal ideation, vaccination, secondary malignancy, cardiac disease; requires experienced clinician</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1830">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1838">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x1838">
							<item>
								<label>•</label>
								<para> 10 mg/kg over 1 hr q2wk for the first 3 doses, then q4wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1842">
					<section type="none" id="sidelem4x1843">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 120, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x1848">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1852">
								<item>
									<label>•</label>
									<para>Only health care providers prepared to manage anaphylaxis should administer this product; may give premedication for prophylaxis against infusion and hypersensitivity reactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1858">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1862">
									<item>
										<label>•</label>
										<para>Visually inspect particulate matter and discoloration whenever sol and container permits</para>
									</item>
									<item>
										<label>•</label>
										<para>Give as IV infusion only; do not give IV bolus or push; give over 1 hr and slow or stop if infusion reactions occur</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give with any other agents in the same IV line</para>
									</item>
									<item>
										<label>•</label>
										<para>Allow to stand at room temperature for 10-15 min before using</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute with the appropriate amount of sterile water for injection (80 mg/ml); add 1.5 ml of sterile water (120 mg/vial) or 4.8 ml of sterile water (400 mg/vial)</para>
									</item>
									<item>
										<label>•</label>
										<para>Direct the stream of sterile water toward the side of the vial to minimize foaming; gently swirl for 60 sec, allow to sit during reconstitution, gently swirl for 60 sec q5min until the powder is dissolved; do not shake; reconstitution is complete in 10-30 min</para>
									</item>
									<item>
										<label>•</label>
										<para>If a mechanical reconstitution device (swirler) is used, max 500 rpm swirled for ≤30 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Sol should be opalescent and colorless to pale yellow and without particles; small air bubbles are expected; protect from sunlight</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilution: only dilute in normal saline for injection; dilute reconstituted sol with enough normal saline to 250 ml; from a 250-ml infusion bag or bottle of normal saline, withdraw and discard a volume equal to the volume of the reconstituted sol required for dose; add the required volume of the reconstituted sol to the infusion bag/bottle; gently invert to mix</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard any unused sol</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in refrigerator or at room temperature; total time from reconstitution to completion of infusion max 8 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1918">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1921">
					<section type="none" id="sidelem4x1922">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, anxiety, depression, fever, insomnia, migraine, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1929">
						<sec_title>GU:</sec_title>
						<para> UTI</para>
					</section>
					<section type="none" id="sidelem4x1934">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, hypotension</para>
					</section>
					<section type="none" id="sidelem4x1939">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x1944">
						<sec_title>MISC:</sec_title>
						<para> Rash, dyspnea, cystitis, leukopenia, myalgia, rash, bronchitis, nasopharyngitis, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x1949">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema, antibody formation, secondary malignancy, infection, influenza, infusion reactions</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1956">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 19.4 days; distribution half-life 1.75 days</para>
			</section>
			<section type="considerations" id="sidelem4x1961">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1964">
					<section type="none" id="sidelem4x1965">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1973">
							<label>•</label>
							<sec_title>SLE</sec_title>
							<para>
								<list id="lidelem4x1973">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">SLE:</emphasis> monitor for decreasing fever, malaise, fatigue, joint pain, myalgias</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1980">
							<label>•</label>
							<sec_title>Suicidal ideation</sec_title>
							<para>
								<list id="lidelem4x1980">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Suicidal ideation:</emphasis> more common in those with preexisting depression</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1987">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x1987">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> determine if a chronic or acute infection is present, may be fatal when used with this product; do not begin therapy if any products are being used for a chronic infection; leukopenia may occur with this product and susceptibility to infections increased</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1996">
							<label>•</label>
							<sec_title>Anaphylaxis, infusion site reactions<route> if these occur, stop infusion</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2002">
							<label>•</label>
							<sec_title>African descent patients<route> use cautiously in these patients, may not respond to this product</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2005">
								<item>
									<label>•</label>
									<para>Cardiac disease: monitor closely for cardiovascular side effects, bradycardia, hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2013">
							<label>•</label>
							<sec_title>Pregnancy<route> determine if pregnant or if pregnancy is planned or suspected; if pregnant, call 1-877-681-6269 to enroll in registry</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2016">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2020">
								<item>
									<label>•</label>
									<para>Positive response: decreasing symptoms of SLE: decreasing fatigue, fever, malaise</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2026">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2034">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; to use reliable contraception during and for 4 mo after final treatment; to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2037">
								<item>
									<label>•</label>
									<para>To seek treatment immediately for serious hypersensitive reactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2042">
								<item>
									<label>•</label>
									<para>Not to receive live vaccinations during treatment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active" ha="yes">
			<mono_name> belinostat</mono_name>
			<info>
				<pronunciation>(beh-lih′noh-stat′)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x20540">Beleodaq</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-biologic response modifier</class>
				<class type="chem"> Histone deacetylase inhibitors</class>
			</info>
			<section type="actions" id="sidelem4x2064">
				<sec_title>Action:</sec_title>
				<para> A class I and II inhibitor of the histone deacetylase (HDAC) enzymes. Overexpression of HDACs is present in some cancer cells. HDAC inhibitors have been shown to activate differentiation, inhibit the cell cycle, and induce apoptosis</para>
			</section>
			<section type="uses" id="sidelem4x2069">
				<sec_title>Uses:</sec_title>
				<para> For the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL)</para>
			</section>
			<section type="contra" id="sidelem4x2074">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity, pregnancy (D)</para>
				<section type="none" id="sidelem4x2079">
					<section type="none" id="sidelem4x2080">
						<sec_title>Precautions:</sec_title>
						<para> Hematologic toxicity (thrombocytopenia, leukopenia, neutropenia, lymphopenia, anemia), serious infections (pneumonia, sepsis), fatal hepatic toxicity, tumor lysis syndrome (TLS), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2085">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2093">
					<label>•</label>
					<sec_title>
						<route>IV</route>
					</sec_title>
					<para>
						<list id="lidelem4x2093">
							<item>
								<label>•</label>
								<para>Adult:  1000 mg/m<emphasis style="sup">2</emphasis> over 30 min on days 1-5 q21days. Reduce the dose to 750 mg/m<emphasis style="sup">2</emphasis> in those who are homozygous for the UGT1A1*28 allele. Cycles should be repeated until disease progression or unacceptable toxicity</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2104">
					<section type="none" id="sidelem4x2105">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 500 mg</para>
					</section>
					<section type="none" id="sidelem4x2110">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2113">
							<sec_title>Intermittent IV route</sec_title>
							<para>
								<list id="lidelem4x2117">
									<item>
										<label>•</label>
										<para>Reconstitution: Add 9 ml of sterile water for injection/500 mg, swirl until there are no visible particles in the solution (50 mg/ml); stable at room temperature for up to 12 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Withdraw the appropriate amount from the reconstituted vial and further dilute in 250 ml 0.9% sodium chloride for injection, the final solution is stable at room temperature for up to 36 hr, including infusion time; use a 0.22-micron in-line filter; give over 30 min, if pain occurs at infusion site, run over 45 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2129">
						<sec_title>Dose adjustments due to treatment-related toxicity</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x2133">
						<sec_title>Hematologic toxicities:</sec_title>
						<section type="none" id="sidelem4x2141">
							<label>•</label>
							<sec_title>
								<route>Do not begin the next cycle of treatment until the absolute neutrophil count (ANC) is ≥1000/mm</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2155">
							<label>•</label>
							<sec_title>
								<route>ANC nadir ≥500/mm</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2173">
							<label>•</label>
							<sec_title>
								<route>ANC nadir &lt;500/mm</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2204">
							<label>•</label>
							<sec_title>
								<route>Platelet nadir &lt;25,000/mm</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2232">
						<sec_title>Nonhematologic toxicities:</sec_title>
						<section type="none" id="sidelem4x2240">
							<label>•</label>
							<sec_title>Grade 3 or 4 nausea, vomiting, or diarrhea for &gt;7 days with supportive management, or other grade 3 or 4 toxicity of any duration<route> hold treatment. When toxicity resolves to grade ≤2, restart the next cycle at a reduced dose of 750 mg/m</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2253">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2256">
					<section type="none" id="sidelem4x2257">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, headache, dizziness, fever, chills</para>
					</section>
					<section type="none" id="sidelem4x2262">
						<sec_title>CV:</sec_title>
						<para> Hypotension, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2269">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, anorexia, abdominal pain, nausea, vomiting, diarrhea,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2278">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">thrombocytopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2285">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough</para>
					</section>
					<section type="none" id="sidelem4x2290">
						<sec_title>INTEG:</sec_title>
						<para> Injection-site reactions, rash, phlebitis,</para>
					</section>
					<section type="none" id="sidelem4x2295">
						<sec_title>MISC:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x2300">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Multi-organ failure, TLS, serious infections</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2307">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life of 1.1 hr; 92.9%-95.8% protein bound, 80%-90% metabolized by hepatic UGT1A1; metabolized in the liver, 40% excreted renally, primarily as metabolites</para>
			</section>
			<section type="interactions" id="sidelem4x2312">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2315">
					<section type="none" id="sidelem4x2316">
						<sec_title>Increase:</sec_title>
						<para> belinostat—strong UGT1A1 inhibitors</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2321">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2324">
					<section type="none" id="sidelem4x2325">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2333">
							<label>•</label>
							<sec_title>Hematologic toxicity (thrombocytopenia, leukopenia, neutropenia, lymphopenia, anemia)<route> Monitor CBC before starting therapy and then every week. Dose modifications may be necessary in patients with bone marrow suppression and should be determined by the ANC and platelet count nadirs of the previous cycle of therapy. Platelet counts should be ≥50,000/mm</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2349">
							<label>•</label>
							<sec_title>Serious infections (pneumonia, sepsis)<route> May be fatal. Do not use in those with an active infection. Use caution in patients with a history of extensive or intensive chemotherapy, as they may be at higher risk of life-threatening infections</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2355">
							<label>•</label>
							<sec_title>Fatal hepatic toxicity<route> Monitor LFTs before the start of each cycle. Those with signs of hepatic disease may require dose modification or discontinuation</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2361">
							<label>•</label>
							<sec_title>TLS<route> Those with high tumor burden or advanced stage disease are at greater risk for development of TLS; consider tumor lysis prophylaxis with antihyperuricemic agents and hydration beginning 12-24 hr before treatment; for TLS treatment, administer aggressive IV hydration, antihyperuricemic agents, correct electrolyte abnormalities, and monitor renal function</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2367">
							<label>•</label>
							<sec_title>Pregnancy (D) and breastfeeding<route> Consider discontinuing breastfeeding, identify whether the patient is pregnant before using</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2373">
							<label>•</label>
							<sec_title>Renal studies</sec_title>
							<para>
								<list id="lidelem4x2373">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal studies:</emphasis> Monitor BUN/creatinine periodically</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2377">
						<sec_title>Evaluate:</sec_title>
						<section type="none" id="sidelem4x2385">
							<label>•</label>
							<sec_title>Therapeutic response</sec_title>
							<para>
								<list id="lidelem4x2385">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Therapeutic response:</emphasis> Prevention of spread of disease</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2389">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2397">
							<label>•</label>
							<sec_title>
								<route>To avoid use in breastfeeding, and not to use in pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2400">
								<item>
									<label>•</label>
									<para>To report infusion-site reactions, rash, severe constipation or diarrhea, abdominal pain</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>benazepril (Rx)</mono_name>
			<info>
				<pronunciation>(ben-aze′uh-pril)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24110">Lotensin</tradename>
				</tradenames>
				<class type="func"> Antihypertensive ​</class>
				<class type="chem"> Angiotensin-converting enzyme (ACE) inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2421">
				<para>
					<confusion>
						<tradename id="tnidelem4x24210">benazepril</tradename>
						<drug type="generic" refid="idelem4x24210">Benadryl</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2425">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE, thus preventing conversion of angiotensin I to angiotensin II</para>
			</section>
			<section type="uses" id="sidelem4x2430">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with thiazide diuretics</para>
				<section type="none" id="sidelem4x2435">
					<section type="none" id="sidelem4x2436">
						<sec_title>Unlabeled uses:</sec_title>
						<para> CHF, diabetic nephropathy, proteinuria, renal impairment</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2441">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity to ACE inhibitors, angioedema</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x2456">
					<section type="none" id="sidelem4x2457">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, impaired renal/hepatic function, dialysis patients, hypovolemia, blood dyscrasias, CHF, asthma, bilateral renal artery stenosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2462">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2470">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2470">
							<item>
								<label>•</label>
								<para> 10 mg/day initially, then 20-40 mg/day divided bid or daily (without a diuretic); reduce initial dose to 5 mg  daily (with a diuretic); max 80 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2480">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2480">
							<item>
								<label>•</label>
								<para> used on the basis of the clinical response</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2487">
					<label>•</label>
					<sec_title>Child ≥6 yrs<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2487">
							<item>
								<label>•</label>
								<para> 0.2 mg/kg/day max 5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2491">
					<section type="none" id="sidelem4x2492">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2500">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min 5 mg PO daily, max 40 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2503">
						<sec_title>Renal impairment due to diabetic nephropathy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2511">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2511">
									<item>
										<label>•</label>
										<para> 5-10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2515">
						<sec_title>Heart failure (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2523">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2523">
									<item>
										<label>•</label>
										<para> 2-20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2527">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x2532">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2536">
								<item>
									<label>•</label>
									<para>May give without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not discontinue product abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at 86° F (30° C) or less</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2552">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2555">
					<section type="none" id="sidelem4x2556">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, hypertonia, insomnia, paresthesia, headache, dizziness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x2561">
						<sec_title>CV:</sec_title>
						<para> Hypotension, postural hypotension, syncope, palpitations, angina</para>
					</section>
					<section type="none" id="sidelem4x2566">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, vomiting, gastritis, melena, diarrhea, <emphasis style="bold">hepatotoxicity, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2573">
						<sec_title>GU:</sec_title>
						<para> Increased BUN, creatinine, decreased libido, impotence, UTI, renal insufficiency</para>
					</section>
					<section type="none" id="sidelem4x2578">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2585">
						<sec_title>INTEG:</sec_title>
						<para> Rash, flushing, sweating, alopecia</para>
					</section>
					<section type="none" id="sidelem4x2590">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x2595">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Angioedema, Stevens-Johnson syndrome</emphasis>, hypersensitivity</para>
					</section>
					<section type="none" id="sidelem4x2603">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, arthritis, myalgia</para>
					</section>
					<section type="none" id="sidelem4x2608">
						<sec_title>RESP:</sec_title>
						<para> Cough, asthma, bronchitis, dyspnea, sinusitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2613">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr fasting, 2-4 hr after food; protein binding 89%-95%; half-life 10-11 hr; metabolized by liver (metabolites); excreted in urine 33%</para>
			</section>
			<section type="interactions" id="sidelem4x2618">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—phenothiazines, nitrates, acute alcohol ingestion, diuretics, other antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics, potassium supplements</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—azaTHIOprine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum levels of lithium, digoxin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypotensive effects—NSAIDs</para>
				<section type="none" id="sidelem4x2641">
					<section type="none" id="sidelem4x2642">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra (Ma huang)</para>
					</section>
					<section type="none" id="sidelem4x2653">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, bilirubin, uric acid, blood glucose, potassium</para>
						<para>
							<emphasis style="bold">Positive:</emphasis> ANA titer</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> ANA titer</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2669">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2672">
					<section type="none" id="sidelem4x2673">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2681">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x2681">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, pulse at baseline, periodically; orthostatic hypotension, syncope when used with diuretic; notify prescriber of changes; monitor compliance</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2688">
							<label>•</label>
							<sec_title>Blood dyscrasias<route> neutrophils, decreased platelets; WBC with differential at baseline, q3mo; if neutrophils &lt;1000/mm3, discontinue treatment; recommended with collagen-vascular disease</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2694">
								<item>
									<label>•</label>
									<para>Renal studies: protein, BUN, creatinine; increased levels may indicate nephrotic syndrome; monitor urine for protein; LFTs, uric acid, glucose may be increased; diuretic should be discontinued 3 days before initiation of benazepril, if hypertension is not controlled, a diuretic can be added; measure B/P at peak 2-4 hr and trough (before next dose); this product is less effective in African descent patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2699">
								<item>
									<label>•</label>
									<para>Potassium levels, although hyperkalemia rarely occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2707">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x2707">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash, fever, pruritus, urticaria; product should be discontinued if antihistamines fail to help; </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2713">
								<item>
									<label>•</label>
									<para>Renal symptoms: polyuria, oliguria, frequency, dysuria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2721">
							<label>•</label>
							<sec_title>CHF (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x2721">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF (unlabeled):</emphasis> edema in feet, legs daily; weight daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2725">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2729">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2735">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2739">
								<item>
									<label>•</label>
									<para>Not to use OTC products (cough, cold, allergy) unless directed by prescriber; not to use salt substitutes that contain potassium without consulting prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>The importance of complying with dosage schedule, even if feeling better
<bbw>To notify prescriber of pregnancy (D); product will need to be discontinued</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2761">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2769">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain, bruising, bleeding, swelling of face, tongue, lips, difficulty breathing</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2772">
								<item>
									<label>•</label>
									<para>To report excessive perspiration, dehydration, vomiting, diarrhea; may lead to fall in B/P; to use caution in hot weather</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2777">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, lightheadedness; that this may occur during first few days of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2782">
								<item>
									<label>•</label>
									<para>That product may cause skin rash or impaired perspiration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2787">
								<item>
									<label>•</label>
									<para>How to take B/P, and normal readings for age group</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2792">
								<item>
									<label>•</label>
									<para>To avoid potassium-containing products (salt substitutes)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x2797">
				<sec_title>Treatment of overdose:</sec_title>
				<para>0.9% NaCl IV INFUSION, hemodialysis</para>
			</section>
		</monograph>
<monograph id="11" status="active" ha="yes">
			<mono_name> bendamustine (Rx)</mono_name>
			<info>
				<pronunciation>(ben-da-muss′teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x28090">Treanda</tradename>
				</tradenames>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Mechlorethamine derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x2819">
				<sec_title>Action:</sec_title>
				<para>Cross-linking DNA that causes single-strand and double-strand breaks, inhibits several mitotic checkpoints, combines alkylating and antimetabolite properties</para>
			</section>
			<section type="uses" id="sidelem4x2824">
				<sec_title>Uses:</sec_title>
				<para>Chronic lymphocytic leukemia, non-Hodgkin’s lymphoma</para>
			</section>
			<section type="contra" id="sidelem4x2829">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), fetal harm may occur; breastfeeding, children, hepatic disease, renal impairment, hypersensitivity to product or mannitol</para>
				<section type="none" id="sidelem4x2834">
					<section type="none" id="sidelem4x2835">
						<sec_title>Precautions:</sec_title>
						<para> Hyperuricemia, infusion-related reactions, myelosuppression, infection, skin reactions</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2841">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2844">
					<section type="none" id="sidelem4x2845">
						<sec_title>Chronic lymphocytic leukemia</sec_title>
						<section type="none" id="sidelem4x2853">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2853">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis> over 30 min on days 1, 2 q28days up to 6 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2860">
						<sec_title>Non-Hodgkin’s lymphoma</sec_title>
						<section type="none" id="sidelem4x2868">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2868">
									<item>
										<label>•</label>
										<para> 120 mg/m<emphasis style="sup">2</emphasis> over 60 min on days 1, 2 q21days up to 8 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2875">
						<sec_title>Mantle cell lymphoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2883">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2883">
									<item>
										<label>•</label>
										<para> 90 mg/m<emphasis style="sup">2</emphasis> on days 1, 2 with rituximab on day 1 q28days for 6 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2890">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x2898">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION CCr &lt;40 ml/min, do not use; AST or ALT 2.5-10 3 upper limit normal or bilirubin 1.5-3 3 ULN, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2901">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 25, 100 mg; solution for injection 180 mg/2 ml, 45 mg/0.5 ml</para>
					</section>
					<section type="none" id="sidelem4x2906">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2914">
							<label>•</label>
							<sec_title>
								<route>Allopurinol for 1-2 wk to those at high risk for tumor lysis syndrome; usually develops in first treatment cycle</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2917">
								<item>
									<label>•</label>
									<para>Blood transfusions; RBC colony-stimulating factors to counter anemia unless cure is the intent</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2922">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before giving product to prevent vomiting</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2927">
								<item>
									<label>•</label>
									<para>All medications PO; if possible, avoid IM inj if platelets are &lt;100,000/mm<emphasis style="sup">3</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2934">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x2939">
									<item>
										<label>•</label>
										<para>Prepare in biologic cabinet wearing gown, gloves, mask; avoid contact with skin, can cause burning, stain the skin brown; use cytotoxic handling procedures</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x2947">
								<label>•</label>
								<sec_title>
									<route>reconstituting</route>
								</sec_title>
								<para>
									<list id="lidelem4x2947">
										<item>
											<label>•</label>
											<para>After  100 mg product/20 ml or 25 mg/5 ml sterile water for inj (5 mg/ml), sol should be clear, colorless to pale yellow, completely dissolve in 5 min; if particulate is present, do not use</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x2955">
								<label>•</label>
								<sec_title>
									<route>further dilute</route>
								</sec_title>
								<para>
									<list id="lidelem4x2955">
										<item>
											<label>•</label>
											<para>Within 30 min of reconstitution, withdraw volume needed and  in 500 ml NS or D<emphasis style="inf">2.5/0.45</emphasis>%NS to a final concentration of 0.2-0.6 mg/ml; doses of ≤100 mg/m<emphasis style="sup">2</emphasis>,  over 30 min; doses of &gt;100 mg/m<emphasis style="sup">2</emphasis>,  over 60 min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x2975">
									<item>
										<label>•</label>
										<para>Monitor for infusion reactions; may use antihistamines or corticosteroids for grade 1, 2 reactions; if grade 3 or 4 occurs, discontinue if needed</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2980">
									<item>
										<label>•</label>
										<para>Store reconstituted sol in refrigerator for 24 hr or at room temperature for 3 hr; protect from light; store vials at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2985">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2988">
					<section type="none" id="sidelem4x2989">
						<sec_title>CNS:</sec_title>
						<para> Asthenia, <emphasis style="italic">fatigue,</emphasis> fever, <emphasis style="italic">headache,</emphasis> chills, hypertension</para>
					</section>
					<section type="none" id="sidelem4x3000">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">hypertensive crisis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3007">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> hyperbilirubinemia, <emphasis style="italic">constipation,</emphasis> stomatitis, <emphasis style="italic">anorexia</emphasis>, weight loss</para>
					</section>
					<section type="none" id="sidelem4x3021">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3028">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia, lymphocytopenia, neutropenia, secondary malignancy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3035">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Bulbous rash, pruritus,</emphasis> extravasation</para>
					</section>
					<section type="none" id="sidelem4x3043">
						<sec_title>META:</sec_title>
						<para> Hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x3048">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> infection, dehydration, <emphasis style="bold">severe skin toxicities, tumor lysis syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, tumor lysis syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3058">
				<sec_title>Pharmacokinetics</sec_title>
				<para>95% protein binding, metabolized by hydrolysis via CYP450 1A2, 2 metabolites are produced, half-life 40 min, 90% excreted unchanged (feces)</para>
			</section>
			<section type="interactions" id="sidelem4x3063">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: agranulocytosis risk—cloZAPine (do not use concurrently)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—aspirin, anticoagulants, NSAIDs, platelet inhibitors, thrombolytics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—myelosuppressive agents</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—other antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions, decreased antibody reaction—live vaccines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bendamustine—CYP1A2 inhibitors (atazanavir, cimetidine, ciprofloxacin, enoxacin, ethyl estradiol, fluvoxaMINE, mexiletine, norfloxacin, tacrine, thiabendazole, zileuton)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> bendamustine—CYP1A2 inducers (barbiturates, carBAMazepine, rifampin)</para>
				<section type="none" id="sidelem4x3094">
					<section type="none" id="sidelem4x3095">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3102">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3105">
					<section type="none" id="sidelem4x3106">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3114">
							<label>•</label>
							<sec_title>Blood dyscrasias</sec_title>
							<para>
								<list id="lidelem4x3114">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood dyscrasias:</emphasis> CBC, differential, platelet count weekly; withhold product if WBC is &lt;1000 or if platelet count is &lt;75,000; notify prescriber of results</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3118">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3123">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr before, during therapy; I&amp;O ratio; report fall in urine output of 30 or 40 ml/hr; electrolytes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3128">
								<item>
									<label>•</label>
									<para>Monitor for cold, cough, fever (may indicate beginning infection)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3133">
								<item>
									<label>•</label>
									<para>For malignancy regression</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3138">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, petechiae, mucosa, orifices q8hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3146">
							<label>•</label>
							<sec_title>Serious skin toxicities<route> toxic epidermal necrolysis, Stevens-Johnson syndrome; product should be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3152">
							<label>•</label>
							<sec_title>Tumor lysis syndrome<route> monitor uric acid, potassium; may occur during 1st treatment cycle; use allopurinol for patients at high risk for this condition, usually during the 1st 2 wk; provide adequate hydration</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3155">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3159">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in blood counts, morphology</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3165">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3170">
								<item>
									<label>•</label>
									<para>To avoid hazardous activity that requires mental alertness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3175">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with upper respiratory infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3180">
								<item>
									<label>•</label>
									<para>To report immediately fever, sore throat, flulike symptoms; indicates infection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3188">
							<label>•</label>
							<sec_title>
								<route>To report immediately allergic reaction, facial swelling, difficulty breathing, itchy rash</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3191">
								<item>
									<label>•</label>
									<para>Until reaction is known, not to breastfeed; males should also use contraception during and for 3 mo after</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3199">
							<label>•</label>
							<sec_title>
								<route>To use contraception during therapy and for 3 mo after pregnancy (D)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x3205">
							<label>•</label>
							<sec_title>
								<route>To avoid use of aspirin, ibuprofen, razors, commercial mouthwash</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3208">
								<item>
									<label>•</label>
									<para>To report signs of anemia (fatigue, irritability, SOB, faintness)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3216">
							<label>•</label>
							<sec_title>
								<route>To report signs of infection, myelosuppression, skin toxicities, diarrhea, nausea, vomiting</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>benzocaine topical</mono_name>
			<section type="none" id="sidelem4x3222">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="13" status="active" ru="yes">
			<mono_name> benzonatate (Rx)</mono_name>
			<info>
				<pronunciation>(ben-zoe′na-tate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x32331">Tessalon Perles</tradename>
					<tradename id="tnidelem4x32330">Zonatuss</tradename>
				</tradenames>
				<class type="func"> Antitussive, nonopioid</class>
			</info>
			<section type="uses" id="sidelem4x3239">
				<sec_title>Uses:</sec_title>
				<para>Nonproductive cough</para>
			</section>
			<section type="contra" id="sidelem4x3244">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x3249">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3257">
					<label>•</label>
					<sec_title>Adult and child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3257">
							<item>
								<label>•</label>
								<para> 100 mg up to tid; max 600 mg/day</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>benztropine (Rx)</mono_name>
			<info>
				<pronunciation>(benz′troe-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x32660">Cogentin</tradename>
				</tradenames>
				<class type="func"> Cholinergic blocker, antiparkinson’s agent</class>
				<class type="chem"> Tertiary amine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3276">
				<sec_title>Action:</sec_title>
				<para>Blockade of central acetylcholine receptors, balances cholinergic activity</para>
			</section>
			<section type="uses" id="sidelem4x3281">
				<sec_title>Uses:</sec_title>
				<para>Parkinson’s symptoms, EPS associated with neuroleptic products, acute dystonic reactions</para>
				<section type="none" id="sidelem4x3286">
					<section type="none" id="sidelem4x3287">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hypersalivation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3292">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;3 yr, hypersensitivity, closed-angle glaucoma, dementia, tardive dyskinesia</para>
				<section type="none" id="sidelem4x3297">
					<section type="none" id="sidelem4x3298">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, tachycardia, renal/hepatic disease, substance abuse history, dysrhythmias, hypo/hypertension, myasthenia gravis, GI/GU obstruction, peptic ulcer, megacolon, prostate hypertrophy, psychosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3305">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3308">
					<section type="none" id="sidelem4x3309">
						<sec_title>Drug-induced EPS</sec_title>
						<section type="none" id="sidelem4x3317">
							<label>•</label>
							<sec_title>Adult<route> IM/IV/PO</route></sec_title>
							<para>
								<list id="lidelem4x3317">
									<item>
										<label>•</label>
										<para> 1-4 mg daily/bid; give  dose as soon as possible</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3327">
							<label>•</label>
							<sec_title>Child &gt;3 yr<route> IM/IV/PO</route></sec_title>
							<para>
								<list id="lidelem4x3327">
									<item>
										<label>•</label>
										<para> 0.02-0.05 mg/kg/dose 1-2×/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3331">
						<sec_title>Parkinson’s symptoms</sec_title>
						<section type="none" id="sidelem4x3339">
							<label>•</label>
							<sec_title>Adult<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x3339">
									<item>
										<label>•</label>
										<para> 0.5-1 mg at bedtime; increase by 0.5 mg q5-6days titrated to patient response, max 6 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3343">
						<sec_title>Acute dystonic reactions</sec_title>
						<section type="none" id="sidelem4x3351">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x3351">
									<item>
										<label>•</label>
										<para> 1-2 mg, may increase to 1-2 mg bid </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3357">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1, 2 mg; inj 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x3362">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3365">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3369">
									<item>
										<label>•</label>
										<para>With or after meals to prevent GI upset; may give with fluids other than water</para>
									</item>
									<item>
										<label>•</label>
										<para>At bedtime to avoid daytime drowsiness with parkinsonism</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3385">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x3389">
									<item>
										<label>•</label>
										<para>Inject deeply in muscle; use filtered needle to remove solution from ampule</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3395">
							<sec_title>IV, direct route</sec_title>
							<para>
								<list id="lidelem4x3399">
									<item>
										<label>•</label>
										<para>Use in emergencies</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Metoclopramide, perphenazine</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, aminophylline, ascorbic acid injection, atracurium, atropine, azaTHIOprine, aztreonam, bumetanide, buprenorphine, butorphanol, calcium chloride, gluconate, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, clindamycin, cyanocobalamin, cycloSPORINE, dexamethasone, digoxin, diphenhydrAMINE, DOBUTamine, DOPamine, doxycycline, enalaprilat, ePHEDrine, epinephrine, epoetin alfa, erythromycin lactobionate, esmolol, famotidine, fentaNYL, fluconazole, folic acid (as sodium salt), gentamicin, glycopyrrolate, heparin, hydrocortisone sodium succinate, hydrOXYzine, imipenem-cilastatin, inamrinone, insulin (regular), isoproterenol, ketorolac, labetalol, lactated Ringer’s, lidocaine, magnesium sulfate, mannitol, meperidine, metaraminol, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, midazolam, minocycline, morphine, multiple vitamins injection, nafcillin, nalbuphine, naloxone, netilmicin, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxytocin, papaverine, penicillin G potassium/sodium, pentamidine, pentazocine, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, Ringer’s injection, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, theophylline, thiamine, ticarcillin, ticarcillin-clavulanate, tobramycin, tolazoline, urokinase, vancomycin, vasopressin, verapamil</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3413">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3416">
					<section type="none" id="sidelem4x3417">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, restlessness, irritability, delusions, hallucinations, headache, sedation, depression, incoherence, dizziness, memory loss; <emphasis style="italic">confusion;</emphasis> delirium (geriatric patients)</para>
					</section>
					<section type="none" id="sidelem4x3425">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, hypotension, bradycardia</para>
					</section>
					<section type="none" id="sidelem4x3430">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, photophobia, dilated pupils, difficulty swallowing</para>
					</section>
					<section type="none" id="sidelem4x3435">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dryness of mouth, constipation,</emphasis> nausea, vomiting, abdominal distress, <emphasis style="bold">paralytic ileus</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3445">
						<sec_title>GU:</sec_title>
						<para> Urinary hesitancy/retention, dysuria</para>
					</section>
					<section type="none" id="sidelem4x3450">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, dermatoses</para>
					</section>
					<section type="none" id="sidelem4x3455">
						<sec_title>MISC:</sec_title>
						<para> Increased temperature, flushing, decreased sweating, <emphasis style="bold">hyperthermia, heat stroke,</emphasis> numbness of fingers</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3463">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x3466">
					<section type="none" id="sidelem4x3467">
						<sec_title>PO:</sec_title>
						<para> Onset 1 hr, duration 6-10 hr</para>
					</section>
					<section type="none" id="sidelem4x3472">
						<sec_title>IM/IV:</sec_title>
						<para> Onset 15 min, duration 6-10 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3477">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effect—amantadine; antihistamines, phenothiazines, tricyclics, disopyramide, quiNIDine; reduce dose</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—antidiarrheals, antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> anticholinergic effect of—cholinergics</para>
			</section>
			<section type="considerations" id="sidelem4x3494">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3497">
					<section type="none" id="sidelem4x3498">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3506">
							<label>•</label>
							<sec_title>Parkinsonism</sec_title>
							<para>
								<list id="lidelem4x3506">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinsonism:</emphasis> EPS, shuffling gait, muscle rigidity, involuntary movements, loss of balance</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3513">
							<label>•</label>
							<sec_title>Paralytic ileus</sec_title>
							<para>
								<list id="lidelem4x3513">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Paralytic ileus:</emphasis> abdominal pain, intermittent constipation/diarrhea</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3517">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; commonly causes decreased urinary output; urinary hesitancy, retention; palpate bladder if retention occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3522">
								<item>
									<label>•</label>
									<para>Constipation: increase fluids, bulk, exercise if this occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3527">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, CNS depression, worsening of mental symptoms during early therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3532">
								<item>
									<label>•</label>
									<para>Use caution during hot weather; product may increase susceptibility to heat stroke by decreasing sweating</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3537">
								<item>
									<label>•</label>
									<para>With benztropine “buzz” or “high,” patients may imitate EPS</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3542">
								<item>
									<label>•</label>
									<para>Hard candy, gum, frequent drinks to relieve dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3547">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3551">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of involuntary movements after 2 days of treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3557">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3561">
								<item>
									<label>•</label>
									<para>To report urinary hesitancy/retention, dysuria</para>
								</item>
								<item>
									<label>•</label>
									<para>That tabs may be crushed, mixed with food; may take whole dose at bedtime if approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly; to taper off over 1 wk or withdrawal symptoms may occur (EPS, tremors, insomnia, tachycardia, restlessness); to take as directed; not to double dose</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities; drowsiness/dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications: cough, cold preparations with alcohol, antihistamines, antacids, antidiarrheals within 2 hr unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To use good oral hygiene, frequent sips of water, sugarless gum for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>bepotastine</mono_name>
			<info>
				<pronunciation>(beh-pot′uh-steen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x36020">Bepreve</tradename>
				</tradenames>
				<class type="func"> Antihistamine (ophthalmic)</class>
				<class type="chem"> Histamine 1 receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3612">
				<sec_title>Action:</sec_title>
				<para>A topically active, direct H<emphasis style="inf">1</emphasis>-receptor antagonist and mast cell stabilizer; by reducing these inflammatory mediators, relieves the ocular pruritus associated with allergic conjunctivitis</para>
			</section>
			<section type="uses" id="sidelem4x3620">
				<sec_title>Uses:</sec_title>
				<para>Ocular pruritus associated with signs and symptoms of allergic conjunctivitis</para>
			</section>
			<section type="contra" id="sidelem4x3625">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3630">
					<section type="none" id="sidelem4x3631">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, contact lenses</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3636">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3644">
					<label>•</label>
					<sec_title>Adult/Child ≥2 yrs<route> OPHTH</route></sec_title>
					<para>
						<list id="lidelem4x3644">
							<item>
								<label>•</label>
								<para> Instill 1 drop in affected eye bid, max 2 drops/day in each eye</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3648">
					<section type="none" id="sidelem4x3649">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 1.5%</para>
					</section>
					<section type="none" id="sidelem4x3654">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3657">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x3661">
									<item>
										<label>•</label>
										<para>For topical ophthalmic use only</para>
									</item>
									<item>
										<label>•</label>
										<para>Wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger; squeeze the prescribed number of drops into the conjunctival sac and gently close eyes for 1-2 min; do not blink</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>Wait ≥10 min after instilling the ophthalmic solution before inserting contact lenses; contact lenses should not be worn if eye is red; the preservative in this product may be absorbed by soft contact lenses</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not share ophthalmic drops with others</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3689">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3692">
					<section type="none" id="sidelem4x3693">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x3698">
						<sec_title>EENT:</sec_title>
						<para> Taste change, ocular irritation, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x3703">
						<sec_title>SYST:</sec_title>
						<para> Hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3708">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3711">
					<section type="none" id="sidelem4x3712">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3716">
								<item>
									<label>•</label>
									<para>Eyes: for itching, redness, use of soft or hard contact lenses</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3722">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3726">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of redness, itching in the eyes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3732">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x3735">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x3740">
									<item>
										<label>•</label>
										<para>Product is for topical ophthalmic use only</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3745">
									<item>
										<label>•</label>
										<para>Wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger; squeeze the prescribed number of drops into the conjunctival sac and gently close eyes for 1-2 min; do not blink</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3750">
									<item>
										<label>•</label>
										<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3755">
									<item>
										<label>•</label>
										<para>Wait ≥10 min after instilling the ophthalmic solution before inserting contact lenses; contact lenses should not be worn if eye is red</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3760">
									<item>
										<label>•</label>
										<para>Do not share ophthalmic drops with others</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3768">
								<label>•</label>
								<sec_title>
									<route>contact lenses</route>
								</sec_title>
								<para>
									<list id="lidelem4x3768">
										<item>
											<label>•</label>
											<para>Remove  before use because the preservative, benzalkonium chloride, may be absorbed by soft contact lenses; product should not be used to treat contact lens–related irritation</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active" ru="yes">
			<mono_name> beractant (Rx)</mono_name>
			<info>
				<pronunciation>(ber-ak′tant)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x37800">Survanta</tradename>
				</tradenames>
				<class type="func"> Natural lung surfactant</class>
			</info>
			<section type="uses" id="sidelem4x3786">
				<sec_title>Uses:</sec_title>
				<para>Prevention and treatment (rescue) of respiratory distress syndrome in premature infants</para>
			</section>
			<section type="doses" id="sidelem4x3791">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3799">
					<label>•</label>
					<sec_title>Newborn<route> INTRATRACHEAL INSTILL</route></sec_title>
					<para>
						<list id="lidelem4x3799">
							<item>
								<label>•</label>
								<para> 4 doses can be administered during the 1st 48 hr of life; give doses no more frequently than q6hr; each dose is 100 mg of phospholipids/kg birth weight</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>betamethasone (topical)</mono_name>
			<info>
				<pronunciation>(bay-ta-meth′a-sone)</pronunciation>
			</info>
		</monograph>
<monograph id="18" status="active">
			<mono_name>betamethasone dipropionate</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x38111">Diprolene</tradename>
					<tradename id="tnidelem4x38110">Diprolene AF</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="19" status="active">
			<mono_name>betamethasone augmented dipropionate</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x38160"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="20" status="active">
			<mono_name>betamethasone valerate</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x38201">Beta-Val</tradename>
					<tradename id="tnidelem4x38200">Luxiq</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, topical</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3826">
				<sec_title>Action:</sec_title>
				<para>Crosses cell membrane to attach to receptors to decrease inflammation, itching; inhibits multiple inflammatory cytokines</para>
			</section>
			<section type="uses" id="sidelem4x3831">
				<sec_title>Uses:</sec_title>
				<para>Inflammation/itching corticosteroid-responsive dermatoses on the skin/scalp</para>
			</section>
			<section type="contra" id="sidelem4x3836">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, use of some preparations on face, axilla, groin</para>
				<section type="none" id="sidelem4x3841">
					<section type="none" id="sidelem4x3842">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), skin infections</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3847">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3855">
					<label>•</label>
					<sec_title>Adult<route> TOP</route></sec_title>
					<para>
						<list id="lidelem4x3855">
							<item>
								<label>•</label>
								<para> 1-2 times/day (dipropionate) or 1-3 times/day (valerate)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3860">
					<section type="none" id="sidelem4x3861">
						<sec_title>Available forms:</sec_title>
						<para> dipropionate: gel, lotion, ointment, cream 0.05%; valerate: cream, lotion, ointment 0.1%, foam 0.12%</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3866">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3869">
					<section type="none" id="sidelem4x3870">
						<sec_title>INTEG:</sec_title>
						<para> Burning, folliculitis, pruritus, dermatitis, maceration, erythema</para>
					</section>
					<section type="none" id="sidelem4x3875">
						<sec_title>MISC:</sec_title>
						<para> Hyperglycemia; glycosuria, Cushing syndrome, HPA axis suppression</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3880">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Unknown</para>
			</section>
			<section type="considerations" id="sidelem4x3885">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3888">
					<section type="none" id="sidelem4x3889">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3897">
							<label>•</label>
							<sec_title>Skin reactions</sec_title>
							<para>
								<list id="lidelem4x3897">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Skin reactions:</emphasis> burning pruritus, folliculitis, dermatitis</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3901">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3905">
								<item>
									<label>•</label>
									<para>Decreased itching, inflammation on the skin, scalp</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3911">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x3914">
							<sec_title>Topical route:</sec_title>
							<section type="none" id="sidelem4x3922">
								<label>•</label>
								<sec_title>
									<route>not to use dipropionate with occlusive dressings</route>
								</sec_title>
								<para>
									<list id="lidelem4x3922">
										<item>
											<label>•</label>
											<para>That betamethasone valerate may be used with occlusive dressings for psoriasis or recalcitrant conditions; </para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3926">
							<sec_title>Cream/ointment/lotion:</sec_title>
							<para>
								<list id="lidelem4x3930">
									<item>
										<label>•</label>
										<para>To apply sparingly in a thin film, using gloves, and rub gently into the cleansed, slightly moist affected area</para>
									</item>
									<item>
										<label>•</label>
										<para>Not to use on broken, wet skin, area of infection, face, or groin, axilla</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3941">
							<sec_title>Gel:</sec_title>
							<para>
								<list id="lidelem4x3945">
									<item>
										<label>•</label>
										<para>To apply sparingly in a thin film, using gloves, and rub gently into the cleansed, slightly moist affected area</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3951">
							<sec_title>Scalp foam:</sec_title>
							<para>
								<list id="lidelem4x3955">
									<item>
										<label>•</label>
										<para>To invert can and dispense a small amount of foam onto a saucer or other cool surface; not to dispense directly onto hands; to pick up small amounts of foam with fingers and gently massage into affected area until foam disappears; repeat until entire affected scalp area is treated</para>
									</item>
									<item>
										<label>•</label>
										<para>That treatment should be limited to 2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>betamethasone (augmented) topical</mono_name>
			<section type="none" id="sidelem4x3969">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>betaxolol (ophthalmic)</mono_name>
			<info>
				<pronunciation>(beh-tax′oh-lol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x39781">Betoptic-S</tradename>
					<tradename id="tnidelem4x39780">Kerlone</tradename>
				</tradenames>
				<class type="func"> Antiglaucoma</class>
				<class type="chem"> β-Blocker</class>
			</info>
			<section type="actions" id="sidelem4x3988">
				<sec_title>Action:</sec_title>
				<para>Can decrease aqueous humor and increase outflows</para>
			</section>
			<section type="uses" id="sidelem4x3993">
				<sec_title>Uses:</sec_title>
				<para>Treatment of chronic open-angle glaucoma and ocular hypertension; <emphasis style="bold">PO</emphasis> for hypertension</para>
			</section>
			<section type="contra" id="sidelem4x4001">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, AV block, heart failure, bradycardia, sick sinus syndrome</para>
				<section type="none" id="sidelem4x4006">
					<section type="none" id="sidelem4x4007">
						<sec_title>Precautions:</sec_title>
						<para> Abrupt discontinuation, children, pregnancy, breastfeeding, asthma, COPD, depression, diabetes mellitus, myasthenia gravis, hyperthyroidism, pulmonary disease, angle-closure glaucoma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4012">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4015">
					<section type="none" id="sidelem4x4016">
						<sec_title>Chronic open-angle glaucoma</sec_title>
						<section type="none" id="sidelem4x4024">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x4024">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> Instill 1-2 drops in the affected eye(s) bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4028">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic sol 0.5%; ophthalmic susp 0.25%, tabs 10, 20 mg</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4033">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4036">
					<section type="none" id="sidelem4x4037">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x4042">
						<sec_title>CV:</sec_title>
						<para> Palpitations</para>
					</section>
					<section type="none" id="sidelem4x4047">
						<sec_title>EENT:</sec_title>
						<para> Eye stinging/burning, tearing, photophobia</para>
					</section>
					<section type="none" id="sidelem4x4052">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4059">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4062">
					<section type="none" id="sidelem4x4063">
						<sec_title>Ophthalmic: </sec_title>
						<para>Onset 30 min, peak 2 hr, duration ≥12 hr</para>
					</section>
					<section type="none" id="sidelem4x4068">
						<sec_title>PO: </sec_title>
						<para>Peak 3 hr</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4074">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4077">
					<section type="none" id="sidelem4x4078">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4084">
								<item>
									<para>
										<emphasis alert="nurse">Systemic absorption: When used in the eye, systemic absorption is common, with the same adverse reactions and interactions</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4089">
								<item>
									<label>•</label>
									<para>Glaucoma: monitor intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4094">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4098">
								<item>
									<label>•</label>
									<para>Decreasing intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4104">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4108">
								<item>
									<label>•</label>
									<para>That strength is expressed in betaxolol base</para>
								</item>
								<item>
									<label>•</label>
									<para>That drug for ophthalmic use only; shake the ophthalmic suspension well before use</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>To wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch; close eyes to spread drops; to avoid excessive systemic absorption, apply finger pressure on the lacrimal sac for 1-2 min following use</para>
								</item>
								<item>
									<label>•</label>
									<para>That if more than one topical ophthalmic drug product is being used, the drugs should be administered at least 5 min apart</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid contamination or the spread of infection, do not use dropper for more than one person</para>
								</item>
								<item>
									<label>•</label>
									<para>To report symptoms of heart failure (PO)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>bethanechol (Rx)</mono_name>
			<info>
				<pronunciation>(be-than′e-kole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41490">Urecholine</tradename>
				</tradenames>
				<class type="func"> Urinary tract stimulant, cholinergic</class>
				<class type="chem"> Synthetic choline ester</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4159">
				<sec_title>Action:</sec_title>
				<para>Stimulates muscarinic ACH receptors directly; mimics effects of parasympathetic nervous system stimulation; stimulates gastric motility, micturition; increases lower esophageal sphincter pressure</para>
			</section>
			<section type="uses" id="sidelem4x4165">
				<sec_title>Uses:</sec_title>
				<para>Urinary retention (postoperative, postpartum), neurogenic atony of bladder with retention</para>
				<section type="none" id="sidelem4x4170">
					<section type="none" id="sidelem4x4171">
						<sec_title>Unlabeled uses:</sec_title>
						<para>Ileus, GERD, anticholinergic syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4176">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe bradycardia, asthma, severe hypotension, hyperthyroidism, peptic ulcer, parkinsonism, seizure disorders, CAD, COPD, coronary occlusion, mechanical obstruction, peritonitis, recent urinary/GI surgery, GI/GU obstruction</para>
				<section type="none" id="sidelem4x4181">
					<section type="none" id="sidelem4x4182">
						<sec_title>Precautions:</sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;8 yr, hypertension</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4187">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4195">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4195">
							<item>
								<label>•</label>
								<para> 10-50 mg bid-qid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4202">
					<label>•</label>
					<sec_title>Child (unlabeled)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4202">
							<item>
								<label>•</label>
								<para> 0.6 mg/kg/day in 3-4 divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4206">
					<section type="none" id="sidelem4x4207">
						<sec_title>Ileus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4215">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4215">
									<item>
										<label>•</label>
										<para> 10-20 mg tid-qid before meals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4219">
						<sec_title>Available forms:</sec_title>
						<para>Tabs 5, 10, 25, 50 mg</para>
					</section>
					<section type="none" id="sidelem4x4224">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4228">
								<item>
									<label>•</label>
									<para>To avoid nausea, vomiting, take on an empty stomach</para>
								</item>
								<item>
									<label>•</label>
									<para>Only after all other cholinergics have been discontinued</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4244">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4247">
					<section type="none" id="sidelem4x4248">
						<sec_title>CNS:</sec_title>
						<para>Dizziness, headache, malaise</para>
					</section>
					<section type="none" id="sidelem4x4253">
						<sec_title>CV:</sec_title>
						<para>Hypotension, bradycardia, reflex tachycardia, <emphasis style="bold">cardiac arrest, circulatory collapse</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4260">
						<sec_title>EENT:</sec_title>
						<para>Miosis, increased salivation, lacrimation, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x4265">
						<sec_title>GI:</sec_title>
						<para>
							<emphasis style="italic">Nausea, bloody diarrhea, belching, vomiting, cramps, fecal incontinence</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4271">
						<sec_title>GU:</sec_title>
						<para>Urgency</para>
					</section>
					<section type="none" id="sidelem4x4276">
						<sec_title>INTEG:</sec_title>
						<para>Rash, urticaria, flushing, increased sweating</para>
					</section>
					<section type="none" id="sidelem4x4281">
						<sec_title>RESP:</sec_title>
						<para>
							<emphasis alert="lifethreat">Acute asthma, dyspnea, bronchoconstriction</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4287">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4290">
					<section type="none" id="sidelem4x4291">
						<sec_title>PO:</sec_title>
						<para>Onset 30-90 min, duration 6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4296">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypotension—ganglionic blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action or toxicity—cholinergic agonists, anticholinesterase agents</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of anticholinergics, procainamide, quiNIDine</para>
				<section type="none" id="sidelem4x4311">
					<section type="none" id="sidelem4x4312">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, lipase/amylase, bilirubin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4319">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4322">
					<section type="none" id="sidelem4x4323">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4331">
							<label>•</label>
							<sec_title>Urinary patterns</sec_title>
							<para>
								<list id="lidelem4x4331">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urinary patterns:</emphasis> retention, urgency</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4335">
								<item>
									<label>•</label>
									<para>B/P, pulse: observe after parenteral dose for 1 hr; may need to use atropine subcut 0.6 mg or IV push slowly for bronchoconstriction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4340">
								<item>
									<label>•</label>
									<para>I&amp;O ratio: check for urinary retention, urge incontinence</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4348">
							<label>•</label>
							<sec_title>Toxicity<route> bradycardia, hypotension, bronchospasm, headache, dizziness, seizures, respiratory depression; product should be discontinued if toxicity occurs</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4351">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4355">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of urinary retention, abdominal distention</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4361">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4365">
								<item>
									<label>•</label>
									<para>To take product exactly as prescribed; 1 hr before meals or 2 hr after meals</para>
								</item>
								<item>
									<label>•</label>
									<para>To make position changes slowly; orthostatic hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, hazardous activities until effects are known</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x4381">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Administer atropine 0.6-1.2 mg IV or IM (adult)</para>
			</section>
		</monograph>
<monograph id="24" status="active" ha="yes">
			<mono_name> bevacizumab (Rx)</mono_name>
			<info>
				<pronunciation>(beh-va-kiz′you-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x43930">Avastin</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Monoclonal antibody</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4403">
				<para>
					<confusion>
						<tradename id="tnidelem4x44030">Avastin</tradename>
						<drug type="generic" refid="idelem4x44030">Astelin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4407">
				<sec_title>Action:</sec_title>
				<para>Monoclonal antibody selectively binds to and inhibits activity of human vascular endothelial growth factor (VEGF) to reduce microvascular growth and metastatic disease progression</para>
			</section>
			<section type="uses" id="sidelem4x4412">
				<sec_title>Uses:</sec_title>
				<para>Non–small-cell lung cancer (NSCLC), metastatic carcinoma of the colon or rectum, renal cell carcinoma, glioblastoma</para>
				<section type="none" id="sidelem4x4417">
					<section type="none" id="sidelem4x4418">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Adjunctive for ovarian cancer; (wet) macular degeneration</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4423">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, serious bleeding, hypertensive crisis, recent surgery</para>
				<section type="none" id="sidelem4x4428">
					<section type="none" id="sidelem4x4429">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, blood dyscrasias, CV disease, hypertension, surgery, thromboembolic disease, hamster protein/murine hypersensitivity</para>
						<para>
							<bbw>GI perforation, wound dehiscence, bleeding</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4444">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4447">
					<section type="none" id="sidelem4x4448">
						<sec_title>Non–small-cell lung cancer</sec_title>
						<section type="none" id="sidelem4x4456">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4456">
									<item>
										<label>•</label>
										<para> 15 mg/kg over 60-90 min with CARBOplatin and paclitaxel q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4460">
						<sec_title>Metastatic colorectal cancer</sec_title>
						<section type="none" id="sidelem4x4468">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x4468">
									<item>
										<label>•</label>
										<para> in combination with 5-fluorouracil 5-10 mg/kg q14days given over 90 min; if well tolerated, next infusion may be given over 60 min; if 60-min infusion well tolerated, subsequent infusion may be given over 30 min; (second line) 5 mg/kg q2wk or 7.5 mg/kg q3wk with fluoropyrimidine and irinotecan or fluoropyramide and oxaliplatin-based agent</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4472">
						<sec_title>Metastatic cervical cancer</sec_title>
						<section type="none" id="sidelem4x4480">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4480">
									<item>
										<label>•</label>
										<para> 15 mg/kg q3wk with paclitaxel and Cisplatin or paclitaxel and topotecan</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4484">
						<sec_title>Metastatic renal cell carcinoma</sec_title>
						<section type="none" id="sidelem4x4492">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4492">
									<item>
										<label>•</label>
										<para> 10 mg/kg q2wk with interferon alfa 9 million units SUBCUT 3×/wk up to 52 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4496">
						<sec_title>Glioblastoma single agent</sec_title>
						<section type="none" id="sidelem4x4504">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4504">
									<item>
										<label>•</label>
										<para> 10 mg/kg q2wk given over 60-90 min; 28-day cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4509">
						<sec_title>Metastatic breast cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4517">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4517">
									<item>
										<label>•</label>
										<para> 15 mg/kg on day 1 with docetaxel 100 mg/m<emphasis style="sup">2</emphasis> q3wk, up to 9 cycles (those who have not received previous chemotherapy)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4524">
						<sec_title>Metastatic renal cell cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4532">
							<label>•</label>
							<sec_title>Adult (single agent)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4532">
									<item>
										<label>•</label>
										<para> 10 mg/kg over 60-90 min q2wk; may be given in combination with other products</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4536">
						<sec_title>Ovarian cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4544">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4544">
									<item>
										<label>•</label>
										<para> 15 mg/kg q21days until unacceptable toxicity, disease progression</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4548">
						<sec_title>Neovascular (wet) macular degeneration (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4556">
							<label>•</label>
							<sec_title>Adult<route> INTRAVITREOUS INJ</route></sec_title>
							<para>
								<list id="lidelem4x4556">
									<item>
										<label>•</label>
										<para> 1.25 mg monthly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4560">
						<sec_title>Available forms:</sec_title>
						<para> Inj 25 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x4565">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4568">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4573">
									<item>
										<label>•</label>
										<para>Do not give by IV bolus, IV push; do not shake vial</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4581">
								<para>
									<list id="lidelem4x4581">
										<item>
											<label>•</label>
											<para>Withdraw amount of product to be given, dilute in 100 ml 0.9% NaCl, discard any unused portion
<bbw>
													<emphasis alert="lifethreat">Wound dehiscence:</emphasis> do not give for ≥28 days after surgery; make sure wound is healed before giving product</bbw>
</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x4594">
									<item>
										<label>•</label>
										<para>Give as IV infusion over 90 min for 1st dose and 60 min thereafter if well tolerated; subsequent infusion may be given over 30 min; do not admix with dextrose</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4602">
								<label>•</label>
								<sec_title>Rapid infusion rate (unlabeled)</sec_title>
								<para>
									<list id="lidelem4x4602">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Rapid infusion rate (unlabeled):</emphasis> give at rate of 0.5 mg/kg/min for all doses including initial infusion (5 mg/kg over 10 min; 10 mg/kg over 20 min; 15 mg/kg over 30 min)</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4606">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4609">
					<section type="none" id="sidelem4x4610">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Asthenia, dizziness,</emphasis><emphasis style="bold">intracranial hemorrhage</emphasis> (malignant glioma), headache, fatigue, confusion, weakness</para>
					</section>
					<section type="none" id="sidelem4x4620">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Deep vein thrombosis,</emphasis> arterial thrombosis, hypo/hypertension, <emphasis style="bold">hypertensive crisis,</emphasis> heart failure</para>
					</section>
					<section type="none" id="sidelem4x4631">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, <emphasis style="italic">anorexia, diarrhea,</emphasis> constipation, <emphasis style="italic">abdominal pain,</emphasis> colitis, taste change, dyspepsia, stomatitis, <emphasis style="bold">GI hemorrhage/perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4644">
						<sec_title>GU:</sec_title>
						<para> Proteinuria, urinary frequency/urgency, <emphasis style="bold">nephrotic syndrome,</emphasis> ovarian failure</para>
					</section>
					<section type="none" id="sidelem4x4652">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, neutropenia, thrombocytopenia, microangiopathic hemolytic anemia, thromboembolism, bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4659">
						<sec_title>META:</sec_title>
						<para> Bilirubinemia, hypokalemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x4664">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Exfoliative dermatitis, hemorrhage,</emphasis> non-GI fistula formation, <emphasis style="italic">alopecia, impaired wound healing,</emphasis><emphasis style="bold">osteonecrosis of the jaw,</emphasis> antibody formation, back pain myalgia</para>
					</section>
					<section type="none" id="sidelem4x4677">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, upper respiratory tract infection</para>
					</section>
					<section type="none" id="sidelem4x4682">
						<sec_title>INTEG:</sec_title>
						<para> Skin discoloration, infusion reactions</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4687">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 20 days, steady state 100 days</para>
			</section>
			<section type="interactions" id="sidelem4x4692">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x4700">
					<label>•</label>
					<sec_title>
						<route>Avoid concurrent use with SUNItinib; microangiopathic hemolytic anemia may occur</route>
					</sec_title>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4703">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4706">
					<section type="none" id="sidelem4x4707">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4712">
								<item>
									<label>•</label>
									<para>B/P; take frequently if hypertension develops</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4717">
								<item>
									<label>•</label>
									<para>For symptoms of infection; may be masked by product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4725">
							<label>•</label>
							<sec_title>CNS reaction</sec_title>
							<para>
								<list id="lidelem4x4725">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS reaction:</emphasis> dizziness, confusion</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4732">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x4732">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> crackles, jugular venous distention, dyspnea during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4737">
								<item>
									<para>
										<emphasis alert="nurse">GU status (proteinuria): nephrotic syndrome may occur; monitor urinalysis for increasing protein level; product should be held if protein ≥2 g/24 hr; resume when &lt;2 g/24 hr</emphasis>
<bbw>
											<emphasis alert="lifethreat">Wound dehiscence:</emphasis> Hold for ≥28 days until incision is healed</bbw>

<bbw>
											<emphasis alert="lifethreat">GI perforation, serious bleeding, nephrotic syndrome, hypertensive crisis;</emphasis> product should be discontinued permanently, surgery should be postponed</bbw>

<bbw>
											<emphasis alert="lifethreat">Bleeding:</emphasis> if severe, discontinue product, occurs primarily in small-cell lung cancer</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4779">
							<label>•</label>
							<sec_title>Pregnancy/Breastfeeding<route> Drug may lead to fetal harm, avoid pregnancy, do not breastfeed</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4785">
							<label>•</label>
							<sec_title>Reversible posterior leukoencephalopathy syndrome (RPLS)<route> discontinue if this disorder develops</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4788">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4792">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size of tumors</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4798">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4803">
								<item>
									<label>•</label>
									<para>To avoid hazardous tasks because confusion, dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4808">
								<item>
									<label>•</label>
									<para>To report signs of infection: sore throat, fever, diarrhea, vomiting</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4813">
								<item>
									<label>•</label>
									<para>To report bleeding, changes in urinary patterns, edema, abdominal pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4818">
								<item>
									<label>•</label>
									<para>To avoid immunizations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4823">
								<item>
									<label>•</label>
									<para>Need to discontinue a month before surgery and not restarted until wound is healed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4831">
							<label>•</label>
							<sec_title>Pregnancy/Breastfeeding<route> Fetal harm may occur, do not breastfeed, not to become pregnant while taking this product or for several months after discontinuing treatment</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>bimatoprost (ophthalmic/topical)</mono_name>
			<info>
				<pronunciation>(by-mat′oh-prost)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x48391">Latisse</tradename>
					<tradename id="tnidelem4x48390">Lumigan</tradename>
				</tradenames>
				<class type="func"> Antiglaucoma agent</class>
				<class type="chem"> Prostaglandin agonist</class>
			</info>
			<section type="confusion" id="sidelem4x4849">
				<para>
					<confusion>
						<tradename id="tnidelem4x48490">latanoprost/</tradename>
						<drug type="generic" refid="idelem4x48490"/>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4853">
				<sec_title>Action:</sec_title>
				<para/>
				<section type="none" id="sidelem4x4857">
					<sec_title>
						<emphasis style="italic">Latisse</emphasis>
					</sec_title>
					<para>
						<emphasis style="bold">Promotion of eyelash growth, thickness, and darkness</emphasis>: unknown; possible increase in the percent of hairs and an increase in the duration of the hair growth (anagen) phase</para>
				</section>
				<section type="none" id="sidelem4x4865">
					<sec_title>
						<emphasis style="italic">Lumigan</emphasis>
					</sec_title>
					<para>
						<emphasis style="bold">Reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma;</emphasis> selectively mimics endogenous prostamides to produce ocular hypotension</para>
				</section>
			</section>
			<section type="uses" id="sidelem4x4873">
				<sec_title>Uses:</sec_title>
				<para>Increased intraocular pressure in those with open-angle glaucoma/ocular hypertension (Lumigan); eyelash hypotrichosis (Latisse)</para>
			</section>
			<section type="contra" id="sidelem4x4878">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, benzalkonium chloride</para>
				<section type="none" id="sidelem4x4883">
					<section type="none" id="sidelem4x4884">
						<sec_title>Precautions:</sec_title>
						<para> Children, intraocular inflammation, closed-angle glaucoma, macular edema, contact lenses, ocular infection, surgery, trauma; corneal abrasion, iritis, urethritis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4889">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4892">
					<section type="none" id="sidelem4x4893">
						<sec_title>Increased intraocular pressure/ocular hypertension (Lumigan)</sec_title>
						<section type="none" id="sidelem4x4901">
							<label>•</label>
							<sec_title>Adult<route> OPHTH Instill</route></sec_title>
							<para>
								<list id="lidelem4x4901">
									<item>
										<label>•</label>
										<para> 1 drop in each affected eye (conjunctival sac) every night</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4905">
						<sec_title>Eyelash hypotrichosis (Latisse)</sec_title>
						<section type="none" id="sidelem4x4913">
							<label>•</label>
							<sec_title>Adult<route> Apply</route></sec_title>
							<para>
								<list id="lidelem4x4913">
									<item>
										<label>•</label>
										<para> 1 drop to skin of upper eyelid margin at base of eyelashes every night using a new supplied disposable sterile applicator</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4917">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.01%; topical solution 0.03%</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4922">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4925">
					<section type="none" id="sidelem4x4926">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Conjunctival hyperemia, growth of eyelashes (hypertrichosis), ocular pigment changes ocular pruritus</emphasis>, xerophthalmia, visual disturbance, ocular irritation/burning, foreign body sensation, ocular pain, blepharitis, cataracts, superficial punctate keratitis</para>
					</section>
					<section type="none" id="sidelem4x4934">
						<sec_title>INTEG:</sec_title>
						<para> Hyperpigmentation of the periocular skin, eyelash darkening, lacrimation, photophobia, conjunctivitis, asthenopia, iritis, macular edema</para>
					</section>
					<section type="none" id="sidelem4x4939">
						<sec_title>MISC:</sec_title>
						<para> Influenza, upper respiratory tract infections, asthenia, headache, hirsutism</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4944">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Ophthalmic: Onset 4 hr, peak 8-12 hr; half-life 45 min</para>
			</section>
			<section type="interactions" id="sidelem4x4950">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> Intraocular pressure–lowering effect—latanoprost, travoprost (no longer available in the U.S.)</para>
				<section type="none" id="sidelem4x4957">
					<section type="none" id="sidelem4x4958">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4965">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4968">
					<section type="none" id="sidelem4x4969">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4977">
							<label>•</label>
							<sec_title>Intraocular pressure</sec_title>
							<para>
								<list id="lidelem4x4977">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Intraocular pressure:</emphasis> in those with ongoing increased IOP or those using latanoprost, travoprost (no longer available in the U.S.)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4981">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4985">
								<item>
									<label>•</label>
									<para>Decreasing IOP or increased growth of eyelashes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4991">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x4994">
							<sec_title>Ophthalmic route (Lumigan):</sec_title>
							<para>
								<list id="lidelem4x4998">
									<item>
										<label>•</label>
										<para>To wash hands before and after use; remove contact lenses before use and reinsert 15 min after use; Lumigan contains benzalkonium chloride, which can be absorbed by soft contact lenses</para>
									</item>
									<item>
										<label>•</label>
										<para>To tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch and gently close the eyes for 1-2 min; do not blink; to avoid contamination, do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>That the solution may be used concomitantly with other topical ophthalmic drug products to lower IOP; if more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 min apart</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5014">
							<sec_title>Topical route (Latisse):</sec_title>
							<para>
								<list id="lidelem4x5018">
									<item>
										<label>•</label>
										<para>To ensure the patient’s face is clean and makeup is removed before using Latisse; the disposable sterile applicator is the only applicator that should be used; each applicator should be used for 1 eye only; dispose of the applicator after each use; after applying 1 drop of solution to the applicator, apply evenly along the skin of the upper eyelid margin at the base of the eyelashes; blot excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth; do not apply to the lower eyelash line</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>bisacodyl (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(bis-a-koe′dill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50327">
						<country code="CAN">Carter’s Little Pills</country>
					</tradename>
					<tradename id="tnidelem4x50326">
						<country code="CAN">Codulax</country>
					</tradename>
					<tradename id="tnidelem4x50325">Dacodyl</tradename>
					<tradename id="tnidelem4x50324">Doxidan</tradename>
					<tradename id="tnidelem4x50323">Dulcolax</tradename>
					<tradename id="tnidelem4x50322">Ex-Lax Ultra</tradename>
					<tradename id="tnidelem4x50321">Femilax</tradename>
					<tradename id="tnidelem4x50320">
						<country code="CAN">Soflax-Ex</country>
					</tradename>
				</tradenames>
				<class type="func"> Laxative, stimulant</class>
				<class type="chem"> Diphenylmethane</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5050">
				<sec_title>Action:</sec_title>
				<para>Acts directly on intestine by increasing motor activity; thought to irritate colonic intramural plexus</para>
			</section>
			<section type="uses" id="sidelem4x5055">
				<sec_title>Uses:</sec_title>
				<para>Short-term treatment of constipation; bowel or rectal preparation for surgery, examination</para>
			</section>
			<section type="contra" id="sidelem4x5060">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, abdominal pain, nausea, vomiting, appendicitis, acute surgical abdomen, ulcerated hemorrhoids, acute hepatitis, fecal impaction, intestinal/biliary tract obstruction</para>
				<section type="none" id="sidelem4x5065">
					<section type="none" id="sidelem4x5066">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, rectal fissures, severe CV disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5071">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5079">
					<label>•</label>
					<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5079">
							<item>
								<label>•</label>
								<para> 5-15 mg in <emphasis style="smallcaps">pm</emphasis> or <emphasis style="smallcaps">am</emphasis>; may use up to 30 mg for bowel or rectal preparation;  10 mg as a single dose; 30-ml enema</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5095">
					<label>•</label>
					<sec_title>Child 3-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5095">
							<item>
								<label>•</label>
								<para> 5-10 mg as a single dose;  5-10 mg as a single dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5102">
					<section type="none" id="sidelem4x5103">
						<sec_title>Available forms:</sec_title>
						<para> Tabs del rel 5, 10 mg; enteric-coated tabs 5 mg; supp 5, 10 mg; enema 10 mg/30 ml</para>
					</section>
					<section type="none" id="sidelem4x5108">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5111">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5115">
									<item>
										<label>•</label>
										<para>Swallow tabs whole with full glass of water; do not break, crush, chew tabs</para>
									</item>
									<item>
										<label>•</label>
										<para>Alone only with water for better absorption; do not take within 1 hr of other products or within 1 hr of antacids, milk, H<emphasis style="inf">2</emphasis> antagonists; do not take enteric product with proton-pump inhibitors</para>
									</item>
									<item>
										<label>•</label>
										<para>In <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5139">
							<sec_title>Rectal route</sec_title>
							<para>
								<list id="lidelem4x5143">
									<item>
										<label>•</label>
										<para>Insert high in rectum</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5150">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5153">
					<section type="none" id="sidelem4x5154">
						<sec_title>CNS:</sec_title>
						<para> Muscle weakness</para>
					</section>
					<section type="none" id="sidelem4x5159">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, cramps,</emphasis> diarrhea, rectal burning (suppositories)</para>
					</section>
					<section type="none" id="sidelem4x5167">
						<sec_title>META:</sec_title>
						<para> Protein-losing enteropathy, alkalosis, hypokalemia, <emphasis style="bold">tetany;</emphasis> electrolyte, fluid imbalances</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5175">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Small amounts absorbed/metabolized by liver; excreted in urine, bile, feces, breast milk</para>
				<section type="none" id="sidelem4x5180">
					<section type="none" id="sidelem4x5181">
						<sec_title>PO:</sec_title>
						<para> Onset 6-10 hr</para>
					</section>
					<section type="none" id="sidelem4x5186">
						<sec_title>RECT:</sec_title>
						<para> Onset 15-60 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5191">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> gastric irritation—antacids, milk, H<emphasis style="inf">2</emphasis>-blockers, gastric acid pump inhibitors</para>
				<section type="none" id="sidelem4x5201">
					<section type="none" id="sidelem4x5202">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x5206">
								<item>
									<label>•</label>
									<para>Increase irritation—dairy products separate by 2 hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5212">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> Sodium phosphate</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Calcium, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5223">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5226">
					<section type="none" id="sidelem4x5227">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5232">
								<item>
									<label>•</label>
									<para>Blood, urine electrolytes if product is used often by patient</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5237">
								<item>
									<label>•</label>
									<para>I&amp;O ratio to identify fluid loss</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5242">
								<item>
									<label>•</label>
									<para>Cause of constipation; identify whether fluids, bulk, exercise missing from lifestyle; determine use of constipating products</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5250">
							<label>•</label>
							<sec_title>GI symptoms</sec_title>
							<para>
								<list id="lidelem4x5250">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI symptoms:</emphasis> cramping, rectal bleeding, nausea, vomiting; if these symptoms occur, product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5254">
								<item>
									<label>•</label>
									<para>Multiple products/routes may be used for bowel prep</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5259">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5263">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5269">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5273">
								<item>
									<label>•</label>
									<para>Not to use laxatives for long-term therapy because bowel tone will be lost; 1-wk use is usually sufficient</para>
								</item>
								<item>
									<label>•</label>
									<para>That normal bowel movements do not always occur daily</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use in presence of abdominal pain, nausea, vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if constipation is unrelieved or if symptoms of electrolyte imbalance occur: muscle cramps, pain, weakness, dizziness</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with a full glass of water; not to take with dairy products, separate by 1 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Identify bulk, water, constipating products, exercise in patient’s life</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>bismuth subsalicylate (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(bis′muth sub-sal-iss′uh-late)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x53128">Bismatrol</tradename>
					<tradename id="tnidelem4x53127">
						<country code="CAN">Bismed</country>
					</tradename>
					<tradename id="tnidelem4x53126">
						<country code="CAN">Bismylate</country>
					</tradename>
					<tradename id="tnidelem4x53125">Kaopectate</tradename>
					<tradename id="tnidelem4x53124">Kao-Tin</tradename>
					<tradename id="tnidelem4x53123">Peptic Relief</tradename>
					<tradename id="tnidelem4x53122">Pepto-Bismol</tradename>
					<tradename id="tnidelem4x53121">Pink Bismuth</tradename>
					<tradename id="tnidelem4x53120">
						<country code="CAN">Stomak-care</country>
					</tradename>
				</tradenames>
				<class type="func"> Antidiarrheal, weak antacid</class>
				<class type="chem"> Salicylate</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5330">
				<para>
					<confusion>
						<tradename id="tnidelem4x53300">Kaopectate</tradename>
						<drug type="generic" refid="idelem4x53300">Kayoxalate</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5334">
				<sec_title>Action:</sec_title>
				<para>Inhibits the prostaglandin synthesis responsible for GI hypermotility, intestinal inflammation; stimulates absorption of fluid and electrolytes; binds toxins produced by <emphasis style="italic">Escherichia coli</emphasis></para>
			</section>
			<section type="uses" id="sidelem4x5341">
				<sec_title>Uses:</sec_title>
				<para>Diarrhea (cause undetermined), prevention of diarrhea when traveling; may be included to treat <emphasis style="italic">Helicobacter pylori,</emphasis> heartburn, indigestion, nausea</para>
				<section type="none" id="sidelem4x5349">
					<section type="none" id="sidelem4x5350">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Traveler’s diarrhea, gastric/duodenal ulcer, <emphasis style="italic">H. pylori</emphasis> eradication</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5358">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;3 yr, children with chickenpox, history of GI bleeding, flulike symptoms, hypersensitivity to product or salicylates, PUD</para>
				<section type="none" id="sidelem4x5363">
					<section type="none" id="sidelem4x5364">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, gout, diabetes mellitus, bleeding disorders, previous hypersensitivity to NSAIDs, <emphasis style="italic">Clostridium-difficile–</emphasis>associated diarrhea when used with antiinfectives for <emphasis style="italic">H. pylori</emphasis></para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5375">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5378">
					<section type="none" id="sidelem4x5379">
						<sec_title>Antidiarrheal/Gastric Distress</sec_title>
						<section type="none" id="sidelem4x5387">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5387">
									<item>
										<label>•</label>
										<para> 2 tabs or 30 ml (15 ml extra/max strength) q30min or 2 tabs q60min, max 4.2 g/24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5391">
						<sec_title>Antiulcer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5399">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5399">
									<item>
										<label>•</label>
										<para> 525 mg qid, max 4.2 g/24 hr; given with metroNIDAZOLE or tetracycline and acid-suppressive therapy × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5403">
						<sec_title>Traveler’s diarrhea (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5411">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5411">
									<item>
										<label>•</label>
										<para> 30 ml q30min (8×/day regular strength, 4×/day max strength)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5415">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 262 mg; chewable tabs 262 mg, liquid 262mg /15ml, 525 mg/15 ml</para>
					</section>
					<section type="none" id="sidelem4x5420">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5423">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5428">
									<item>
										<label>•</label>
										<para>Increased fluids to rehydrate patient</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5436">
								<label>•</label>
								<sec_title>Susp</sec_title>
								<para>
									<list id="lidelem4x5436">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Susp:</emphasis> shake liquid before using, use measuring cup/syringe</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5440">
									<item>
										<label>•</label>
										<para>Tabs can be chewed, dissolved in mouth; caplets to be swallowed whole with water</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5445">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5448">
					<section type="none" id="sidelem4x5449">
						<sec_title>CNS:</sec_title>
						<para> Confusion, twitching, <emphasis style="bold">neurotoxicity (high doses)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5456">
						<sec_title>EENT:</sec_title>
						<para> Hearing loss, tinnitus, metallic taste, blue gums, black tongue</para>
					</section>
					<section type="none" id="sidelem4x5461">
						<sec_title>GI:</sec_title>
						<para> Increased fecal impaction (high doses), dark stools, constipation, diarrhea, nausea</para>
					</section>
					<section type="none" id="sidelem4x5466">
						<sec_title>HEMA:</sec_title>
						<para> Increased bleeding time</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5471">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5474">
					<section type="none" id="sidelem4x5475">
						<sec_title>PO:</sec_title>
						<para> Onset 1 hr, peak 2 hr, duration 4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5480">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—salicylates, methotrexate</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of anticoagulants (PO), antidiabetics (PO)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of tetracycline, quinolones, phenytoin, separate for ≥2 hr</para>
				<section type="none" id="sidelem4x5495">
					<section type="none" id="sidelem4x5496">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> radiographic studies of GI system</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5503">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5506">
					<section type="none" id="sidelem4x5507">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5515">
							<label>•</label>
							<sec_title>Diarrhea</sec_title>
							<para>
								<list id="lidelem4x5515">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Diarrhea:</emphasis> bowel pattern before product therapy, after treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5519">
								<item>
									<label>•</label>
									<para>Electrolytes K, Na, Cl if diarrhea is severe or continues long term; assess skin turgor, other signs of dehydration</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5524">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5528">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased diarrhea, absence of diarrhea when traveling; resolution of ulcers</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5534">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5538">
								<item>
									<label>•</label>
									<para>To chew, dissolve medication in mouth; not to swallow whole; to shake liquid before using, maintain hydration</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid other salicylates unless directed by prescriber; not to give to children, possibility of Reye’s syndrome</para>
								</item>
								<item>
									<label>•</label>
									<para>That stools may turn black; that tongue may darken; that impaction may occur in debilitated patients</para>
								</item>
								<item>
									<label>•</label>
									<para>To stop use if symptoms do not improve within 2 days or become worse, or if diarrhea is accompanied by high fever</para>
								</item>
								<item>
									<label>•</label>
									<para>Separate quinolones, phenytoin, tetracycline by ≥2 hr</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>bisoprolol (Rx)</mono_name>
			<info>
				<pronunciation>(bis-oh′pro-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x55690">Zebeta</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> β-Blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5582">
				<para>
					<confusion>
						<tradename id="tnidelem4x55820">Zebeta</tradename>
						<drug type="generic" refid="idelem4x55820">DiaBeta/Zetia</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5586">
				<sec_title>Action:</sec_title>
				<para>Preferentially and competitively blocks stimulation of β<emphasis style="inf">1</emphasis>-adrenergic receptors within cardiac muscle (decreases rate of SA node discharge, increases recovery time), slows conduction of AV node, decreases heart rate, which decreases O<emphasis style="inf">2</emphasis> consumption in myocardium; decreases renin-angiotensin-aldosterone system; inhibits β<emphasis style="inf">2</emphasis>-receptors in bronchial and vascular smooth muscle at high doses</para>
			</section>
			<section type="uses" id="sidelem4x5600">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate hypertension</para>
				<section type="none" id="sidelem4x5605">
					<section type="none" id="sidelem4x5606">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Stable angina, stable CHF</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5611">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to β-blockers, cardiogenic shock, heart block (2nd, 3rd degree), sinus bradycardia, acute cardiac failure</para>
				<section type="none" id="sidelem4x5618">
					<section type="none" id="sidelem4x5619">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, major surgery, diabetes mellitus, CHF, thyroid/renal/hepatic disease, COPD, asthma, well-compensated heart failure, aortic or mitral valve disease, peripheral vascular disease, myasthenia gravis</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5634">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5637">
					<section type="none" id="sidelem4x5638">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x5646">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5646">
									<item>
										<label>•</label>
										<para> 5 mg/day; reduce to 2.5 mg in bronchospastic disease; may increase to 20 mg/day if necessary; max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5650">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x5658">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;40 ml/min 2.5 mg, titrate upward</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5661">
						<sec_title>Angina (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5669">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5669">
									<item>
										<label>•</label>
										<para> 5-20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5673">
						<sec_title>Heart failure (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5681">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5681">
									<item>
										<label>•</label>
										<para> 1.25 mg/day × 48 hr, then 2.5 mg/day for 1st mo, then 5 mg/day; max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5685">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x5690">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5694">
								<item>
									<label>•</label>
									<para>Tab may be crushed, swallowed whole; may give without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Reduced dosage with renal/hepatic dysfunction</para>
								</item>
								<item>
									<label>•</label>
									<para>Store protected from light, moisture; place in cool environment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5710">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5713">
					<section type="none" id="sidelem4x5714">
						<sec_title>CNS:</sec_title>
						<para> Vertigo, headache, insomnia, fatigue, dizziness, mental changes, memory loss, hallucinations, depression, lethargy, drowsiness, strange dreams, catatonia, peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x5719">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Ventricular dysrhythmias, profound hypotension, bradycardia, CHF,</emphasis> cold extremities, postural hypotension, <emphasis style="bold">2nd-or 3rd-degree heart block,</emphasis> peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x5730">
						<sec_title>EENT:</sec_title>
						<para> Sore throat; dry, burning eyes</para>
					</section>
					<section type="none" id="sidelem4x5735">
						<sec_title>ENDO:</sec_title>
						<para> Increased hypoglycemic response to insulin</para>
					</section>
					<section type="none" id="sidelem4x5740">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, vomiting, <emphasis style="bold">mesenteric arterial thrombosis,</emphasis> ischemic colitis, flatulence, gastritis, gastric pain</para>
					</section>
					<section type="none" id="sidelem4x5748">
						<sec_title>GU:</sec_title>
						<para> Impotence, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x5753">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia,</emphasis> purpura, eosinophilia</para>
					</section>
					<section type="none" id="sidelem4x5761">
						<sec_title>INTEG:</sec_title>
						<para> Rash, flushing, alopecia, pruritus, sweating</para>
					</section>
					<section type="none" id="sidelem4x5766">
						<sec_title>MISC:</sec_title>
						<para> Facial swelling, weight gain, decreased exercise tolerance</para>
					</section>
					<section type="none" id="sidelem4x5771">
						<sec_title>MS:</sec_title>
						<para> Joint pain, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x5776">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, wheezing, cough, nasal stuffiness, upper respiratory infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5784">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-4 hr, half-life 9-12 hr, 50% excreted unchanged in urine, protein binding 30%-36%, metabolized in liver to inactive metabolites</para>
			</section>
			<section type="interactions" id="sidelem4x5789">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—reserpine, guanethidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myocardial depression—calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—ACE inhibitors, α-blockers, calcium channel blockers, diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia—digoxin, amiodarone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> peripheral ischemia—ergots</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antidiabetic effect—antidiabetics; may make hypoglycemic symptoms</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x5820">
					<section type="none" id="sidelem4x5821">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> β-blocking effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> β-blocking effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x5832">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, ANA titer, blood glucose, BUN, uric acid, potassium, lipoprotein</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> glucose/insulin tolerance tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5843">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5846">
					<section type="none" id="sidelem4x5847">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5855">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x5855">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P during beginning treatment, periodically thereafter; pulse q4hr: note rate, rhythm, quality; apical/radial pulse before administration; notify prescriber of any significant changes (pulse &lt;50 bpm)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5861">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5869">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x5869">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> I&amp;O, weight daily; increased weight, jugular venous distention, dyspnea, crackles, edema in feet, legs daily</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5873">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status, especially for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5878">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5882">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P after 1-2 wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5888">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Not to discontinue product abruptly; may cause precipitate angina, rebound hypertension; evaluate noncompliance</bbw>
						</para>
						<para>
							<list id="lidelem4x5903">
								<item>
									<label>•</label>
									<para>Not to use OTC products that contain α-adrenergic stimulants (e.g., nasal decongestants, OTC cold preparations) unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5908">
								<item>
									<label>•</label>
									<para>To report bradycardia, dizziness, confusion, depression, fever, cold extremities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5913">
								<item>
									<label>•</label>
									<para>To take pulse at home; advise when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5918">
								<item>
									<label>•</label>
									<para>To avoid alcohol, smoking, sodium intake</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5923">
								<item>
									<label>•</label>
									<para>To comply with weight control, dietary adjustments, modified exercise program</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5928">
								<item>
									<label>•</label>
									<para>To carry emergency ID to identify product, allergies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5933">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness is present</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5939">
								<item>
									<para>
										<emphasis alert="nurse">To report symptoms of CHF: difficulty breathing, especially on exertion or when lying down, night cough, swelling of extremities</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5944">
								<item>
									<label>•</label>
									<para>That if diabetic, product may mask signs of hypoglycemia or alter blood glucose levels</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x5949">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, IV atropine for bradycardia; IV theophylline for bronchospasm; digoxin, O<emphasis style="inf">2</emphasis>, diuretic for cardiac failure; hemodialysis, IV glucose for hypoglycemia; IV diazepam or phenytoin for seizures</para>
			</section>
		</monograph>
<monograph id="29" status="active" ha="yes">
			<mono_name> bivalirudin (Rx)</mono_name>
			<info>
				<pronunciation>(bye-val-i-rue′din)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x59640">Angiomax</tradename>
				</tradenames>
				<class type="func"> Anticoagulant</class>
				<class type="chem"> Thrombin inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x5974">
				<sec_title>Action:</sec_title>
				<para>Direct inhibitor of thrombin that is highly specific; able to inhibit free and clot-bound thrombin</para>
			</section>
			<section type="uses" id="sidelem4x5979">
				<sec_title>Uses:</sec_title>
				<para>Unstable angina in patients undergoing percutaneous transluminal coronary angioplasty (PTCA), used with aspirin; heparin-induced thrombocytopenia, with/without thrombosis syndrome, PCI with iib/iiia</para>
				<section type="none" id="sidelem4x5984">
					<section type="none" id="sidelem4x5985">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute MI, DVT prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5990">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, active bleeding, cerebral aneurysm, intracranial hemorrhage, recent surgery, CVA</para>
				<section type="none" id="sidelem4x5995">
					<section type="none" id="sidelem4x5996">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal function impairment, hepatic disease, asthma, blood dyscrasias, thrombocytopenia, GI ulcers, hypertension, inflammatory bowel disease, vitamin K deficiency, asthma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6001">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6009">
					<label>•</label>
					<sec_title>Adult<route> IV BOL</route></sec_title>
					<para>
						<list id="lidelem4x6009">
							<item>
								<label>•</label>
								<para> 0.75 mg/kg, then  1.75 mg/kg/hr for 4 hr; another  may be used at 0.2 mg/kg/hr for ≤20 hr; this product is intended to be used with aspirin (325 mg/day) adjusted to body weight</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6019">
					<section type="none" id="sidelem4x6020">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6028">
							<label>•</label>
							<sec_title>Adult<route> IV CCr ≥30 ml/min no adjustment; CrL 10-29 ml/min consider reducing to 1 mL/kg/hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6031">
						<sec_title>Acute MI (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6039">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x6039">
									<item>
										<label>•</label>
										<para> 0.25 mg/kg, then  0.5 mg/kg/hr × 12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6047">
						<sec_title>DVT prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6055">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x6055">
									<item>
										<label>•</label>
										<para> 1 mg/kg q8hr for those undergoing orthopedic surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6059">
						<sec_title>Available forms:</sec_title>
						<para> Inj, lyophilized 250 mg/vial</para>
					</section>
					<section type="none" id="sidelem4x6064">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6068">
								<item>
									<label>•</label>
									<para>Before PTCA; give with aspirin (325 mg)</para>
								</item>
								<item>
									<label>•</label>
									<para>Store reconstituted vials in refrigerator for up to 24 hr; store diluted concentrations at room temperature for 24 hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6079">
							<sec_title>IV, direct route</sec_title>
							<para>
								<list id="lidelem4x6083">
									<item>
										<label>•</label>
										<para>Dilute by adding 5 ml of sterile water for inj/250 mg bivalirudin, swirl until dissolved, further dilute in 50 ml of D<emphasis style="inf">5</emphasis>W or 0.9% NaCl (5 mg/ml), give by bolus inj 0.75 mg/kg, then intermittent infusion</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6092">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6096">
									<item>
										<label>•</label>
										<para>To each 250-mg vial add 5 ml of sterile water for inj, swirl until dissolved, further dilute in 500 ml D<emphasis style="inf">5</emphasis>W or 0.9% NaCl (0.5 mg/ml); give infusion after bolus dose at a rate of 1.75 mg/kg/hr; may give an additional infusion at 0.2 mg/kg/hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not mix other IV medications with bivalirudin or provide via the same IV line as bivalirudin</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Abciximab, acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, arsenic trioxide, atenolol, atracurium, atropine, azithromycin, aztreonam, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, capreomycin, CARBOplatin, carmustine, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin, DAUNOrubicin liposome, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, dolasetron, DOPamine, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoprostenol, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoMYcin, mitoXANtrone, mivacurium, morphine, moxifloxacin, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, polymyxin B, potassium acetate/chloride/phosphates, procainamide, promethazine, propranolol, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, topotecan, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, warfarin, zidovudine, zoledronic acid</para>
						</section>
						<section type="none" id="sidelem4x6114">
							<sec_title>SUBCUT injection (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x6118">
									<item>
										<label>•</label>
										<para>May be used for DVT prophylaxis</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6125">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6128">
					<section type="none" id="sidelem4x6129">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia, anxiety, nervousness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6136">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypo/hypertension, bradycardia,</emphasis><emphasis style="bold">ventricular fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6145">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain, dyspepsia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6152">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemorrhage, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6159">
						<sec_title>MISC:</sec_title>
						<para> Pain at inj site, pelvic pain, urinary retention, fever, <emphasis style="bold">anaphylaxis,</emphasis> infection</para>
					</section>
					<section type="none" id="sidelem4x6167">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Back pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6174">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, <emphasis style="bold">renal failure, oliguria</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6181">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in urine, half-life 25 min, duration 1 hr, no protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x6186">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, aspirin, treprostinil, thrombolytics, NSAIDs, salicylates, cephalosporins, antineoplastics, sulfinpyrazone, GPIIb/IIIa inhibitors</para>
				<section type="none" id="sidelem4x6193">
					<section type="none" id="sidelem4x6194">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—angelica, chamomile, devil’s claw, dong quai, garlic, ginger, ginkgo, ginseng, horse chestnut, licorice, saw palmetto</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6201">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6204">
					<section type="none" id="sidelem4x6205">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6210">
								<item>
									<label>•</label>
									<para>Baseline and periodic ACT, APTT, PT, INR, TT, platelets, Hgb, Hct</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6216">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding: check arterial and venous sites, IM inj sites, catheters; all punctures should be minimized; fall in B/P or Hct may indicate hemorrhage, hematoma, hemorrhage at puncture site are more common in the elderly</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6221">
								<item>
									<label>•</label>
									<para>Fever, skin rash, urticaria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6226">
								<item>
									<label>•</label>
									<para>CV status: B/P, watch for hypo/hypertension, bradycardia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6231">
								<item>
									<label>•</label>
									<para>Neurologic status: any focal or generalized deficits should be reported immediately</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6239">
							<label>•</label>
							<sec_title>PCI use<route> possible thrombosis, stenosis, unplanned stent, prolonged ischemia, decreased reflow</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6242">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6246">
								<item>
									<label>•</label>
									<para>Therapeutic response: anticoagulation with PTCA; resolution of heparin-induced thrombocytopenia, thrombosis syndrome</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6252">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6256">
								<item>
									<label>•</label>
									<para>About the reason for the product and expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>To report black, tarry stools; blood in urine; difficulty breathing</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use any OTC, herbal products unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use hard-bristle toothbrush or regular razor to avoid any injury; hemorrhage may result</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active" ha="yes">
			<mono_name> bleomycin (Rx)</mono_name>
			<info>
				<pronunciation>(blee-oh-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x62840">
						<country code="CAN">Blenoxane</country>
					</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antibiotic</class>
				<class type="chem"> Glycopeptide</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x6296">
				<sec_title>Action:</sec_title>
				<para>Inhibits synthesis of DNA, RNA, protein; derived from <emphasis style="italic">Streptomyces verticillus;</emphasis> phase specific to the G<emphasis style="inf">2</emphasis> and M phases; a nonvesicant, sclerosing agent</para>
			</section>
			<section type="uses" id="sidelem4x6307">
				<sec_title>Uses:</sec_title>
				<para>Cancer of head, neck, penis, cervix, vulva of squamous cell origin; Hodgkin’s/non-Hodgkin’s disease; testicular carcinoma; as a sclerosing agent for malignant pleural effusion</para>
				<section type="none" id="sidelem4x6312">
					<section type="none" id="sidelem4x6313">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cutaneous T-cell lymphoma, hemangioma, Kaposi’s sarcoma, malignant ascites, verruca plantaris/vulgaris, osteogenic sarcoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6318">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, prior idiosyncratic reaction</para>
				<section type="none" id="sidelem4x6323">
					<section type="none" id="sidelem4x6324">
						<sec_title>Precautions:</sec_title>
						<para> Patients &gt;70 yr old, renal/hepatic disease, respiratory disease, max lifetime dose 400 units</para>
						<para>
							<bbw>Idiosyncratic reaction, pulmonary fibrosis, fever, requires specialized care setting, experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6340">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6343">
					<section type="none" id="sidelem4x6344">
						<sec_title>Test dose</sec_title>
						<section type="none" id="sidelem4x6352">
							<label>•</label>
							<sec_title>Adult and child (unlabeled)<route> IM/IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x6352">
									<item>
										<label>•</label>
										<para> ≤2 units for first 2 doses followed by 24 hr of observation</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6359">
							<label>•</label>
							<sec_title>Adult and child<route> SUBCUT/IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x6359">
									<item>
										<label>•</label>
										<para> 0.25-0.5 unit/kg 1-2×/wk or 10-20 units/m<emphasis style="sup">2</emphasis>, then 1 unit/day or 5 units/wk; may also be given by  max total dose of 400 units during lifetime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6370">
						<sec_title>Hodgkin’s lymphoma</sec_title>
						<section type="none" id="sidelem4x6378">
							<label>•</label>
							<sec_title>Adult/Child<route> IV/IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x6378">
									<item>
										<label>•</label>
										<para> 5-20 units/m<emphasis style="sup">2</emphasis>, may give in combination</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6385">
						<sec_title>Testicular cancer</sec_title>
						<section type="none" id="sidelem4x6393">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6393">
									<item>
										<label>•</label>
										<para> 10-20 units/m<emphasis style="sup">2</emphasis> 1-2×/wk, may be given in combination</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6400">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6408">
							<label>•</label>
							<sec_title>Adult/child<route> CCr 40-50 ml/min reduce dose by 30%; CCr 30-39 ml/min reduce dose by 40%; CCr 20-29 ml/min reduce dose by 45%; CCr 10-19 ml/min reduce dose by 55%; CCr 5-10 ml/min reduce dose by 60%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6411">
						<sec_title>Kaposi’s sarcoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6419">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6419">
									<item>
										<label>•</label>
										<para> 15 units q2wk with DOXOrubicin and vinCRIStine</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6423">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj, 15, 30 units/vial</para>
					</section>
					<section type="none" id="sidelem4x6428">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6432">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before giving product to prevent vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>Topical or systemic analgesics for pain of stomatitis as ordered; antihistamines and antipyretics for fever, chills</para>
								</item>
								<item>
									<label>•</label>
									<para>May be given IM, subcut, IV, intrapleurally, intralesionally, intraarterially</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6448">
							<sec_title>IM/SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x6452">
									<item>
										<label>•</label>
										<para>After reconstituting 15 units/1-5 ml or 30 mg/2-10 ml of 0.9% NaCl or bacteriostatic water for inj, max concentrations 5 units/ml, rotate inj sites; do not use products that contain benzyl alcohol when giving to neonates or that contain dextrose because of loss of potency</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6458">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x6462">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures</para>
									</item>
									<item>
										<label>•</label>
										<para>After reconstituting 15- or 30-unit vial with 5 or 10 ml of NS, respectively, inj slowly over 10 min or after further dilution with 50-100 ml 0.9% NaCl; give 15 units or less over 10 min through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock</para>
									</item>
									<item>
										<label>•</label>
										<para>For patients with lymphoma, give 2 test doses of 2-5 units before initial dose; monitor for anaphylaxis</para>
									</item>
									<item>
										<label>•</label>
										<para>Store for 2 wk after reconstituting if refrigerated or for 24 hr at room temperature; discard unused portions</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone sodium succinate, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, metaraminol, methohexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, potassium phosphates, procainamide, prochlorperazine, promethazine, propranolol, quiNIDine, ranitidine, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate, sodium bicarbonate, sodium phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tirofiban, tobramycin, tolazoline, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6492">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6495">
					<section type="none" id="sidelem4x6496">
						<sec_title>CNS:</sec_title>
						<para> Pain at tumor site, headache, confusion, fever, chills, malaise</para>
					</section>
					<section type="none" id="sidelem4x6501">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6508">
						<sec_title>GI:</sec_title>
						<para>  <emphasis style="italic">Nausea, vomiting, anorexia, stomatitis, weight loss,</emphasis> ulceration of mouth, lips</para>
					</section>
					<section type="none" id="sidelem4x6516">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hemolytic-uremic syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6523">
						<sec_title>IDIOSYNCRATIC REACTION:</sec_title>
						<para> Hypotension, <emphasis style="italic">confusion, fever,</emphasis> chills, wheezing</para>
					</section>
					<section type="none" id="sidelem4x6531">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, hyperkeratosis, nail changes, alopecia,</emphasis> pruritus, acne, striae, peeling, hyperpigmentation, phlebitis</para>
					</section>
					<section type="none" id="sidelem4x6539">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Fibrosis, pneumonitis,</emphasis> wheezing, <emphasis style="bold">pulmonary toxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6549">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> radiation recall, Raynaud’s phenomenon</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6557">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 2-4 hr; when CCr is &gt;35 ml/min, half-life is increased with lower clearance; metabolized in liver; 50% excreted in urine (unchanged)</para>
			</section>
			<section type="interactions" id="sidelem4x6562">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x6566">
						<item>
							<label>•</label>
							<para>Avoid live virus vaccines concurrently</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—other antineoplastics, radiation therapy, general anesthesia, filgrastim, sargramostim</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> serum phenytoin levels—phenytoin, fosphenytoin</para>
				<section type="none" id="sidelem4x6580">
					<section type="none" id="sidelem4x6581">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> pulmonary function tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6592">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6595">
					<section type="none" id="sidelem4x6596">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6604">
							<para>
								<list id="lidelem4x6604">
									<item>
										<label>•</label>
										<para>IM test dose in patients with lymphoma of 1-2 units before 1st 2 doses
<bbw>
												<emphasis alert="lifethreat">Pulmonary toxicity/fibrosis:</emphasis> pulmonary function tests; chest x-ray before, during therapy, should be obtained q2wk during treatment; pulmonary diffusion capacity for carbon monoxide (DLCO) monthly, if &lt;40% of pretreatment value, stop treatment; treat pulmonary infection before treatment; dyspnea, crackles, unproductive cough, chest pain, tachypnea, fatigue, increased pulse, pallor, lethargy, more common in the elderly, radiation therapy, pulmonary disease; <emphasis alert="lifethreat">usually occurs with cumulative doses &gt;400 units</emphasis></bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6620">
								<item>
									<label>•</label>
									<para>Temperature; fever may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6625">
								<item>
									<label>•</label>
									<para>Renal status: serum creatinine/BUN; CBC</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6630">
								<item>
									<label>•</label>
									<para>Effects of alopecia, skin color alterations on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6635">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6640">
								<item>
									<label>•</label>
									<para>Local irritation, pain, burning, discoloration at inj site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6646">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, pruritus, urticaria, purpuric skin lesions, itching, flushing, wheezing, hypotension; have emergency equipment available</emphasis>
<bbw>
											<emphasis alert="lifethreat">Idiosyncratic reaction:</emphasis> hypotension, mental confusion, fever, chills, wheezing in lymphoma</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6662">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6667">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6671">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6677">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6682">
								<item>
									<label>•</label>
									<para>To report any changes in breathing, coughing, fever</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6687">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment and that wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6694">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6699">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth; to examine mouth daily and report symptoms; decreased urination</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6707">
							<label>•</label>
							<sec_title>
								<route>To use contraception during treatment (pregnancy [D]), to avoid breastfeeding</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x6713">
							<label>•</label>
							<sec_title>
								<route>Not to receive vaccines during treatment</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>boceprevir</mono_name>
			<info>
				<pronunciation>(boe-se′pre-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x67210">Victrelis</tradename>
				</tradenames>
				<class type="func"> Antiviral, antihepatitis agents</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x6727">
				<sec_title>Action:</sec_title>
				<para>Prevents hepatitis C viral (HCV) replication by blocking the activity of HCV NS3/4A serine protease. Hepatitis C virus NS3/4A serine protease is an enzyme responsible for the conversion of HCV-encoded polyproteins to mature/functioning viral proteins</para>
			</section>
			<section type="uses" id="sidelem4x6732">
				<sec_title>Uses:</sec_title>
				<para>Hepatitis C infection in combination with peginterferon alfa and ribavirin with compensated liver function</para>
			</section>
			<section type="contra" id="sidelem4x6737">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), male partners of women who are pregnant</para>
				<section type="none" id="sidelem4x6742">
					<section type="none" id="sidelem4x6743">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, neonates, infants, children, adolescents &lt;18 years of age, anemia, neutropenia, thrombocytopenia, HIV, hepatitis B, decompensated hepatic disease, in liver or other organ transplants, hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6748">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6751">
					<section type="none" id="sidelem4x6752">
						<sec_title>Chronic hepatitis C infection (genotype 1) compensated liver disease (without cirrhosis, previously untreated with interferon and ribavirin therapy)/(partial responders/relapsers/null responders)</sec_title>
						<section type="none" id="sidelem4x6760">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6760">
									<item>
										<label>•</label>
										<para> Before starting therapy peginterferon alfa and ribavirin must be given 4 wk, then add boceprevir 800 mg (four 200 mg caps) PO TID (7-9 hr); treatment length is determined by HCV RNA concentrations at treatment wk 4, 8, 12, and 24; if patient has undetectable HCV RNA concentrations at wk 8 and 24, discontinue all 3 medications at wk 28 (previously untreated); 36 wk (partial responders/relapsers); if HCV RNA is detectable at wk 8 but undetectable at wk 24, the 3-drug regimen through wk 36, then give only peginterferon alfa and ribavirin through treatment wk 48; if the patient has a poor response to peginterferon alfa and ribavirin during the initial 4 wk, continue treatment with all 3 medications for a total of 48 wk; discontinue the 3-drug regimen if the HCV RNA concentrations &gt;100 international units/ml at treatment wk 12 or a detectable HCA RNA concentration at treatment wk 24</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6764">
						<sec_title>Chronic hepatitis C infection (genotype 1) compensated liver disease with cirrhosis</sec_title>
						<section type="none" id="sidelem4x6772">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6772">
									<item>
										<label>•</label>
										<para> Before starting therapy with boceprevir, peginterferon alfa and ribavirin must be given 4 wk; then add boceprevir 800 mg (four 200 mg caps) PO TID (7-9 hr) to peginterferon alfa and ribavirin for an additional 44 wk (48 wk total)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6776">
						<sec_title>Available forms:</sec_title>
						<para> Caps 200 mg</para>
					</section>
					<section type="none" id="sidelem4x6781">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6789">
							<label>•</label>
							<sec_title>
								<route>Only use in combination with peginterferon alfa and ribavirin; never give as monotherapy</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x6795">
							<label>•</label>
							<sec_title>
								<route>Discontinue in hepatitis C virus (HCV)if RNA concentrations ≥100 international units/ml at wk 12 or a confirmed detectable HCV RNA concentrations at wk 24</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x6801">
							<label>•</label>
							<sec_title>
								<route>Any contraindication to peginterferon alfa or ribavirin also applies to boceprevir</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6804">
								<item>
									<label>•</label>
									<para>Give with food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6809">
				<sec_title>Side effects</sec_title>
				<para>
					<emphasis alert="lifethreat">When used in combination with peginterferon/ribavarin</emphasis>
				</para>
				<section type="none" id="sidelem4x6815">
					<section type="none" id="sidelem4x6816">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fatigue, chills, asthenia</emphasis>, insomnia, irritability, dizziness</para>
					</section>
					<section type="none" id="sidelem4x6825">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, dysgeusia, decreased appetite, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x6830">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia (Hgb &lt; 10 g/dL), neutropenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6837">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia, rash</emphasis>, xerosis</para>
					</section>
					<section type="none" id="sidelem4x6845">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Arthralgia, exertional dyspnea,</emphasis><emphasis style="bold">drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6854">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: life-threatening reactions of each product: alfuzosin, ergots (dihydroergotamine, ergotamine, ergonovine, methylergonovine), cisapride, pimozide, lovastatin, simvastatin, ezetimibe, niacin with simvastatin and boceprevir; triazolam, oral midazolam; sildenafil, tadalafil (pulmonary arterial hypertension); do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions of each product—phosphodiesterase type 5 (PDE5) inhibitors (for erectile dysfunction), acetaminophen, alfentanil, aliskiren, almotriptan, alosetron, ALPRAZolam, aminophylline, amiodarone, amitriptyline, amLODIPine, ARIPiprazole, astemizole, atorvastatin, atorvastin, bepridil, boceprevir, bosentan, budesonide, bupivacaine, buprenorphine, busPIRone, carvedilol, cevimeline, chloroquine, cilostazol, cinacalcet, citalopram, clarithromycin, clomiPRAMINE, clonazePAM, clopidogrel, cloZAPine, colchicine, cyclobenzaprine, cycloSPORINE, dapsone, DAUNOrubicin, desipramine, desloratadine, dexamethasone, dexlansoprazole, dextromethorphan, diazepam, diclofenac, digoxin, diltiazem, disopyramide, disulfiram, DOCEtaxel, dolasetron, donepezil, DOXOrubicin, droperidol, dutasteride, ebastine, eletriptan, eplerenone, erlotinib, erythromycin, estazolam, eszopiclone, ethosuximide, etoposide, exemestane, felodipine, fentaNYL, fexofenadine, finasteride, flecainide, flunitrazepam, flurazepam, galantamine, gefitinib, glyburide, granisetron, halofantrine, haloperidol, HYDROcodone, ifosfamide, imipramine, indiplon, irinotecan, isradipine, itraconazole, ivermectin, ixabepilone, ketoconazole, lansoprazole, lidocaine, loperamide, loratadine, losartan, maraviroc, mefloquine, meloxicam, mirtazapine, mitoMYcin, montelukast, morphine, nateglinide, niCARdipine, NIFEdipine, nisoldipine, nortriptyline, omeprazole, ondansetron, oxybutynin, oxyCODONE, PACLitaxel, palonosetron, paricalcitol, plicamycin, posaconazole, prasugrel, praziquantel, propafenone, quazepam, QUEtiapine, quinacrine, quiNIDine, ramelteon, repaglinide, rifabutin, risperiDONE, ropivacaine, salmeterol, selegiline, sertraline, sibutramine, silodosin, sirolimus, sitaxsentan, solifenacin, SUFentanil, SUNItinib, systemic corticosteroids, tacrolimus, telithromycin, teniposide, terfenadine, testosterone, theophylline, tiaGABine, tinidazole, tolterodine, tolvaptan, traMADol, traZODone, vardenafil, venlafaxine, verapamil, vinBLAStine, vinCRIStine, voriconazole, warfarin, and others; use cautiously, may need to reduce dose</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—drospirenone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> estrogen levels—ethinyl estradiol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> boceprevir effect—CYP3A4 inhibitors (phenytoin, carBAMazepine, PHENobarbital, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—methadone</para>
				<para>
					<emphasis style="bold">Possible treatment failure:</emphasis> efavirenz, ritonavir, atazanavir, lopinavir with ritonavir</para>
				<section type="none" id="sidelem4x6886">
					<section type="none" id="sidelem4x6887">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x6891">
								<item>
									<label>•</label>
									<para>Do not use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6897">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6904">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6907">
					<section type="none" id="sidelem4x6908">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6914">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy: obtain a pregnancy test before, monthly during, and for 6 mo after treatment is completed; those who are not willing to practice strict contraception should not receive treatment; report any cases of prenatal ribavirin exposure to the Ribavirin Pregnancy Registry at (800) 593-2214</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6922">
							<label>•</label>
							<sec_title>Anemia</sec_title>
							<para>
								<list id="lidelem4x6922">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Anemia:</emphasis> monitor Hgb, CBC with differential before, at treatment wk 2, 8, 12, and as needed. If Hgb is &lt;10 g/dL, decrease ribavirin dosage; if Hgb is &lt;8.5 g/dL, discontinuation of therapy is recommended; dosage should not be altered based on adverse reactions; anemia may be managed through ribavirin dose modifications; never alter the dose of boceprevir; if anemia persists despite a reduction in ribavirin dose, consider discontinuing boceprevir; if management of anemia requires permanent discontinuation of ribavirin, treatment with boceprevir MUST also be permanently discontinued; once boceprevir has been discontinued, it must not be restarted; monitor CBC with differential at treatment wk 4, 8, 12, and at other treatment points as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6931">
							<label>•</label>
							<sec_title>Serious skin disorders (DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis)<route> These reactions may be due to combination use with peginterferon alfa, ribavarin; if serious skin reactions occur, discontinue all 3 products</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6934">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6939">
								<item>
									<label>•</label>
									<para>To take with food to increase absorption; do not start new meds/herbs without prescriber’s approval</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6944">
								<item>
									<label>•</label>
									<para>To use precautions to prevent transmission of hepatitis C</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6949">
								<item>
									<label>•</label>
									<para>To inform prescriber of all medications, herbs, supplements used</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6957">
							<label>•</label>
							<sec_title>
								<route>To use 2 forms of effective contraception (intrauterine devices and barrier methods) during treatment and for 6 mo after treatment (pregnancy [X]); to avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active" ha="yes">
			<mono_name> bortezomib (Rx)</mono_name>
			<info>
				<pronunciation>(bor-tez′oh-mib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x69670">Velcade</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Proteasome inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x6977">
				<sec_title>Action:</sec_title>
				<para>Reversible inhibitor of chymotrypsin-like activity in mammalian cells; causes delay in tumor growth by disrupting normal homeostatic mechanisms of 26S proteasome</para>
			</section>
			<section type="uses" id="sidelem4x6982">
				<sec_title>Uses:</sec_title>
				<para>Multiple myeloma previously untreated or when at least 2 other treatments have failed; mantle cell lymphoma who have received ≥1 prior therapy</para>
				<section type="none" id="sidelem4x6987">
					<section type="none" id="sidelem4x6988">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Non-Hodgkin’s lymphoma (NHL)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6993">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding; hypersensitivity to product, boron, mannitol</para>
				<section type="none" id="sidelem4x6998">
					<section type="none" id="sidelem4x6999">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, peripheral neuropathy, cardiac/hepatic disease, hypotension, tumor lysis syndrome, thrombocytopenia, infection, diabetes mellitus, bone marrow suppression, intracranial bleeding, injection site irritation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7004">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7007">
					<section type="none" id="sidelem4x7008">
						<sec_title>Multiple myeloma (previously untreated)</sec_title>
						<section type="none" id="sidelem4x7016">
							<label>•</label>
							<sec_title>Adult<route> IV BOL/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x7016">
									<item>
										<label>•</label>
										<para> Give for nine 6-wk cycles; cycles 1-4, 1.3 mg/m<emphasis style="sup">2</emphasis>/dose given on days 1, 4, 8, 11, then a 10-day rest period (days 12-21), then give again on days 22, 25, 29, 32, then a 10-day rest period (days 33-42); given with melphalan (9 mg/m<emphasis style="sup">2</emphasis>/day on days 1-4) and predniSONE (60 mg/m<emphasis style="sup">2</emphasis>/day on days 1-4); during cycles 5-9, give bortezomib 1.3 mg/m<emphasis style="sup">2</emphasis>/dose on days 1, 8, 22, 29 with melphalan (9 mg/m<emphasis style="sup">2</emphasis>/day on days 1-4) and predniSONE (60 mg/m<emphasis style="sup">2</emphasis>/day on days 1-4); this 6-wk cycle is considered 1 course; at least 72 hr should elapse between consecutive doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7040">
						<sec_title>Mantle cell lymphoma in combination</sec_title>
						<section type="none" id="sidelem4x7048">
							<label>•</label>
							<sec_title>Adult<route> IV BOL/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x7048">
									<item>
										<label>•</label>
										<para> 1.3 mg/m<emphasis style="sup">2</emphasis>/dose on days 1, 4, 8, 11 followed by a 10-day rest period (days 12-21); ×6 (3-wk) cycles with rituximab 375 mg/m<emphasis style="sup">2</emphasis>, cyclophosphamide 750 mg/m<emphasis style="sup">2</emphasis>, doxorubicin 50 mg/m<emphasis style="sup">2</emphasis> all on day 1, and prednisone 100 mg/m<emphasis style="sup">2</emphasis> daily on days 1-5, give bortezomib before rituximab</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7067">
						<sec_title>Relapsed mantle cell lymphoma patients who have received ≥1 prior therapy</sec_title>
						<section type="none" id="sidelem4x7075">
							<label>•</label>
							<sec_title>Adult<route> IV BOL/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x7075">
									<item>
										<label>•</label>
										<para> 1.3 mg/m<emphasis style="sup">2</emphasis>/dose on days 1, 4, 8, 11 followed by a 10-day rest period</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7082">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x7090">
							<label>•</label>
							<sec_title>Adult<route> IV bilirubin &gt;1.5 × ULN, reduce to 0.7 mg/m2 during cycle 1; consider dose escalation to 1 mg/m2 or further reduction to 0.5 mg/m2 during next cycles based on tolerability</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7102">
						<sec_title>Non-Hodgkin’s Lymphoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7110">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x7110">
									<item>
										<label>•</label>
										<para> 1.3 mg/m<emphasis style="sup">2</emphasis> on days 1, 4, 8, 11 repeated every 21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7117">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder for inj 3.5 mg</para>
					</section>
					<section type="none" id="sidelem4x7122">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7125">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x7129">
									<item>
										<label>•</label>
										<para>Use 2.5 mg/ml, rotate inj sites; if inj site reaction occurs, use 1 mg/ml</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7135">
							<sec_title>IV bolus route</sec_title>
							<section type="none" id="sidelem4x7143">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x7143">
										<item>
											<label>•</label>
											<para> each vial with 3.5 ml of 0.9% NaCl (1 mg/ml); sol should be clear/colorless;  as bolus over 3-5 sec</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x7150">
									<item>
										<label>•</label>
										<para>Store unopened product at room temperature, protect from light</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7155">
									<item>
										<label>•</label>
										<para>Wear protective clothing during handling, preparation; avoid contact with skin</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7160">
									<item>
										<label>•</label>
										<para>Check for extravasation at inj site</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7165">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7168">
					<section type="none" id="sidelem4x7169">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, insomnia, dizziness, headache, <emphasis style="italic">peripheral neuropathy,</emphasis> rigors, paresthesia, fever, headache</para>
					</section>
					<section type="none" id="sidelem4x7177">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> edema</para>
					</section>
					<section type="none" id="sidelem4x7185">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, <emphasis style="italic">constipation, diarrhea,</emphasis> dyspepsia, <emphasis style="italic">nausea, vomiting,</emphasis> anorexia</para>
					</section>
					<section type="none" id="sidelem4x7196">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="italic">Anemia,</emphasis><emphasis style="bold">neutropenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7205">
						<sec_title>MISC:</sec_title>
						<para> Dehydration, weight loss, herpes zoster, <emphasis style="italic">rash,</emphasis> pruritus, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x7213">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Fatigue, malaise, weakness,</emphasis> arthralgia, bone pain, muscle cramps, myalgia, back pain, <emphasis style="bold">tumor lysis syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7223">
						<sec_title>RESP:</sec_title>
						<para> Cough, pneumonia, dyspnea, URI, <emphasis style="bold">ARDs, pneumonitis, interstitial pneumonia, lung infiltration</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7230">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 9-15 hr, protein binding 83%, metabolized by CYP450 enzymes (3A4, 2D6, 2C19, 2C9, 1A2)</para>
			</section>
			<section type="interactions" id="sidelem4x7235">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x7243">
					<label>•</label>
					<sec_title>
						<route>Do not use hematopoietic progenitor cells (sargramostim, filgrastim) within 24 hr of chemotherapy</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x7246">
						<item>
							<label>•</label>
							<para>Oral hypoglycemics: may result in hypo/hyperglycemia</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk for bleeding—anticoagulants, NSAIDs, platelet inhibitors, salicylates, thrombolytics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> peripheral neuropathy—amiodarone, antivirals (amprenavir; atazanavir; didanosine, lamiVUDine, 3TC; ritonavir; stavudine, zidovudine), chloramphenicol, CISplatin, colchicine, cycloSPORINE, dapsone, disulfiram, DOCEtaxel, gold salts, HMG-CoA reductase inhibitors, iodoquinol, INH, metroNIDAZOLE, nitrofurantoin, oxaliplatin, PACLitaxel, penicillamine, phenytoin, sulfaSALAzine, thalidomide, vinBLAStine, vinCRIStine, zalcitabine ddc, isoniazid, statins, others</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity or decrease efficacy when administered with products that induce or inhibit CYP3A4</para>
				<para>
					<emphasis alert="lifethreat">Decrease: effect of norethindrone, estradiol, combination oral contraceptives, another nonhormonal contraceptive should be used</emphasis>
				</para>
				<section type="none" id="sidelem4x7270">
					<section type="none" id="sidelem4x7271">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> toxicity or decrease efficacy—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7279">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7282">
					<section type="none" id="sidelem4x7283">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="lifethreat">Fatal pulmonary toxicity: assess for risk factors or new worsening pulmonary symptoms</emphasis>
						</para>
						<para>
							<emphasis alert="lifethreat">Tumor lysis syndrome: usually with those with a high tumor burden</emphasis>
							<list id="lidelem4x7292">
								<item>
									<label>•</label>
									<para>Hematologic status: platelets, CBC throughout treatment; platelets ≥70 × 10<emphasis style="sup">9</emphasis>/L and ANC ≥1.0 × 10<emphasis style="sup">9</emphasis>/L before any cycle; nonhematologic toxicities should be grade 1 or baseline before any cycle</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P, fluid status, peripheral neuropathy symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7309">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7313">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement of multiple myeloma symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7319">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x7327">
							<label>•</label>
							<sec_title>
								<route>To use contraception while taking this product (pregnancy [D]); to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7330">
								<item>
									<label>•</label>
									<para>To monitor blood glucose levels if diabetic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7335">
								<item>
									<label>•</label>
									<para>To contact prescriber about new or worsening peripheral neuropathy, severe vomiting, diarrhea, easy bruising, bleeding, infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7340">
								<item>
									<label>•</label>
									<para>To avoid driving, operating machinery until effect is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7345">
								<item>
									<label>•</label>
									<para>To avoid using other medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7350">
								<item>
									<label>•</label>
									<para>To report peripheral neuropathy (burning, discomfort)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7355">
								<item>
									<label>•</label>
									<para>Bleeding risk (report bruising, bleeding)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active">
			<mono_name>bosentan (Rx)</mono_name>
			<info>
				<pronunciation>(boh′sen-tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x73650">Tracleer</tradename>
				</tradenames>
				<class type="func"> Vasodilator</class>
				<class type="chem"> Endothelin receptor antagonist</class>
			</info>
			<section type="actions" id="sidelem4x7375">
				<sec_title>Action:</sec_title>
				<para>Peripheral vasodilation occurs via the antagonism of the effect of endothelin on endothelium and vascular smooth muscle</para>
			</section>
			<section type="uses" id="sidelem4x7380">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary arterial hypertension with WHO class III, IV symptoms</para>
				<section type="none" id="sidelem4x7385">
					<section type="none" id="sidelem4x7386">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Septic shock to improve microcirculatory blood flow, functional class II pulmonary arterial hypertension</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7391">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, CVA, CAD</para>
				<para>
					<bbw>Pregnancy X</bbw>
				</para>
				<section type="none" id="sidelem4x7406">
					<section type="none" id="sidelem4x7407">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, mitral stenosis, anemia, edema, jaundice, hypovolemia, hypotension</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7422">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7430">
					<label>•</label>
					<sec_title>Adult and adolescent ≥40 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7430">
							<item>
								<label>•</label>
								<para> 62.5 mg bid × 4 wk, then 125 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7437">
					<label>•</label>
					<sec_title>Adult and adolescent &lt;40 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7437">
							<item>
								<label>•</label>
								<para> 62.5 mg bid, max 125 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7441">
					<section type="none" id="sidelem4x7442">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x7450">
							<label>•</label>
							<sec_title>Adult<route> PO baseline AST/ALT&lt;3×ULN no dosage change, monitor LFTs monthly reduce or interrupt if elevated; AST/ALT&gt;3 and ≤5× ULN repeat test, if confirmed reduce to 62.5 mg bid or interrupt; monitor LFTs q2wk, if interrupted, restart when LFTs &lt;3× ULN, check LFTs within 3 days; increase in AST/ALT&gt;5 and ≤5× ULN; during treatment repeat test to confirm, discontinue, monitor LFTs q2wk until LFTs &lt;3× ULN, restart at starting dose; AST/ALT &gt;8× ULN discontinue permanently</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7453">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 62.5, 125 mg</para>
					</section>
					<section type="none" id="sidelem4x7458">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7462">
								<item>
									<label>•</label>
									<para>Give without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Only available through the TAP program; 866-228-3546</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not stop product abruptly; taper</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7483">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7486">
					<section type="none" id="sidelem4x7487">
						<sec_title>CNS:</sec_title>
						<para> Headache, flushing, fatigue, fever</para>
					</section>
					<section type="none" id="sidelem4x7492">
						<sec_title>CV:</sec_title>
						<para> Hypotension, chest pain, palpitations, edema of lower limbs, fluid retention</para>
					</section>
					<section type="none" id="sidelem4x7498">
						<sec_title>GI:</sec_title>
						<para> Abnormal hepatic function, diarrhea, dyspepsia, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7505">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7512">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, <emphasis style="bold">anaphylaxis,</emphasis> rash, <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7522">
						<sec_title>MISC:</sec_title>
						<para> Oligospermia, <emphasis style="bold">tumor lysis syndrome,</emphasis> respiratory infection, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x7530">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7537">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by inducer of CYP2C9, CYP3A4, possibly CYP2C19; metabolized by the liver; terminal half-life 5 hr; steady state 3-5 days</para>
			</section>
			<section type="interactions" id="sidelem4x7542">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x7550">
					<label>•</label>
					<sec_title>
						<route>Do not coadminister cycloSPORINE with bosentan; bosentan is increased, cycloSPORINE is decreased</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x7556">
					<label>•</label>
					<sec_title>
						<route>Do not coadminister glyBURIDE with bosentan; glyBURIDE is decreased significantly, bosentan is also decreased, hepatic enzymes may be increased</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> bosentan effects—CYP2C9, CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bosentan level—ketoconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of warfarin, hormonal contraceptives, statins</para>
				<section type="none" id="sidelem4x7571">
					<section type="none" id="sidelem4x7572">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Increase:</emphasis> ALT, AST</bbw>
						</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, Hct</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7592">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7595">
					<section type="none" id="sidelem4x7596">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7604">
							<label>•</label>
							<sec_title>Serious skin toxicities<route> Angioedema occurring 8-21 days after initiating therapy</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7607">
								<item>
									<label>•</label>
									<para>B/P, pulse during treatment until stable</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7612">
								<item>
									<label>•</label>
									<para>Blood studies: Hct, Hgb after 1 mo, 3 mo, then every 3 mo may be decreased</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7620">
							<label>•</label>
							<sec_title>Pulmonary hypertension/CHF</sec_title>
							<para>
								<list id="lidelem4x7620">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pulmonary hypertension/CHF:</emphasis> Fluid retention, weight gain, increased leg edema; may occur within weeks
<bbw>
												<emphasis alert="lifethreat">Hepatic toxicity:</emphasis> vomiting, jaundice; product should be discontinued; hepatic studies: AST, ALT, bilirubin; hepatic enzymes may increase; if ALT/AST &gt;3× and ≤5× ULN, decrease dose or interrupt treatment and monitor AST/ALT q2wk; if bilirubin &gt;2× ULN or signs of hepatitis or hepatic disease are present, stop treatment</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7636">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7640">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pulmonary hypertension</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7646">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7650">
								<item>
									<label>•</label>
									<para>To report jaundice, dark urine, joint pain, fatigue, malaise, bruising, easy bleeding, fluid retention
<bbw>Pregnancy (X), monitor pregnancy test monthly; patient must use nonhormonal contraception during and ≥1 month after conclusion of treatment</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>That lab work will be required periodically</para>
								</item>
								<item>
									<label>•</label>
									<para>To take without regard to food, do not take new meds/herbs without prescriber approval</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active">
			<mono_name>bosutinib</mono_name>
			<info>
				<pronunciation>(boe-sue′ti-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x76800">Bosulif</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic response modifiers</class>
				<class type="chem"> Signal transduction inhibitors (STIs), tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x7690">
				<sec_title>Action:</sec_title>
				<para>Inhibits bcr-abl tyrosine kinase created in patients with chronic myeloid leukemia (CML)</para>
			</section>
			<section type="uses" id="sidelem4x7695">
				<sec_title>Uses:</sec_title>
				<para>Treatment of CML (chronic accelerator phase); Philadelphia-chromosome–positive patients in blast-cell crisis</para>
			</section>
			<section type="contra" id="sidelem4x7700">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x7705">
					<section type="none" id="sidelem4x7706">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, diarrhea, geriatric patients, hepatic disease, bone marrow suppression, infection, thrombocytopenia, neutropenia, immunosuppression, fluid retention</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7713">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7721">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7721">
							<item>
								<label>•</label>
								<para> 500 mg daily with food, may increase to 600 mg/day in those who have not developed grade 3 toxicity or in patients who do not reach complete hematological response by wk 8 or complete cytogenic response (CCyR) by wk 12</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7725">
					<section type="none" id="sidelem4x7726">
						<sec_title>Hepatic dosage</sec_title>
						<section type="none" id="sidelem4x7734">
							<label>•</label>
							<sec_title>Adult<route> PO Any baseline hepatic impairment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7737">
						<sec_title>Dosage adjustments for treatment-related toxicity</sec_title>
						<section type="none" id="sidelem4x7740">
							<sec_title>Hematologic toxicity:</sec_title>
							<para>
								<emphasis alert="nurse">
									<emphasis style="italic">ANC &lt;1000 × 10<emphasis style="sup">6</emphasis>/L or platelet count &lt;50,000 × 10<emphasis style="sup">6</emphasis>/L:</emphasis> hold dose until ANC is ≥1000 × 10<emphasis style="sup">6</emphasis>/L and platelets are ≥50,000 × 10<emphasis style="sup">6</emphasis>/L; if recovery within 2 wk, resume therapy at the same dosage; if blood counts remain low after 2 wk, upon recovery, resume at 100 mg/day less than the previous dosage</emphasis>
							</para>
						</section>
						<section type="none" id="sidelem4x7762">
							<sec_title>Diarrhea:</sec_title>
							<para>
								<emphasis alert="nurse">
									<emphasis style="italic">Grade 3 or 4 diarrhea (≥7 stools/day compared with baseline):</emphasis> hold therapy until recovery to grade 1 toxicity or lower; resume therapy at 400 mg/day</emphasis>
							</para>
						</section>
						<section type="none" id="sidelem4x7772">
							<sec_title>Other nonhematologic toxicity:</sec_title>
							<para>
								<emphasis alert="nurse">
									<emphasis style="italic">Significant or moderate or severe toxicity:</emphasis> hold therapy until toxicity resolves; resume therapy at 400 mg/day</emphasis>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7782">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 500 mg</para>
					</section>
					<section type="none" id="sidelem4x7787">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7790">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7794">
									<item>
										<label>•</label>
										<para>Give with food; swallow whole</para>
									</item>
									<item>
										<label>•</label>
										<para>If dose is missed, take within 12 hr of missed dose; if &gt;12 hr have passed, skip dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Follow cytotoxic handling procedures</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7810">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7813">
					<section type="none" id="sidelem4x7814">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, fever, fatigue, weakness</para>
					</section>
					<section type="none" id="sidelem4x7819">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, abdominal pain, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x7824">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia,</emphasis> bleeding</para>
					</section>
					<section type="none" id="sidelem4x7832">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x7837">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia</para>
					</section>
					<section type="none" id="sidelem4x7842">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, pleural effusion, edema</para>
					</section>
					<section type="none" id="sidelem4x7847">
						<sec_title>OTHER:</sec_title>
						<para> Elevated LFTs</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7852">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 96%; metabolized by CYP3A4; half-life 22.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7857">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bosutinib concentrations—CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin), P-gb inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of simvastatin, calcium channel blockers, ergots</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> bosutinib concentrations—CYP3A4 inducers (dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital), antacids, proton-pump inhibitors</para>
				<section type="none" id="sidelem4x7872">
					<section type="none" id="sidelem4x7873">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> increase bosutinib effect—grapefruit juice; avoid use while taking product</para>
					</section>
					<section type="none" id="sidelem4x7880">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> bosutinib concentration—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x7887">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, magnesium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> bicarbonates, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7898">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7901">
					<section type="none" id="sidelem4x7902">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7908">
								<item>
									<para>
										<emphasis alert="nurse">Myelosuppression: anemia, thrombocytopenia, neutropenia; obtain a CBC weekly × 1 mo, then monthly as needed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7913">
								<item>
									<label>•</label>
									<para>LFTs every mo × 3 mo, then as clinically indicated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7918">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7922">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in leukemic cells or size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7929">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x7937">
							<label>•</label>
							<sec_title>
								<route>To report adverse reactions immediately, bleeding; report diarrhea, hepatic, hematologic symptoms/toxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7940">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7948">
							<label>•</label>
							<sec_title>
								<route>To use effective contraception during treatment and up to 30 days after discontinuing treatment</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active" ha="yes">
			<mono_name> brentuximab</mono_name>
			<info>
				<pronunciation>(bren-tuk′see-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x79580">Adcetris</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Monoclonal antibody</class>
			</info>
			<section type="actions" id="sidelem4x7968">
				<sec_title>Action:</sec_title>
				<para>The anticancer activity is due to the binding of the ADC to CD30-expressing cells, followed by the internalization and transportation of the ADC-CD30 complex to lysosomes and the release of MMAE via selective proteolytic cleavage; MMAE binds to tubulin and disrupts the microtubule network within the cell, inducing cell cycle arrest and apoptotic death of the cells</para>
			</section>
			<section type="uses" id="sidelem4x7973">
				<sec_title>Uses:</sec_title>
				<para>For the treatment of Hodgkin’s disease after failure of autologous stem cell transplant (ASCT) or after failure of at least 2 prior multiagent chemotherapy regimens in patients who are not ASCT candidates; for the treatment of non-Hodgkin’s lymphoma (NHL); for the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 prior multiagent chemotherapy regimen</para>
			</section>
			<section type="contra" id="sidelem4x7978">
				<sec_title>Contraindications</sec_title>
				<para>Hypersensitivity, pregnancy (category D)</para>
				<section type="none" id="sidelem4x7983">
					<section type="none" id="sidelem4x7984">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, infants, neonates, neutropenia, peripheral neuropathy, tumor lysis syndrome (TLS)</para>
						<para>
							<bbw>Progressive multifocal leukoencephalopathy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7999">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8007">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x8007">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis>   1.8 mg/kg over 30 min every 3 wk until disease progression, or unacceptable toxicity; for patients &gt;100 kg, max weight used for dosage calculation should be 100 kg, which translates to no more than 180 mg/dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8014">
					<section type="none" id="sidelem4x8015">
						<sec_title>Dose adjustments for toxicity due to peripheral neuropathy:</sec_title>
						<section type="none" id="sidelem4x8023">
							<label>•</label>
							<sec_title>For grade &lt;3<route> no dosage adjustments are recommended; for new or worsening grade 2-3</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8026">
						<sec_title>Dose adjustments for toxicity due to neutropenia:</sec_title>
						<section type="none" id="sidelem4x8034">
							<label>•</label>
							<sec_title>For neutropenia grade &lt;3<route> no dosage adjustments; for grade 3-4 neutropenia</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8037">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 50 mg</para>
					</section>
					<section type="none" id="sidelem4x8042">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8045">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x8049">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration whenever sol and container permit</para>
									</item>
									<item>
										<label>•</label>
										<para>Only as an IV infusion, do not give as an IV push or bolus</para>
									</item>
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not mix, or administer as an infusion, with other IV products</para>
									</item>
									<item>
										<label>•</label>
										<para>Calculate the dose (mg) and the number of vials required. For patients weighing &gt;100 kg, use 100 kg to calculate the dose; reconstitute each 50-mg vial per 10.5 ml of sterile water for inj (5 mg/ml)</para>
									</item>
									<item>
										<label>•</label>
										<para>Direct the stream of sterile water toward the wall of the vial and not directly at the cake or powder; gently swirl the vial to aid in dissolution, do not shake</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard any unused portion left in the vial</para>
									</item>
									<item>
										<label>•</label>
										<para>After reconstitution, dilute immediately with ≥100 ml of 0.9% sodium chloride, 5% dextrose, or lactated Ringer’s solution to a final concentration (0.4 mg/ml-1.8 mg/ml)</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse over 30 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Use the diluted sol immediately or store in refrigerator for ≤24 hr after reconstitution; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8101">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8104">
					<section type="none" id="sidelem4x8105">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, <emphasis style="italic">fever,</emphasis> peripheral neuropathy, anxiety, chills, confusion, <emphasis style="italic">fatigue,</emphasis> paresthesias, insomnia, night sweats, <emphasis style="bold">progressive multifocal leukoencephalopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8118">
						<sec_title>CV:</sec_title>
						<para> Peripheral edema, supraventricular arrhythmia</para>
					</section>
					<section type="none" id="sidelem4x8123">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, nausea, vomiting,</emphasis> constipation, <emphasis style="italic">diarrhea,</emphasis> weight loss</para>
					</section>
					<section type="none" id="sidelem4x8134">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus, alopecia, xerosis</para>
					</section>
					<section type="none" id="sidelem4x8142">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pneumothorax, pneumonitis, pulmonary embolism,</emphasis> dyspnea, <emphasis style="italic">cough</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8152">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, tumor lysis syndrome, antibody formation, Stevens-Johnson syndrome, infusion reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8159">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, neutropenia, thrombocytopenia, lymphadenopathy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8166">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding is 68%-82%, only a small amount is metabolized; potent inhibitors or inducers of CYP3A4 may alter action; ADC peak at end of infusion; MME peak 1-3 days; terminal half-life is 4-6 days; 3 components are released: MMAE (monomethyl auristatin E), ADC, and the total antibody; the half-life of MMAE a component is 3.43-3.6 days</para>
			</section>
			<section type="interactions" id="sidelem4x8171">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> brentuximab action: CYP3A4 inducers, P-gb inhibitors, ketoconazole, boceprevir, delavirdine, isoniazid, indinavir, itraconazole, dalfopristin; quinupristin, telithromycin, tipranavir, rifampin, ritonavir</para>
				<para>
					<emphasis alert="lifethreat">Increase: noninfectious pulmonary toxicity bleomycin, do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> brentuximab action-CYP3A4 inducers</para>
				<section type="none" id="sidelem4x8185">
					<section type="none" id="sidelem4x8186">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x8190">
								<item>
									<label>•</label>
									<para>Increased brentuximab component action: St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8196">
						<sec_title>Drug/Lab:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets, RBCs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8207">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8210">
					<section type="none" id="sidelem4x8211">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8219">
							<label>•</label>
							<sec_title>Tumor lysis syndrome (TLS)<route> assess for hyperkalemia, hypophosphatemia, hypocalcemia; may develop renal failure; may use allopurinol or rasburicase to prevent TLS; monitor serum BUN/creatinine</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8225">
							<label>•</label>
							<sec_title>Pregnancy<route> determine if pregnancy is planned or suspected, pregnancy category D</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8231">
							<label>•</label>
							<sec_title>Peripheral neuropathy, progressive multifocal leukoencephalopathy<route> assess for weakness or paralysis, vision loss, impaired speech, and cognitive deterioration; often fatal</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8234">
								<item>
									<label>•</label>
									<para>Monitor CBC, and differential, LFTs, serum bilirubin (direct and indirect), electrolytes, uric acid, neurologic function</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8239">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8243">
								<item>
									<label>•</label>
									<para>Decreasing symptoms of Hodgkin’s disease (increased lymph nodes, night sweats, weight loss, splenomegaly, hepatomegaly)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8249">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8257">
							<label>•</label>
							<sec_title>
								<route>To report immediately weakness, change in vision, impaired speech; peripheral neuropathy, neutropenia if severe</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8263">
							<label>•</label>
							<sec_title>
								<route>To use reliable contraception (pregnancy [D]); to avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>brimonidine (ophthalmic)</mono_name>
			<info>
				<pronunciation>(bri-moe′ni-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x82710">Alphagan P</tradename>
				</tradenames>
				<class type="func"> Antiglaucoma</class>
				<class type="chem"> Selective α-2 agonist</class>
			</info>
			<section type="confusion" id="sidelem4x8281">
				<para>
					<confusion>
						<tradename id="tnidelem4x82810">brimonidine</tradename>
						<drug type="generic" refid="idelem4x82810">bimatoprost</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8285">
				<sec_title>Action:</sec_title>
				<para>Select α-agonist that decreases aqueous humor and increases outflows</para>
			</section>
			<section type="uses" id="sidelem4x8290">
				<sec_title>Uses:</sec_title>
				<para>Treatment of chronic open-angle glaucoma and ocular hypertension</para>
			</section>
			<section type="contra" id="sidelem4x8295">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, AV block, heart failure, bradycardia, sick sinus syndrome, within 14 days of MAOIs therapy</para>
				<section type="none" id="sidelem4x8302">
					<section type="none" id="sidelem4x8303">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, depression, cerebrovascular disease, hepatic/renal impairment, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8308">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8316">
					<label>•</label>
					<sec_title>
						<route>Adult/child &gt;</route>
					</sec_title>
					<para>
						<list id="lidelem4x8316">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">2 yr:</emphasis> Instill 1 drop in the affected eye(s) tid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8322">
					<section type="none" id="sidelem4x8323">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.1%, 0.15%, 0.2%</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8328">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8331">
					<section type="none" id="sidelem4x8332">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, bronchitis, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x8337">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, somnolence</para>
					</section>
					<section type="none" id="sidelem4x8342">
						<sec_title>CV:</sec_title>
						<para> Hyper/hypotension, hypercholesterolemia</para>
					</section>
					<section type="none" id="sidelem4x8347">
						<sec_title>EENT:</sec_title>
						<para> Eye stinging/burning, tearing, photophobia, change in vision, sinus infection, blurred vision, pruritus, photophobia, eyelid erythema, ocular pain, nasal dryness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8352">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr, half-life 2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8363">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> intraocular pressure reduction—apraclonidine, dorzolamide, pilocarpine, timolol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of—CNS depressants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> B/P—β-blockers, antihypertensives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> brimonidine effect—tricyclic antidepressants, may cause HTN crisis MAOIs, linezolid</para>
			</section>
			<section type="considerations" id="sidelem4x8382">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8385">
					<section type="none" id="sidelem4x8386">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8390">
								<item>
									<label>•</label>
									<para>Glaucoma: monitor intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8396">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8400">
								<item>
									<label>•</label>
									<para>Decreasing intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8406">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8410">
								<item>
									<label>•</label>
									<para>That drug is for ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>To wash hands before and after use; to tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch; close eyes to spread drops; to avoid excessive systemic absorption, apply finger pressure on the lacrimal sac for 1-2 min following use</para>
								</item>
								<item>
									<label>•</label>
									<para>That if more than one topical ophthalmic drug product is being used, the drugs should be administered at least 10 min apart</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid contamination or the spread of infection, do not use dropper for more than one person</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>brinzolamide ophthalmic</mono_name>
			<section type="none" id="sidelem4x8439">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>bromfenac (ophthalmic)</mono_name>
			<info>
				<pronunciation>(brom′fen-ak)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x84480">Prolensa</tradename>
				</tradenames>
				<class type="func"> Antiinflammatory (ophthalmic)</class>
				<class type="chem"> Nonsteroidal antiflammatory drug</class>
			</info>
			<section type="actions" id="sidelem4x8458">
				<sec_title>Action:</sec_title>
				<para>The mechanism of action is thought to be ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood–aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure</para>
			</section>
			<section type="uses" id="sidelem4x8463">
				<sec_title>Uses:</sec_title>
				<para>To reduce pain and inflammation after cataract surgery</para>
			</section>
			<section type="contra" id="sidelem4x8468">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, sulfites, NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x8473">
					<section type="none" id="sidelem4x8474">
						<sec_title>Precautions:</sec_title>
						<para> Bleeding disorders, complicated ocular surgery, corneal denervation, diabetes mellitus, rheumatoid arthritis, dry eye syndrome, pregnancy (C), breastfeeding</para>
						<para>Do not administer while wearing contact lenses</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8483">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8491">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x8491">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> Instill 1 drop into affected eye twice daily beginning 24 hr before cataract surgery, continued on the day of surgery and through the first 14 days of the postoperative period</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8495">
					<section type="none" id="sidelem4x8496">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.07%, 0.09%</para>
					</section>
					<section type="none" id="sidelem4x8501">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8505">
								<item>
									<label>•</label>
									<para>Apply topically to the eye</para>
								</item>
								<item>
									<label>•</label>
									<para>Remove contact lenses before instilling solution; contact lenses should not be worn during use of this product</para>
								</item>
								<item>
									<label>•</label>
									<para>Instruct patient on proper instillation of eye solution</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not share bottle with other patients</para>
								</item>
								<item>
									<label>•</label>
									<para>If more than one ophthalmic medication is being used, the medications should be administered at least 5 min apart</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8536">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8539">
					<section type="none" id="sidelem4x8540">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x8545">
						<sec_title>EENT:</sec_title>
						<para> Abnormal sensation in eye, conjunctival hyperemia, ocular irritation, ocular pain, ocular pruritus, conjunctival hyperemia, iritis, keratitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8550">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Unknown</para>
			</section>
			<section type="interactions" id="sidelem4x8555">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> corneal erosion, poor healing—topical corticosteroids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> intraocular pressure—latanoprost</para>
				<section type="none" id="sidelem4x8570">
					<section type="none" id="sidelem4x8571">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding time</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8578">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8581">
					<section type="none" id="sidelem4x8582">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8586">
								<item>
									<label>•</label>
									<para>Eyes for pain, inflammation, burning, redness after cataract surgery</para>
								</item>
								<item>
									<label>•</label>
									<para>Identify if patient is using topical corticosteroids, anticoagulants; use cautiously in those using these products</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8597">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8601">
								<item>
									<label>•</label>
									<para>Decreased pain and inflammation after cataract surgery</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8607">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8611">
								<item>
									<label>•</label>
									<para>To apply topically to the eye</para>
								</item>
								<item>
									<label>•</label>
									<para>To remove contact lenses before instilling solution; contact lenses should not be worn during use of this product</para>
								</item>
								<item>
									<label>•</label>
									<para>Proper instillation of eye solution</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to share bottle with other patients</para>
								</item>
								<item>
									<label>•</label>
									<para>That if more than one ophthalmic medication is being used, the medications should be administered at least 5 min apart</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="39" status="active">
			<mono_name>bromocriptine (Rx)</mono_name>
			<info>
				<pronunciation>(broe-moe-krip′teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x86471">Cycloset</tradename>
					<tradename id="tnidelem4x86470">Parlodel</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> Dopamine receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8657">
				<para>
					<confusion>
						<tradename id="tnidelem4x86570">Parlodel</tradename>
						<drug type="generic" refid="idelem4x86570">pindolol/Provera bromocriptine/benztropine/brimonidine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8661">
				<sec_title>Action:</sec_title>
				<para>Inhibits prolactin release by activating postsynaptic dopamine receptors; activation of striatal dopamine receptors may be reason for improvement in Parkinson’s disease</para>
			</section>
			<section type="uses" id="sidelem4x8666">
				<sec_title>Uses:</sec_title>
				<para>Parkinson’s disease, amenorrhea/galactorrhea caused by hyperprolactinemia, infertility, acromegaly, pituitary adenomas, adjunct for type 2 diabetes</para>
				<section type="none" id="sidelem4x8671">
					<section type="none" id="sidelem4x8672">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Neuroleptic malignant syndrome, alcoholism, premenstrual syndrome, mastalgia, cocaine withdrawal, premenstrual breast symptoms</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8677">
				<sec_title>Contraindications:</sec_title>
				<para>Severe ischemic disease, uncontrolled hypertension, severe peripheral vascular disease; hypersensitivity to ergot, bromocriptine; migraine, preeclampsia</para>
				<section type="none" id="sidelem4x8684">
					<section type="none" id="sidelem4x8685">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, renal/hepatic disease, pituitary tumors, peptic ulcer disease, sulfite hypersensitivity, pulmonary fibrosis, dementia, GI bleeding, bipolar disorder</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8690">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8693">
					<section type="none" id="sidelem4x8694">
						<sec_title>Parkinson’s disease</sec_title>
						<section type="none" id="sidelem4x8702">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8702">
									<item>
										<label>•</label>
										<para> 1.25 mg bid with meals; may increase q2-4wk by 2.5 mg/day, max 100 mg/day; levodopa should be continued while bromocriptine is being instituted</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8706">
						<sec_title>Hyperprolactinemia</sec_title>
						<section type="none" id="sidelem4x8714">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8714">
									<item>
										<label>•</label>
										<para> 1.25-2.5 mg with meals; may increase by 2.5 mg q3-7days, usual range 2.5-15 mg/day, max 30 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8718">
						<sec_title>Acromegaly</sec_title>
						<section type="none" id="sidelem4x8726">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8726">
									<item>
										<label>•</label>
										<para> 1.25-2.5 mg × 3 days at bedtime; may increase by 1.25-2.5 mg q3-7days; usual range 20-30 mg/day, max 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8730">
						<sec_title>Pituitary adenoma</sec_title>
						<section type="none" id="sidelem4x8738">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8738">
									<item>
										<label>•</label>
										<para> 1.25 mg bid-tid; may increase over several wk to 10-20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8742">
						<sec_title>Type 2 diabetes (Cycloset only)</sec_title>
						<section type="none" id="sidelem4x8750">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8750">
									<item>
										<label>•</label>
										<para> (initially) 0.8 mg daily in <emphasis style="smallcaps">am</emphasis> within 2 hr of waking; titrate by 0.8 mg/day no more than weekly to max 1.6-4.8 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8757">
						<sec_title>Available forms:</sec_title>
						<para> Caps 5 mg; tabs 2.5 mg (Parodel), 0.8 mg (Cycloset)</para>
					</section>
					<section type="none" id="sidelem4x8762">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8766">
								<item>
									<label>•</label>
									<para>With meal to prevent GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>At bedtime so that dizziness, orthostatic hypotension do not occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature in tight, light-resistant container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8782">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8785">
					<section type="none" id="sidelem4x8786">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> depression, restlessness, anxiety, nervousness, confusion, <emphasis style="bold">seizures,</emphasis><emphasis style="italic">hallucinations,</emphasis> dizziness, fatigue, drowsiness, abnormal involuntary movements, psychosis, weakness</para>
					</section>
					<section type="none" id="sidelem4x8799">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, decreased B/P, palpitations, extrasystole, <emphasis style="bold">shock,</emphasis> dysrhythmias, bradycardia, <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8809">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, diplopia, burning eyes, nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x8814">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> cramps, constipation, diarrhea, dry mouth, <emphasis style="bold">GI hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8824">
						<sec_title>GU:</sec_title>
						<para> Frequency, retention, incontinence, diuresis</para>
					</section>
					<section type="none" id="sidelem4x8829">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash on face, arms;</emphasis> alopecia; coolness, pallor of fingers, toes; peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x8837">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8842">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-3 hr, duration 4-8 hr, 90%-96% protein bound, half-life 3 hr, metabolized by liver (inactive metabolites), 85%-98% of dose excreted in feces, &gt;90% of absorbed dose undergoes 1st-pass metabolism</para>
			</section>
			<section type="interactions" id="sidelem4x8847">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x8851">
						<item>
							<label>•</label>
							<para>Disulfiram-like reaction: alcohol</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of antihypertensives, levodopa, chloramphenicol, probenecid, salicylates, sulfonamides</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of bromocriptine—phenothiazines, oral contraceptives, progestins, estrogens, haloperidol, loxapine, methyldopa, metoclopramide, MAOIs, reserpine</para>
				<para>
					<emphasis style="bold">Decrease/increase:</emphasis> effect of Cyclosert-CYP3A4 inhibitors/inducers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of Cyclosert-butyrophenones, metoclopramide, phenothiazine, thioxanthenes</para>
				<section type="none" id="sidelem4x8873">
					<section type="none" id="sidelem4x8874">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> growth hormone, AST, ALT, CK, BUN, uric acid, alk phos</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8881">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8884">
					<section type="none" id="sidelem4x8885">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8890">
								<item>
									<label>•</label>
									<para>B/P; establish baseline, compare with other readings; this product decreases B/P and causes orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8898">
							<label>•</label>
							<sec_title>Parkinson’s symptoms</sec_title>
							<para>
								<list id="lidelem4x8898">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinson’s symptoms:</emphasis> pill rolling, shuffling gait, restlessness, tremors, postural instability before and during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8906">
							<label>•</label>
							<sec_title>Neuroleptic malignant syndrome<route> decreased temperature, seizures, sweating, pulse indicates resolution of symptoms</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8909">
								<item>
									<label>•</label>
									<para>Change in size of soft-tissue volume with acromegaly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8917">
							<label>•</label>
							<sec_title>Pregnancy<route> may cause postpartum conception, use pregnancy testing q4wk or if menstruation does not occur</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8920">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8924">
								<item>
									<label>•</label>
									<para>Therapeutic response (Parkinson’s disease): decreased dyskinesia, slow movements, drooling</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8930">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8935">
								<item>
									<label>•</label>
									<para>That tabs may be crushed, mixed with food; Cyclosert to be taken within 2 hr of rising</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8940">
								<item>
									<label>•</label>
									<para>To change position slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8948">
							<label>•</label>
							<sec_title>
								<route>To use contraceptives during treatment with this product; that pregnancy may occur; to use methods other than oral contraceptives/subdermal implants</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8951">
								<item>
									<label>•</label>
									<para>That therapeutic effect for Parkinson’s disease may take 2 mo, titrate slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8956">
								<item>
									<label>•</label>
									<para>To avoid hazardous activity if dizziness occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8964">
							<label>•</label>
							<sec_title>
								<route>To report symptoms of MI immediately</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8967">
								<item>
									<label>•</label>
									<para>To take with food, avoid alcohol</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>budesonide (Rx)</mono_name>
			<info>
				<pronunciation>(byoo-des′oh-nide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x89776">Uceris</tradename>
					<tradename id="tnidelem4x89775">Entocort EC</tradename>
					<tradename id="tnidelem4x89774">Pulmicort</tradename>
					<tradename id="tnidelem4x89773">Pulmicort Flexhaler</tradename>
					<tradename id="tnidelem4x89772">Rhinocort Allergy</tradename>
					<tradename id="tnidelem4x89771">Rhinocort Aqua</tradename>
					<tradename id="tnidelem4x89770">Uceris</tradename>
				</tradenames>
				<class type="func"> Glucocorticoid</class>
				<class type="chem"> Nonhalogenated</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8987">
				<sec_title>Action:</sec_title>
				<para>Prevents inflammation by depressing migration of polymorphonuclear leukocytes and fibroblasts, reversal of increased capillary permeability, and lysosomal stabilization; does not suppress hypothalamus or pituitary function</para>
			</section>
			<section type="uses" id="sidelem4x8992">
				<sec_title>Uses:</sec_title>
				<para>Rhinitis; prophylaxis for asthma; Crohn’s disease, ulcerative colitis</para>
				<section type="none" id="sidelem4x8997">
					<section type="none" id="sidelem4x8998">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Microscopic colitis, laryngotracheobronchitis (croup)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9003">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, status asthmaticus, acute bronchospasm</para>
				<section type="none" id="sidelem4x9008">
					<section type="none" id="sidelem4x9009">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), inhaled form (B); breastfeeding; children; TB; fungal, bacterial, systemic viral infections; ocular herpes simplex; nasal septal ulcers; hepatic disease, diabetes, GI disease, increased intraocular pressure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9014">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9017">
					<section type="none" id="sidelem4x9018">
						<sec_title>Rhinitis</sec_title>
						<section type="none" id="sidelem4x9026">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> SPRAY/INH</route></sec_title>
							<para>
								<list id="lidelem4x9026">
									<item>
										<label>•</label>
										<para> 2 sprays in each nostril <emphasis style="smallcaps">am</emphasis>, <emphasis style="smallcaps">pm</emphasis> or 4 sprays in each nostril <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9038">
						<sec_title>Asthma</sec_title>
						<section type="none" id="sidelem4x9046">
							<label>•</label>
							<sec_title>Adult<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x9046">
									<item>
										<label>•</label>
										<para> 360 mcg bid, max 720 mcg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9053">
							<label>•</label>
							<sec_title>Child 1-8 yr previously taking bronchodilator alone</sec_title>
							<para>
								<list id="lidelem4x9053">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child 1-8 yr previously taking bronchodilator alone:</emphasis> (Respules) 0.5 mg daily or 0.25 mg bid; susp via jet nebulizer, max 0.5 mg daily; previously using inhaled corticosteroid 0.5 mg daily or 0.25 mg bid susp via jet nebulizer, max 0.5 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9057">
						<sec_title>Crohn’s disease/ulcerative colitis (Uceris)</sec_title>
						<section type="none" id="sidelem4x9065">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9065">
									<item>
										<label>•</label>
										<para> 9 mg/day <emphasis style="smallcaps">am</emphasis> × 8 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9072">
						<sec_title>Laryngotracheobronchitis (croup) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9080">
							<label>•</label>
							<sec_title>Infant ≥3 mo-child ≤5 yr<route> NEB</route></sec_title>
							<para>
								<list id="lidelem4x9080">
									<item>
										<label>•</label>
										<para> (Pulmicort Respules INH susp) 2 mg inhaled as a single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9084">
						<sec_title>Available forms:</sec_title>
						<para> Dry powder for INH 90, 180; 32 mcg/actuation (Rhinocort Aqua) nasal spray; susp for INH 0.5 mg/2 ml, 0.25 mg/2 ml; cap 3 mg; ext rel tab (Uceris) 9 mg, rectal foam 2 mg/actuation</para>
					</section>
					<section type="none" id="sidelem4x9089">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9092">
							<sec_title>PO route (Crohn’s disease/ulcerative colitis)</sec_title>
							<para>
								<list id="lidelem4x9096">
									<item>
										<label>•</label>
										<para>Swallow caps whole; do not break, crush, chew, take in <emphasis style="smallcaps">am</emphasis></para>
									</item>
									<item>
										<label>•</label>
										<para>May repeat 8-wk course if needed; may taper to 6 mg/day for 2 wk before cessation</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at 59° F-86° F (15° C-30° C); keep away from heat, open flame</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9114">
							<sec_title>Rectal foam route</sec_title>
							<para>
								<list id="lidelem4x9118">
									<item>
										<label>•</label>
										<para>Product is flammable, may use before bedtime, applicators are single use only</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9125">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9128">
					<section type="none" id="sidelem4x9129">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> insomnia, hypertonia, syncope, dizziness, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x9137">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypertension, sinus tachycardia, palpitation</para>
					</section>
					<section type="none" id="sidelem4x9142">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Sinusitis, pharyngitis,</emphasis> rhinitis, oral candidiasis</para>
					</section>
					<section type="none" id="sidelem4x9150">
						<sec_title>ENDO:</sec_title>
						<para> Adrenal insufficiency, growth suppression in children</para>
					</section>
					<section type="none" id="sidelem4x9155">
						<sec_title>GI:</sec_title>
						<para> Dry mouth, dyspepsia, nausea, vomiting, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x9160">
						<sec_title>MISC:</sec_title>
						<para> Ecchymosis, fever, <emphasis style="italic">hypersensitivity,</emphasis> flulike symptoms, epistaxis, dysuria</para>
					</section>
					<section type="none" id="sidelem4x9168">
						<sec_title>MS:</sec_title>
						<para> Back pain, myalgias, fractures</para>
					</section>
					<section type="none" id="sidelem4x9173">
						<sec_title>RESP:</sec_title>
						<para> Nasal irritation, cough, nasal bleeding, <emphasis style="italic">respiratory infections,</emphasis><emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9182">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9185">
					<section type="none" id="sidelem4x9186">
						<sec_title>Peak:</sec_title>
						<para> Respules 4-6 wk, Rhinocort Aqua 2 wk, half-life 2-3.6 hr</para>
					</section>
					<section type="none" id="sidelem4x9191">
						<sec_title>Onset:</sec_title>
						<para> Respules 2-8 days, Rhinocort Aqua 10 hr</para>
						<para>Enters breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9198">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> budesonide effect, CYP3A inhibitors, dose adjustment may be needed<list id="lidelem4x9205">
						<item>
							<label>•</label>
							<para>Avoid concurrent use of varicella live vaccine in pediatric patients</para>
						</item>
					</list></para>
			</section>
			<section type="considerations" id="sidelem4x9211">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9214">
					<section type="none" id="sidelem4x9215">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9220">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, increase in bronchial secretions, wheezing, chest tightness; provide fluids to 2 L/day to decrease thickness of secretions; check for oral candidiasis</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9228">
							<label>•</label>
							<sec_title>Bronchospasm<route> stop treatment, give bronchodilator</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9231">
								<item>
									<label>•</label>
									<para>Viral infections: corticosteroid use can mask infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9236">
								<item>
									<label>•</label>
									<para>Increased intraocular pressure: discontinue use if this occurs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9241">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9245">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of asthma, rhinitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9251">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9255">
								<item>
									<label>•</label>
									<para>To notify prescriber of pharyngitis, nasal bleeding, oral candidiasis</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to exceed recommended dose because adrenal suppression may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID that identifies steroid use</para>
								</item>
								<item>
									<label>•</label>
									<para>To read and follow package directions</para>
								</item>
								<item>
									<label>•</label>
									<para>To prevent exposure to infections (especially viral)</para>
								</item>
								<item>
									<label>•</label>
									<para>To use good oral hygiene if using nebulizer or inhaler</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>That burning or stinging may occur with first few doses of inhalation use</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is not a bronchodilator and not to be used for asthma; to use regularly</para>
								</item>
								<item>
									<label>•</label>
									<para>Teach how to use as described in “administer”</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if symptoms persist after wks, that results usually take 2 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if exposure to measles, chickenpox occurs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>budesonide nasal agent</mono_name>
			<section type="none" id="sidelem4x9319">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="42" status="active">
			<mono_name>bumetanide (Rx)</mono_name>
			<info>
				<pronunciation>(byoo-met′a-nide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x93281">Bumex</tradename>
					<tradename id="tnidelem4x93280">
						<country code="CAN">Burinex</country>
					</tradename>
				</tradenames>
				<class type="func"> Loop diuretic, antihypertensive</class>
				<class type="chem"> Sulfonamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9340">
				<sec_title>Action:</sec_title>
				<para>Acts on ascending loop of Henle by inhibiting reabsorption of chloride, sodium</para>
			</section>
			<section type="uses" id="sidelem4x9345">
				<sec_title>Uses:</sec_title>
				<para>Edema in CHF, heart failure</para>
				<section type="none" id="sidelem4x9350">
					<section type="none" id="sidelem4x9351">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hypercalcemia, hypertension, ascites</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9356">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sulfonamides, anuria, hepatic coma</para>
				<para>
					<bbw>Electrolyte imbalance</bbw>
				</para>
				<section type="none" id="sidelem4x9372">
					<section type="none" id="sidelem4x9373">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, neonates, ascites, severe renal disease, hepatic cirrhosis, blood dyscrasias, ototoxicity, hyperuricemia, hypokalemia, hyperglycemia, oliguria, hypomagnesemia, hypovolemia</para>
						<para>
							<bbw>Dehydration</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9388">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9396">
					<label>•</label>
					<sec_title>Adult and adolescent<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9396">
							<item>
								<label>•</label>
								<para> 0.5-2 mg/day; may give 2nd or 3rd dose at 4-5 hr intervals, max 10 mg/day; may be given on alternate days or intermittently;  0.5-1 mg; may give 2nd or 3rd dose at 2-3 hr intervals, not to exceed 10 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9406">
					<label>•</label>
					<sec_title>Child and infant (unlabeled)<route> PO/IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x9406">
							<item>
								<label>•</label>
								<para> 0.015-0.1 mg/kg daily or every other day, max 10 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9410">
					<section type="none" id="sidelem4x9411">
						<sec_title>Hypercalcemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9419">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9419">
									<item>
										<label>•</label>
										<para> 1-2 mg q1-4hr to maintain urine output of 200-250 ml/hr; give saline before 1st dose of this product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9423">
						<sec_title>Hypertension (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9431">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9431">
									<item>
										<label>•</label>
										<para> 0.5-2 mg/day, max 10 mg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9435">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1, 2, 5 <country code="CAN">FIX_STRUCTURE Tabs 0.5, 1, 2, 5</country> mg; inj 0.25 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x9443">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9447">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep if using product as a diuretic; without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Potassium replacement if potassium is &lt;3.0</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9461">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x9465">
									<item>
										<label>•</label>
										<para>Use in <emphasis style="smallcaps">am</emphasis> to prevent nocturia</para>
									</item>
									<item>
										<label>•</label>
										<para>Without regard to food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9479">
							<sec_title>IV, direct route</sec_title>
							<para>
								<list id="lidelem4x9483">
									<item>
										<label>•</label>
										<para>Direct IV undiluted slowly over 1-2 min through <emphasis style="sans-serif">Y</emphasis>-tube, 3-way stopcock, or heplock</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9492">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9496">
									<item>
										<label>•</label>
										<para>Dilute in LR, D<emphasis style="inf">5</emphasis>W, 0.9% NaCl (rarely given by this method), give over 12 hr with renal disease</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Doxapram</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amoxicillin, amphotericin B lipid complex (Abelcet), amphotericin B liposome (AmBisome), anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefepime, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, ceftobiprole, cefTRIAXone, cefuroxime, cephapirin, chloramphenicol, cimetidine, cisatracurium, CISplatin, cladribine, clarithromycin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone sodium succinate, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, micafungin, miconazole, milrinone, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, penicillin G potassium/sodium, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, rifampin, ritodrine, riTUXimab, rocuronium, sodium acetate, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, traMADol, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9515">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9518">
					<section type="none" id="sidelem4x9519">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fatigue, weakness, <emphasis style="italic">dizziness,</emphasis><emphasis style="bold">encephalopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9531">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Chest pain,</emphasis><emphasis style="italic">hypotension,</emphasis><emphasis style="bold">circulatory collapse,</emphasis> ECG changes, dehydration</para>
					</section>
					<section type="none" id="sidelem4x9543">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Loss of hearing</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9550">
						<sec_title>ELECT:</sec_title>
						<para> <emphasis style="italic">Hypokalemia, hypochloremic alkalosis, hypomagnesemia, hyperuricemia, hypocalcemia, hyponatremia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9557">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="italic">Hyperglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9564">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> diarrhea, dry mouth, vomiting, anorexia, cramps, upset stomach, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x9572">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Polyuria,</emphasis><emphasis style="bold">renal failure,</emphasis> glycosuria, premature ejaculation, hypercholesterolemia</para>
					</section>
					<section type="none" id="sidelem4x9582">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, granulocytopenia, hemoconcentration</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9589">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> purpura, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> sweating</para>
					</section>
					<section type="none" id="sidelem4x9600">
						<sec_title>MS:</sec_title>
						<para> Muscular cramps, arthritis, stiffness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9605">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted by kidneys (50% unchanged), feces (20%); crosses placenta; excreted in breast milk; protein binding &gt;96%; half-life 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
				<section type="none" id="sidelem4x9616">
					<section type="none" id="sidelem4x9617">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, peak 1-2 hr, duration 3-6 hr ​</para>
					</section>
					<section type="none" id="sidelem4x9628">
						<sec_title>IM:</sec_title>
						<para> Onset 40 min, peak 1-2 hr, duration 4-6 hr</para>
					</section>
					<section type="none" id="sidelem4x9633">
						<sec_title>IV:</sec_title>
						<para> Onset 5 min, peak 15-30 min, duration 3-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9638">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x9646">
					<label>•</label>
					<sec_title>Increase</sec_title>
					<para>
						<list id="lidelem4x9646">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Increase:</emphasis> ototoxicity: aminoglycosides, cisplatin</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9653">
					<label>•</label>
					<sec_title>Increase</sec_title>
					<para>
						<list id="lidelem4x9653">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Increase:</emphasis> hypokalemia: potassium-wasting products</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—lithium, digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> diuresis, electrolyte loss—metolazone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> diuretic effect—indomethacin, NSAIDs, probenecid, other diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antidiabetic effects—antidiabetics</para>
				<section type="none" id="sidelem4x9673">
					<section type="none" id="sidelem4x9674">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—hawthorn, horse chestnut</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect of bumetanide—ginseng, ephedra</para>
					</section>
					<section type="none" id="sidelem4x9685">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> chloride, potassium, sodium, calcium, phosphorus</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9696">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9699">
					<section type="none" id="sidelem4x9700">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9705">
								<item>
									<label>•</label>
									<para>For tinnitus; obtain audiometric testing for long-term IV treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9710">
								<item>
									<label>•</label>
									<para>Weight, I&amp;O daily to determine fluid loss; if urinary output decreases or azotemia occurs, product should be discontinued; safest dosage schedule is alternate days</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9718">
							<para>
								<list id="lidelem4x9718">
									<item>
										<label>•</label>
										<para>B/P lying, standing; postural hypotension may occur
<bbw>
												<emphasis alert="lifethreat">Electrolyte imbalances:</emphasis> Potassium, sodium, calcium; include BUN, blood glucose, CBC, serum creatinine, blood pH, ABGs, uric acid, calcium, magnesium; severe electrolyte imbalances should be corrected before starting treatment</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9731">
								<item>
									<label>•</label>
									<para>Blood glucose if patient is diabetic; blood uric acid levels in those with gout</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9736">
								<item>
									<label>•</label>
									<para>Improvement in edema of feet, legs, sacral area daily if medication is being used for CHF</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9741">
								<item>
									<label>•</label>
									<para>Signs of metabolic alkalosis: drowsiness, restlessness</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9749">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x9749">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> postural hypotension, malaise, fatigue, tachycardia, leg cramps, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9753">
								<item>
									<label>•</label>
									<para>Rashes, temperature elevation daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9758">
								<item>
									<label>•</label>
									<para>Confusion, especially in geriatric patients; take safety precautions if needed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9767">
							<label>•</label>
							<sec_title>Digoxin toxicity in patients taking digoxin products<route> anorexia, nausea, vomiting, confusion, paresthesia, muscle cramps; lithium toxicity in those taking lithium</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9770">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9774">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased edema, B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9780">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9784">
								<item>
									<label>•</label>
									<para>To increase fluid intake to 2-3 L/day unless contraindicated; to take potassium supplement; to rise slowly from lying or sitting position</para>
								</item>
								<item>
									<label>•</label>
									<para>To recognize adverse reactions: muscle cramps, weakness, nausea, dizziness, edema, weight gain</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with food, milk for GI symptoms; to avoid alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>To take early in day to prevent nocturia</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunscreen to prevent photosensitivity</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x9810">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if taken orally; monitor electrolytes; administer dextrose in saline; monitor hydration, CV, renal status</para>
			</section>
		</monograph>
<monograph id="43" status="active" ha="yes">
			<mono_name> buprenorphine (Rx)</mono_name>
			<info>
				<pronunciation>(byoo-pre-nor′feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x98222">Belbuca</tradename>
					<tradename id="tnidelem4x98221">Buprenex</tradename>
					<tradename id="tnidelem4x98220">
						<country code="CAN">Butrans</country>
					</tradename>
				</tradenames>
				<class type="func"> Opioid analgesic, partial agonist</class>
				<class type="chem"> Thebaine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="5">V</schedule><schedule num="3">III</schedule> (Parenteral); Schedule III (Tablet, TD)</class>
			</info>
			<section type="confusion" id="sidelem4x9837">
				<para>
					<confusion>
						<tradename id="tnidelem4x98370">Buprenex</tradename>
						<drug type="generic" refid="idelem4x98370">Bumex</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9841">
				<sec_title>Action:</sec_title>
				<para>Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors, partial agonist at μ-opioid receptor</para>
			</section>
			<section type="uses" id="sidelem4x9846">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain, opiate agonist withdrawal/dependence</para>
				<section type="none" id="sidelem4x9851">
					<section type="none" id="sidelem4x9852">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cocaine withdrawal</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9857">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, ileus, status asthmaticus</para>
				<para>
					<bbw>Respiratory depression</bbw>
				</para>
				<section type="none" id="sidelem4x9872">
					<section type="none" id="sidelem4x9873">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, substance abuse/alcoholism, increased intracranial pressure, MI (acute), severe heart disease, respiratory depression, renal/hepatic/pulmonary disease, hypothyroidism, Addison’s disease</para>
						<para>
							<bbw>QT prolongation, accidental exposure, potential for overdose/poisoning, substance abuse</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9888">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9896">
					<label>•</label>
					<sec_title>Adult<route> IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x9896">
							<item>
								<label>•</label>
								<para> 0.3 mg q6-8hr prn, reduce dosage in geriatric patients, may repeat after 30-60 min;  (unlabeled) 4 mcg/kg or 2 mcg/kg (epidural inj);  each patch is worn for 7 days (moderate-severe pain);  (those taking &lt;30 mg of oral morphine or equivalent before beginning treatment with TD buprenorphine), 5 mcg/hr q7days, overestimating dose can be fatal;  titrate from other opioids for up to 7 days to no more than 30 mg oral morphine or equivalent before beginning TD therapy, begin with 5 mcg/hr q7days; for those with daily dose of 30-80 mg oral morphine or equivalent, start with 10 mcg/hr q7days; for those taking &gt;80 mg oral morphine or equivalent, start with 20 mcg/hr q7days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9915">
					<label>•</label>
					<sec_title>Child 2-12 yr<route> IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x9915">
							<item>
								<label>•</label>
								<para> 2-6 mcg/kg q4-8hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9919">
					<section type="none" id="sidelem4x9920">
						<sec_title>Available forms:</sec_title>
						<para> Inj 0.3 mg/ml (1-ml vials); SL tab 2, 8 mg as base; TD system 5, 7.5, 10, 15, 20 mcg/hr (weekly); dissolving film 75, 300, 450, 600, 750, 900 mcg</para>
					</section>
					<section type="none" id="sidelem4x9925">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9928">
							<sec_title>SL route</sec_title>
							<para>
								<list id="lidelem4x9932">
									<item>
										<label>•</label>
										<para>Do not chew, dissolve under tongue, use 2 or more at same time</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9938">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x9942">
									<item>
										<label>•</label>
										<para>Apply to clean, dry, intact skin; each patch should be worn for 7 days; do not apply direct heat source to patch, will increase absorption of product, may use first aid tape if edge of patch is not adhering</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply to upper outer arm, upper chest/back, or side of chest</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9955">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x9959">
									<item>
										<label>•</label>
										<para>In deep muscle mass</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9965">
							<sec_title>IV, direct route</sec_title>
							<section type="none" id="sidelem4x9973">
								<label>•</label>
								<sec_title>
									<route>Give</route>
								</sec_title>
								<para>
									<list id="lidelem4x9973">
										<item>
											<label>•</label>
											<para> undiluted over ≥2 min, titrate to patient response; rapid injection will increase side effects</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x9977">
									<item>
										<label>•</label>
										<para>With antiemetic if nausea, vomiting occur</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9982">
									<item>
										<label>•</label>
										<para>When pain is beginning to return; determine dosage interval by patient response</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, amphotericin B liposome (AmBisone), anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, butorphanol, calcium chloride/gluconate, CARBOplatin, cefamandole, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, D<emphasis style="inf">5</emphasis>W-dextrose 5%, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin HCl, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lactated Ringer’s injection, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s injection, riTUXimab, rocuronium, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA (3-in-1), tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9994">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9997">
					<section type="none" id="sidelem4x9998">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, sedation, euphoria,</emphasis><emphasis style="bold">increased intracranial pressure,</emphasis> amnesia, weakness, CNS depression</para>
					</section>
					<section type="none" id="sidelem4x10008">
						<sec_title>CV:</sec_title>
						<para> Palpitations, bradycardia, change in B/P, tachycardia, <emphasis style="bold">QT prolongation,</emphasis> hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x10016">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, <emphasis style="italic">miosis,</emphasis> diplopia</para>
					</section>
					<section type="none" id="sidelem4x10024">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, anorexia, constipation, cramps, dry mouth, abdominal pain, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10034">
						<sec_title>GU:</sec_title>
						<para> Dysuria, urinary retention</para>
					</section>
					<section type="none" id="sidelem4x10039">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x10047">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression,</emphasis> dyspnea, hypo/hyperventilation</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10056">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver by CYP3A4, excreted by kidneys and in feces, crosses placenta, excreted in breast milk, half-life 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, 96% bound to plasma proteins</para>
				<section type="none" id="sidelem4x10073">
					<section type="none" id="sidelem4x10074">
						<sec_title>IM:</sec_title>
						<para> Onset 15 min, peak 1 hr, duration 6-10 hr</para>
					</section>
					<section type="none" id="sidelem4x10079">
						<sec_title>SL:</sec_title>
						<para> Onset, peak, duration unknown, half-life 37 hr</para>
					</section>
					<section type="none" id="sidelem4x10084">
						<sec_title>IV:</sec_title>
						<para> Onset 1 min, peak 5 min, duration 6 hr, half-life 2.2 hr</para>
					</section>
					<section type="none" id="sidelem4x10089">
						<sec_title>TD:</sec_title>
						<para> Half-life 26 hr</para>
					</section>
					<section type="none" id="sidelem4x10094">
						<sec_title>Epidural:</sec_title>
						<para> Duration dose dependent</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10099">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect with other CNS depressants—alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants, MAOIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> buprenorphine effect—CYP3A4 inhibitors (erythromycin, indinavir, ketoconazole, ritonavir, saquinavir)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> QT prolongation—class IA, III antidysrhythmics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> buprenorphine effect—CYP3A4 inducers (carBAMazepine, PHENobarbital, phenytoin, rifampin)</para>
				<para>
					<emphasis alert="lifethreat">Drug/Herb</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—St. John’s wort</para>
			</section>
			<section type="considerations" id="sidelem4x10125">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10128">
					<section type="none" id="sidelem4x10129">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10137">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x10137">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> intensity, location, type before treatment, after 5 min (IV); need for pain medication, tolerance</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10141">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10146">
								<item>
									<label>•</label>
									<para>Bowel pattern; severe constipation can occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10154">
							<label>•</label>
							<sec_title>
								<route>withdrawal symptoms</route>
							</sec_title>
							<para>
								<list id="lidelem4x10154">
									<item>
										<label>•</label>
										<para>CNS changes, dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction; withdrawal in opioid-dependent persons; if dependence occurs, within 2 wk of discontinuing product  will occur</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10159">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10167">
							<para>
								<list id="lidelem4x10167">
									<item>
										<label>•</label>
										<para>Respiratory dysfunction: respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;12/min
<bbw>Potential for overdose may occur from chewing, swallowing, snorting, or injecting extracted product from TD formulation</bbw>

<bbw>
												<emphasis alert="lifethreat">QT prolongation:</emphasis> in those taking class Ia, III antidysrhythmics; patients with hypokalemia, cardiac instability (TD), max TD 20 mcg/hr q7day</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10189">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10193">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain, absence of grimacing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10199">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10203">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions
<bbw>That psychologic dependence leading to substance abuse may result when used for extended periods; that long-term use not recommended</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities such as driving unless reaction known</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not start new meds/herbs without prescriber approval</para>
								</item>
								<item>
									<label>•</label>
									<para>Start stool softener/laxatives to lessen constipation</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10233">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Naloxone 0.4 mg ampule diluted in 10 ml 0.9% NaCl given by direct IV push 0.02 mg q2min (adult)</para>
			</section>
		</monograph>
<monograph id="44" status="active">
			<mono_name>buPROPion (Rx)</mono_name>
			<info>
				<pronunciation>(byoo-proe′pee-on)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x102437">Aplenzin</tradename>
					<tradename id="tnidelem4x102436">Budeprion XL</tradename>
					<tradename id="tnidelem4x102435">Buproban</tradename>
					<tradename id="tnidelem4x102434">Forfivo XL</tradename>
					<tradename id="tnidelem4x102433">Wellbutrin</tradename>
					<tradename id="tnidelem4x102432">Wellbutrin SR</tradename>
					<tradename id="tnidelem4x102431">Wellbutrin XL</tradename>
					<tradename id="tnidelem4x102430">Zyban</tradename>
				</tradenames>
				<class type="func"> Antidepressant—miscellaneous smoking deterrent</class>
				<class type="chem"> Aminoketone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10253">
				<para>
					<confusion>
						<tradename id="tnidelem4x102530">buPROPion</tradename>
						<drug type="generic" refid="idelem4x102530">busPIRone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10260">
				<sec_title>Action:</sec_title>
				<para>Inhibits reuptake of DOPamine, norepinephrine, serotonin</para>
			</section>
			<section type="uses" id="sidelem4x10266">
				<sec_title>Uses:</sec_title>
				<para>Depression (Wellbutrin), smoking cessation (Zyban); seasonal affective disorder, substance abuse, glaucoma, smoking, cardiac disease, heart failure</para>
				<section type="none" id="sidelem4x10271">
					<section type="none" id="sidelem4x10272">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Neuropathic pain, enhancement of weight loss, ADHD (attention-deficit/hyperactivity disorder)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10277">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, head trauma, stroke, intracranial mass, eating disorders, seizure disorders</para>
				<section type="none" id="sidelem4x10282">
					<section type="none" id="sidelem4x10283">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, renal/hepatic disease, recent MI, cranial trauma, seizure disorder, substance abuse, glaucoma, smoking, cardiac disease, heart failure</para>
						<para>
							<bbw>Children &lt;18 yr, suicidal thinking/behavior (young adults)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10298">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10301">
					<section type="none" id="sidelem4x10302">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x10310">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10310">
									<item>
										<label>•</label>
										<para> 100 mg bid initially, then increase after 3 days to 100 mg tid if needed, max 150 mg single dose;  initially 150 mg <emphasis style="smallcaps">am</emphasis>, increase to 300 mg/day if initial dose is tolerated, after no less than 4 days; after several wk, titrate to 200 mg bid; Aplenzin 174 mg q <emphasis style="smallcaps">am</emphasis>, may increase to 348 mg q <emphasis style="smallcaps">am</emphasis> on day 4, may increase to 522 mg after several weeks if needed; Forfivo XL (not for initial treatment) 450 mg daily after titration with another product (300 mg/day × ≥2 wk)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10329">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10329">
									<item>
										<label>•</label>
										<para> 50-100 mg/day, may increase by 50-100 mg q3-4days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10333">
						<sec_title>Smoking cessation (Zyban)</sec_title>
						<section type="none" id="sidelem4x10341">
							<label>•</label>
							<sec_title>Adult<route> SR</route></sec_title>
							<para>
								<list id="lidelem4x10341">
									<item>
										<label>•</label>
										<para> 150 mg daily × 3 days, then 150 mg bid for remainder of treatment, initiate 1-2 wk before targeted “quit day,” continue for 7-12 wk; in combination with nicotine TD, 150 mg daily × 3 days, then 150 mg bid for remainder of treatment, give ≥8 hr apart, max 300 mg/day, initiate 1-2 wk before targeted “quit day,” continue for 7-12 wk, may be continued for 8-20 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10345">
						<sec_title>Seasonal affective disorder</sec_title>
						<section type="none" id="sidelem4x10353">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10353">
									<item>
										<label>•</label>
										<para>(Wellbutrin XL) 150 mg as a single dose in the <emphasis style="smallcaps">am</emphasis>, after 1 wk may be increased to 300 mg/day; (Aplenzin) 174 mg daily in <emphasis style="smallcaps">am</emphasis>, after 7 days may increase to 348 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10363">
						<sec_title>ADHD (unlabeled) (Wellbutrin)</sec_title>
						<section type="none" id="sidelem4x10371">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10371">
									<item>
										<label>•</label>
										<para> 100 mg bid, after ≥3 days titrate to 100 mg tid;  300 mg/day, 200 mg 8 <emphasis style="smallcaps">am</emphasis>, 100 mg 4 <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10383">
						<sec_title>Diabetic neuropathy/postherpetic neuralgia (unlabeled)(Wellbutrin SR)</sec_title>
						<section type="none" id="sidelem4x10391">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10391">
									<item>
										<label>•</label>
										<para> SR 150-300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10395">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 75, 100 mg; sus rel tabs (SR) 100, 150, 200 ext rel tab (XL) 100, 150, 300, 450 mg; (SR-12 hr, XL-24 hr); tab ext rel (Aplenzin) 174, 348, 522 mg</para>
					</section>
					<section type="none" id="sidelem4x10400">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10403">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x10409">
									<item>
										<para>
											<emphasis alert="nurse">When switching to Aplenzin from Wellbutrin, Wellbutrin SR or XL, use these equivalents: 174 mg buPROPion HBr = 150 mg buPROPion HCl; 348 mg buPROPion HBr = 300 mg buPROPion HCl; 522 mg buPROPion HBr = 450 mg buPROPion HCl</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x10417">
								<label>•</label>
								<sec_title>
									<route>Wellbutrin immediate rel,</route>
								</sec_title>
								<para>
									<list id="lidelem4x10417">
										<item>
											<label>•</label>
											<para> separate by ≥6 hr, give in 3 divided doses;  if multiple doses are used, separate by ≥8 hr;  give daily in <emphasis style="smallcaps">am</emphasis>;  give in 2 divided doses, ≥8 hr apart;  give daily in <emphasis style="smallcaps">am</emphasis>, a larger dose of Aplenzin is needed because these products are not equivalent</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x10439">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew sus rel, ext rel tab</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10444">
									<item>
										<label>•</label>
										<para>At evenly spaced times to prevent seizures; seizure risk increases with high doses</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10449">
									<item>
										<label>•</label>
										<para>Increase fluids, bulk in diet if constipation occurs</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10454">
									<item>
										<label>•</label>
										<para>With food, milk for GI symptoms</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10459">
									<item>
										<label>•</label>
										<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10464">
									<item>
										<label>•</label>
										<para>Avoid giving at night to prevent insomnia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10470">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10473">
					<section type="none" id="sidelem4x10474">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, agitation, dizziness, akinesia, bradykinesia, confusion,</emphasis><emphasis style="bold">seizures,</emphasis> delusions, <emphasis style="italic">insomnia, sedation, tremors,</emphasis><emphasis style="bold">suicidal ideation,</emphasis> mania, hot flashes, myoclonia, chest pain, flushing</para>
					</section>
					<section type="none" id="sidelem4x10489">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Dysrhythmias, hypertension,</emphasis> palpitations, <emphasis style="italic">tachycardia,</emphasis> hypotension, <emphasis style="bold">complete AV block; QRS prolongation (overdose)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10502">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision, auditory disturbance,</emphasis> tinnitus</para>
					</section>
					<section type="none" id="sidelem4x10510">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, diarrhea, <emphasis style="italic">dry mouth,</emphasis> increased appetite, <emphasis style="italic">constipation,</emphasis> altered taste</para>
					</section>
					<section type="none" id="sidelem4x10524">
						<sec_title>GU:</sec_title>
						<para> Impotence, urinary frequency, retention, <emphasis style="italic">menstrual irregularities,</emphasis> nocturia, altered libido</para>
					</section>
					<section type="none" id="sidelem4x10532">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus, <emphasis style="italic">sweating,</emphasis><emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10544">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Weight loss or gain</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10551">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 1-4 wk, half-life 14 hr (immediate release), extensively metabolized by liver, some conversion to active metabolites, steady state 5-8 days, protein binding 84%, excreted in urine and feces</para>
			</section>
			<section type="interactions" id="sidelem4x10556">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x10564">
					<label>•</label>
					<sec_title>
						<route>Do not use within 14 days of MAOIs</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x10568">
						<item>
							<para>
								<emphasis alert="nurse">Increase: adverse reactions, seizures—levodopa, MAOIs, phenothiazines, antidepressants, benzodiazepines, alcohol, theophylline, systemic steroids</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> buPROPion toxicity—ritonavir</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> buPROPion level—cimetidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> buPROPion effect—CYP2D6/CYP2B6 inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of tamoxifen</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> buPROPion effect—carBAMazepine, cimetidine, PHENobarbital, phenytoin or other products (CYP2D6); CYP2B6 inducers</para>
				<section type="none" id="sidelem4x10593">
					<section type="none" id="sidelem4x10594">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x10601">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Positive:</emphasis> urine drug screen for amphetamine possible</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10608">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10611">
					<section type="none" id="sidelem4x10612">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10616">
								<item>
									<label>•</label>
									<para>Hepatic/renal function in patients with hepatic, kidney impairment</para>
								</item>
								<item>
									<label>•</label>
									<para>For increased risk of seizures; if patient has excessively used CNS depressants and OTC stimulants, dosage of buPROPion should not be exceeded</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor weight regularly</para>
								</item>
								<item>
									<label>•</label>
									<para>For smoking cessation after 7-12 wk; if progress has not been made, product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Mental status: mood, sensorium, affect, suicidal tendencies, increase in psychiatric symptoms</bbw>
						</para>
						<para>
							<list id="lidelem4x10648">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy because sedation occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Safety measures, primarily for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10659">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10663">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression, ability to perform daily activities, ability to sleep throughout the night, smoking cessation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10669">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10674">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take 2-4 wk; not to increase dose without prescriber’s approval; that treatment for smoking cessation lasts 7-12 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10679">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities that require alertness; sedation, blurred vision may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10684">
								<item>
									<label>•</label>
									<para>Report hearing, visual, CNS changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10689">
								<item>
									<label>•</label>
									<para>May need to use stool softener/laxative</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10694">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants; alcohol may increase risk of seizures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10699">
								<item>
									<label>•</label>
									<para>Not to use with nicotine patches unless directed by prescriber; may increase B/P</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10704">
								<item>
									<label>•</label>
									<para>To notify prescriber immediately if urinary retention occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10712">
							<label>•</label>
							<sec_title>
								<route>That risk of seizures increased when dose exceeded, if patient has seizure disorder</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10724">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected, planned</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10729">
				<sec_title>Treatment of overdose:</sec_title>
				<para>ECG monitoring; lavage, activated charcoal; administer anticonvulsant</para>
			</section>
		</monograph>
<monograph id="45" status="active">
			<mono_name>busPIRone (Rx)</mono_name>
			<info>
				<pronunciation>(byoo-spye′rone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x107403">BuSpar</tradename>
					<tradename id="tnidelem4x107402">BuSpar Dividose</tradename>
					<tradename id="tnidelem4x107401">
						<country code="CAN">Buspirex</country>
					</tradename>
					<tradename id="tnidelem4x107400">
						<country code="CAN">Bustab</country>
					</tradename>
				</tradenames>
				<class type="func"> Antianxiety, sedative</class>
				<class type="chem"> Azaspirodecanedione</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10755">
				<para>
					<confusion>
						<tradename id="tnidelem4x107550">busPIRone</tradename>
						<drug type="generic" refid="idelem4x107550">buPROPion</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10759">
				<sec_title>Action:</sec_title>
				<para>Acts by inhibiting the action of serotonin (5-HT); has shown little potential for abuse; a good choice with substance abuse</para>
			</section>
			<section type="uses" id="sidelem4x10764">
				<sec_title>Uses:</sec_title>
				<para>Management and short-term relief of generalized anxiety disorders</para>
				<section type="none" id="sidelem4x10769">
					<section type="none" id="sidelem4x10770">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Autism</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10775">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;18 yr, hypersensitivity</para>
				<section type="none" id="sidelem4x10780">
					<section type="none" id="sidelem4x10781">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, impaired hepatic/renal function</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10786">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10794">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10794">
							<item>
								<label>•</label>
								<para> 7.5 mg bid; may increase by 5 mg/day q2-3 days, max 60 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10798">
					<section type="none" id="sidelem4x10799">
						<sec_title>Autism with anxiety (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10807">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10807">
									<item>
										<label>•</label>
										<para> 5-15 mg tid after titration, max 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10814">
							<label>•</label>
							<sec_title>Child ≥5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10814">
									<item>
										<label>•</label>
										<para> 0.2-0.6 mg/kg/day, max 60 mg/day; titrate to higher dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10818">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x10826">
							<label>•</label>
							<sec_title>Adult<route> PO reduce by 25%-50% for mild-moderate hepatic disease; do not use for severe hepatic disease; CCr 11-70 ml/min reduce by 25%-50%, CCr &lt;10 ml/min do not use</route></sec_title>
						</section>
						<para>
							<emphasis style="bold">Available forms:</emphasis> Tabs 5, 7.5, 10, 15, 30 mg</para>
					</section>
					<section type="none" id="sidelem4x10833">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10837">
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms; avoid grapefruit juice; give drug at same time of day, with/without food consistently</para>
								</item>
								<item>
									<label>•</label>
									<para>Crushed if patient unable to swallow medication whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10853">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10856">
					<section type="none" id="sidelem4x10857">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache, depression, stimulation, insomnia, nervousness, light-headedness, numbness, paresthesia, incoordination,</emphasis> nightmares, <emphasis style="italic">tremors,</emphasis> excitement, involuntary movements, confusion, akathisia, hostility</para>
					</section>
					<section type="none" id="sidelem4x10868">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Tachycardia, palpitations,</emphasis> hypo/hypertension, <emphasis style="bold">CVA, CHF, MI,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x10879">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Sore throat, tinnitus, blurred vision, nasal congestion;</emphasis> red, itching eyes; change in taste, smell</para>
					</section>
					<section type="none" id="sidelem4x10887">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, dry mouth, diarrhea, constipation,</emphasis> flatulence, increased appetite, rectal bleeding</para>
					</section>
					<section type="none" id="sidelem4x10895">
						<sec_title>GU:</sec_title>
						<para> Frequency, hesitancy, menstrual irregularity, change in libido</para>
					</section>
					<section type="none" id="sidelem4x10900">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> edema, pruritus, alopecia, dry skin</para>
					</section>
					<section type="none" id="sidelem4x10908">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Sweating,</emphasis> fatigue, weight gain, fever, <emphasis style="bold">serotonin syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10918">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Pain, weakness,</emphasis> muscle cramps, spasms, myalgia</para>
					</section>
					<section type="none" id="sidelem4x10926">
						<sec_title>RESP:</sec_title>
						<para> Hyperventilation, chest congestion, shortness of breath</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10931">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 40-90 min, terminal half-life 2-4 hr, rapidly absorbed, metabolized by liver (CYP3A4), excreted in feces, protein binding 86%</para>
			</section>
			<section type="interactions" id="sidelem4x10936">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> busPIRone—product metabolized by CYP3A4 (erythromycin, itraconazole, nefazodone, ketoconazole, ritonavir, verapamil, diltiazem, several other protease inhibitors)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P—procarbazine, MAOIs; do not use together</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—psychotropic products, alcohol (avoid use)</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin receptor agonists</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> busPIRone effects—rifampin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> busPIRone action—products induced by CYP3A4 (rifampin, phenytoin, PHENobarbital, carBAMazepine, dexamethasone)</para>
				<section type="none" id="sidelem4x10962">
					<section type="none" id="sidelem4x10963">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> peak concentration of busPIRone—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10971">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10974">
					<section type="none" id="sidelem4x10975">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10979">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse; if systolic B/P drops 20 mm Hg, hold product, notify prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>CNS reactions because some may be unpredictable</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, sleeping pattern, drowsiness, dizziness; withdrawal symptoms when dose reduced, product discontinued</para>
								</item>
								<item>
									<label>•</label>
									<para>Safety measures if drowsiness, dizziness occurs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11000">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11004">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, restlessness, sleeplessness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11010">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11015">
								<item>
									<label>•</label>
									<para>That product may be taken consistently with/without food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11020">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations, alcohol ingestion, other psychotropic medications unless approved by prescriber; to avoid large amounts of grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11025">
								<item>
									<label>•</label>
									<para>To avoid activities that require alertness because drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11030">
								<item>
									<label>•</label>
									<para>Not to discontinue medication abruptly after long-term use; if dose missed, do not double</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11035">
								<item>
									<label>•</label>
									<para>To rise slowly because fainting may occur, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11040">
								<item>
									<label>•</label>
									<para>That drowsiness may worsen at beginning of treatment; that 2 wk of therapy may be required before therapeutic effects occur, max effect 3-6 wk</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11048">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> to report immediately (fever, tremor, sweating, diarrhea, delirium)</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active" ha="yes">
			<mono_name> busulfan (Rx)</mono_name>
			<info>
				<pronunciation>(byoo-sul′fan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x110581">Busulfex</tradename>
					<tradename id="tnidelem4x110580">Myleran</tradename>
				</tradenames>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Bifunctional alkylating agent</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11068">
				<para>
					<confusion>
						<tradename id="tnidelem4x110680">Myleran</tradename>
						<drug type="generic" refid="idelem4x110680">Leukeran</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11072">
				<sec_title>Action:</sec_title>
				<para>Changes essential cellular ions to covalent bonding with resultant alkylation; this interferes with the normal biological function of DNA; activity is not phase-specific; action is due to myelosuppression</para>
			</section>
			<section type="uses" id="sidelem4x11077">
				<sec_title>Uses:</sec_title>
				<para>Chronic myelocytic leukemia, bone marrow ablation, stem cell transplant preparation with CML</para>
			</section>
			<section type="contra" id="sidelem4x11082">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 3rd trimester, breastfeeding, blastic phase of chronic myelocytic leukemia, hypersensitivity</para>
				<section type="none" id="sidelem4x11087">
					<section type="none" id="sidelem4x11088">
						<sec_title>Precautions:</sec_title>
						<para> Women of childbearing age, leukopenia, anemia, hepatotoxicity, renal toxicity, seizures, tumor lysis syndrome, hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, radiation, chemotherapy</para>
						<para>
							<bbw>Thrombocytopenia, neutropenia, secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11103">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11106">
					<section type="none" id="sidelem4x11107">
						<sec_title>Chronic myelocytic leukemia</sec_title>
						<section type="none" id="sidelem4x11115">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11115">
									<item>
										<label>•</label>
										<para> 4-8 mg/day or 1.8-4 mg/m<emphasis style="sup">2</emphasis>/day initially, reduce dose if WBC reaches 30,000-40,000/mm<emphasis style="sup">3</emphasis>, discontinue if WBC ≤20,000/mm<emphasis style="sup">3</emphasis>, maintenance 1-3 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11131">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11131">
									<item>
										<label>•</label>
										<para> 0.06-0.12 mg/kg/day or 1.8-4.6 mg/m<emphasis style="sup">2</emphasis>/day; reduce if WBC reaches 30,000-40,000/mm<emphasis style="sup">3</emphasis>, discontinue if WBC ≤20,000/mm<emphasis style="sup">3</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11143">
						<sec_title>Allogenic hemopoietic stem cell transplantation with chronic myelogenous leukemia</sec_title>
						<section type="none" id="sidelem4x11151">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11151">
									<item>
										<label>•</label>
										<para> 0.8 mg/kg over 2 hr, q6hr × 4 days (total 16 doses); give cyclophosphamide  60 mg/kg over 1 hr daily for 2 days starting after 16th dose of busulfan;  (unlabeled) 1 mg/kg q6hr × 16 doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11164">
							<label>•</label>
							<sec_title>Adolescent and child (unlabeled) &gt;12 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11164">
									<item>
										<label>•</label>
										<para> 0.8 mg/kg over 2 hr q6hr × 16 doses (4 days), then high-dose cyclophosphamide 50 mg/kg/day × 4 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11171">
							<label>•</label>
							<sec_title>Infant/child ≤12 kg (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11171">
									<item>
										<label>•</label>
										<para> 1.1 mg/kg over 2 hr q6hr × 16 doses (4 days), then high-dose cyclophosphamide 50 mg/kg/day × 4 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11177">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2 mg; inj 6 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x11182">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11186">
								<item>
									<label>•</label>
									<para>Store in tight container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11192">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x11196">
									<item>
										<label>•</label>
										<para>Give at same time daily on empty stomach</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11202">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x11210">
								<label>•</label>
								<sec_title>
									<route>dilute</route>
								</sec_title>
								<para>
									<list id="lidelem4x11210">
										<item>
											<label>•</label>
											<para>Prepare in biologic cabinet while wearing gloves, gown, mask;  with 10 times volume of product with D<emphasis style="inf">5</emphasis>W, 0.9% NaCl (0.5 mg/ml); when withdrawing product, use needle with 5-micron filter provided, remove amount needed, remove filter, and  product into diluent; always add product to diluent (not vice versa); stable for 8 hr at room temperature (using D<emphasis style="inf">5</emphasis>W) or 12 hr refrigerated;  by central venous catheter over 2 hr q6hr × 4 days, use infusion pump, do not admix</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x11227">
									<item>
										<label>•</label>
										<para>Give antiemetics before IV route on schedule</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11232">
									<item>
										<label>•</label>
										<para>In those with history of seizures, give phenytoin before IV drug to prevent seizures (using 0.9% NaCl)</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, atenolol, bivalirudin, bleomycin, caspofungin, codeine, DAPTOmycin, dexmedetomidine, diltiazem, DOCEtaxel, ertapenem, fenoldopam, gatifloxacin, granisetron, HYDROmorphone, levofloxacin, linezolid, LORazepam, meperidine, metroNIDAZOLE, milrinone, nesiritide, octreotide acetate, ondansetron, palonosetron, pancuronium, piperacillin-tazobactam, riTUXimab, sodium acetate, tacrolimus, tigecycline, tirofiban, trastuzumab, vasopressin</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11241">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11244">
					<section type="none" id="sidelem4x11245">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis><emphasis style="bold">thrombosis,</emphasis><emphasis style="italic">chest pain,</emphasis><emphasis style="bold">tachycardia, atrial fibrillation, heart block, pericardial effusion, cardiac tamponade</emphasis> (high dose with cyclophosphamide)</para>
					</section>
					<section type="none" id="sidelem4x11259">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Anorexia, constipation, diarrhea, dry mouth, nausea, vomiting</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11266">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Alveolar hemorrhage,</emphasis> atelectasis, cough, hemoptysis, hypoxia, pleural effusion, pneumonia, sinusitis, <emphasis style="bold">pulmonary fibrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11276">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">depression, dizziness, insomnia, headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11283">
						<sec_title>EENT:</sec_title>
						<para> blurred vision</para>
					</section>
					<section type="none" id="sidelem4x11288">
						<sec_title>GU:</sec_title>
						<para> Impotence, sterility, amenorrhea, gynecomastia, <emphasis style="bold">renal toxicity,</emphasis> hyperuremia, adrenal-insufficiency–like syndrome</para>
					</section>
					<section type="none" id="sidelem4x11296">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, pancytopenia, severe bone marrow depression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11303">
						<sec_title>INTEG:</sec_title>
						<para> Dermatitis, hyperpigmentation, alopecia</para>
					</section>
					<section type="none" id="sidelem4x11308">
						<sec_title>OTHER:</sec_title>
						<para> <emphasis style="bold">Chromosomal aberrations</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11315">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Irreversible pulmonary fibrosis,</emphasis> pneumonitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11323">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed orally, excreted in urine, crosses placenta, excreted in breast milk, half-life 2.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x11328">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> cardiac tamponade—cyclophosphamide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—other antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk for bleeding—anticoagulants, salicylates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antibody response—live virus vaccines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> busulfan level—phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> busulfan clearance—acetaminophen, itraconazole</para>
				<section type="none" id="sidelem4x11355">
					<section type="none" id="sidelem4x11356">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> breast, bladder, cervix, lung cytology tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11363">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11366">
					<section type="none" id="sidelem4x11367">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>CBC, differential, platelet count weekly; withhold product if WBC is &lt;15,000/mm3 or platelet count is &lt;150,000/mm3; notify prescriber of results; institute thrombocytopenia precautions; levels for withholding product will be different for children</bbw>
						</para>
						<para>
							<bbw>Bone marrow status before chemotherapy; seizure history; bone marrow suppression may be prolonged (up to 2 mo)</bbw>
						</para>
						<section type="none" id="sidelem4x11401">
							<label>•</label>
							<sec_title>Pulmonary fibrosis<route> pulmonary function tests, chest x-ray films before, during therapy; chest film should be obtained q2wk during treatment; pulmonary fibrosis may occur up to 10 yr after treatment with busulfan</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11404">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr before, during therapy; monitor ALT, alk phos, bilirubin, uric acid before and during treatment; I&amp;O ratio; report fall in urine output of &lt;30 ml/hr; hyperuricemia</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>For secondary malignancy within 5-8 yr of chronic oral therapy, long-term follow-up may be required</bbw>
						</para>
						<para>
							<list id="lidelem4x11419">
								<item>
									<label>•</label>
									<para>Monitor for cold, fever, sore throat (may indicate beginning infection)</para>
								</item>
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, petechiae; mucosa, orifices q8hr; no rectal temperatures</para>
								</item>
								<item>
									<label>•</label>
									<para>Dyspnea, crackles, nonproductive cough, chest pain, tachypnea</para>
								</item>
								<item>
									<label>•</label>
									<para>Inflammation of mucosa, breaks in skin; use viscous xylocaine for oral pain</para>
								</item>
								<item>
									<label>•</label>
									<para>Comprehensive oral hygiene</para>
								</item>
								<item>
									<label>•</label>
									<para>Strict medical asepsis, protective isolation if WBC levels low</para>
								</item>
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent urate deposits, calculi formation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11455">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11459">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased exacerbations of chronic myelocytic leukemia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11465">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11470">
								<item>
									<label>•</label>
									<para>To avoid use of products that contain aspirin, ibuprofen; razors; commercial mouthwash</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11478">
							<label>•</label>
							<sec_title>
								<route>To use effective contraception during and for at least 3 mo after treatment; to avoid breastfeeding; may cause infertility, discuss family planning before initiating therapy, pregnancy (D)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x11484">
							<label>•</label>
							<sec_title>
								<route>anemia</route>
							</sec_title>
							<para>
								<list id="lidelem4x11484">
									<item>
										<label>•</label>
										<para>To report signs of  (fatigue, headache, irritability, faintness, shortness of breath); symptoms of  jaundice; persistent cough, congestion, skin pigmentation, darkening of skin; sudden weakness, weight loss (may resemble adrenal insufficiency)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11492">
								<item>
									<label>•</label>
									<para>To report symptoms of bleeding (hematuria, tarry stools)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11497">
								<item>
									<label>•</label>
									<para>To avoid vaccinations, crowds, persons with known infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11502">
								<item>
									<label>•</label>
									<para>That impotence, amenorrhea can occur; that these are reversible after discontinuing treatment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="47" status="active">
			<mono_name>butoconazole vaginal antifungal</mono_name>
			<section type="none" id="sidelem4x11510">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="48" status="active" ha="yes">
			<mono_name> butorphanol (Rx)</mono_name>
			<info>
				<pronunciation>(byoo-tor′fa-nole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x115210">
						<country code="CAN">Stadol</country>
					</tradename>
				</tradenames>
				<class type="func"> Opioid analgesic</class>
				<class type="chem"> Mixed opioid antagonist, partial agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="actions" id="sidelem4x11536">
				<sec_title>Action:</sec_title>
				<para>Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors</para>
			</section>
			<section type="uses" id="sidelem4x11541">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain, general anesthesia induction/maintenance, headache, migraine, preanesthesia</para>
				<section type="none" id="sidelem4x11546">
					<section type="none" id="sidelem4x11547">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Pruritus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11552">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to product, preservative; addiction (opioid)</para>
				<section type="none" id="sidelem4x11557">
					<section type="none" id="sidelem4x11558">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, addictive personality, increased intracranial pressure, respiratory depression, renal/hepatic disease, ileus, COPD</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11564">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11567">
					<section type="none" id="sidelem4x11568">
						<sec_title>Moderate-severe pain</sec_title>
						<section type="none" id="sidelem4x11576">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x11576">
									<item>
										<label>•</label>
										<para> 1-4 mg q3-4hr prn;  0.5-2 mg q3-4hr prn;  1 spray in 1 nostril, may give another dose 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr later; repeat if needed 3-4hr after last dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11595">
							<label>•</label>
							<sec_title>Geriatric<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11595">
									<item>
										<label>•</label>
										<para>
											<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> adult dose at 2× the interval;  if no relief after 90-120 min, may repeat with 1 spray</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11607">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x11615">
							<label>•</label>
							<sec_title>Adult<route> INTRANASAL max 1 mg followed by 1 mg after 90-120 min; IM/IV give 50% of dose (0.5 mg IV, 1 mg IM), do not repeat within 6 hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11618">
						<sec_title>Opioid-induced pruritus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11626">
							<label>•</label>
							<sec_title>Adult<route> INTRANASAL</route></sec_title>
							<para>
								<list id="lidelem4x11626">
									<item>
										<label>•</label>
										<para> 1 mg (1 spray) in each nostril q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11630">
						<sec_title>Intractable pruritus with inflammatory skin or systemic disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11638">
							<label>•</label>
							<sec_title>Adult<route> INTRANASAL</route></sec_title>
							<para>
								<list id="lidelem4x11638">
									<item>
										<label>•</label>
										<para> 1-4 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11642">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1, 2 mg/ml; nasal spray 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x11647">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11651">
								<item>
									<label>•</label>
									<para>With antiemetic if nausea, vomiting occur</para>
								</item>
								<item>
									<label>•</label>
									<para>When pain beginning to return; determine dosage interval according to patient response</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11667">
							<sec_title>Nasal route</sec_title>
							<para>
								<list id="lidelem4x11671">
									<item>
										<label>•</label>
										<para>Prime before first use, point sprayer away from the face, pump activator 7 × until a fine, wide spray occurs, if not used for 48 hr, reprime by pumping 1-2 ×</para>
									</item>
									<item>
										<label>•</label>
										<para>If more than 1 spray is needed, use other nostril</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not share with others</para>
									</item>
									<item>
										<label>•</label>
										<para>Nasal congestion/irritation may occur</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11692">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x11696">
									<item>
										<label>•</label>
										<para>Deeply in large muscle mass</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11702">
							<sec_title>IV direct route</sec_title>
							<para>
								<list id="lidelem4x11706">
									<item>
										<label>•</label>
										<para>Undiluted at a rate of &lt;2 mg/&gt;3-5 min, titrate to patient response; inject directly in vein or tubing of free-flowing compatible IV infusion</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B liposome (AmBisome), anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone phosphate, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, lactated Ringer’s injection, levofloxacin, lidocaine, linezolid injection, LORazepam, magnesium, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, milrinone, minocycline, mitoXANtrone, morphine, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentazocine, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s injection, riTUXimab, rocuronium, sargramostim, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11718">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11721">
					<section type="none" id="sidelem4x11722">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, sedation, euphoria, weakness, hallucinations,</emphasis> insomnia (nasal)</para>
					</section>
					<section type="none" id="sidelem4x11730">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="bold">bradycardia,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x11738">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, miosis, diplopia, nasal congestion, unpleasant taste</para>
					</section>
					<section type="none" id="sidelem4x11743">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, constipation, cramps</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11750">
						<sec_title>GU:</sec_title>
						<para> Urinary retention</para>
					</section>
					<section type="none" id="sidelem4x11755">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x11760">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11767">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted by kidneys, crosses placenta, excreted in breast milk, half-life 2-9 hr, protein binding 80%</para>
				<section type="none" id="sidelem4x11772">
					<section type="none" id="sidelem4x11773">
						<sec_title>IM:</sec_title>
						<para> Onset 5-15 min, peak 30-60 min, duration 3-4 hr</para>
					</section>
					<section type="none" id="sidelem4x11778">
						<sec_title>INTRANASAL:</sec_title>
						<para> Onset within 15 min, peak 1-2 hr, duration 4-5 hr</para>
					</section>
					<section type="none" id="sidelem4x11783">
						<sec_title>IV:</sec_title>
						<para> Onset 1 min, peak 4-5 min, duration 2-4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11788">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS effects—alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants, other CNS depressants, MAOIs</para>
			</section>
			<section type="considerations" id="sidelem4x11795">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11798">
					<section type="none" id="sidelem4x11799">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11804">
								<item>
									<label>•</label>
									<para>For decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11810">
								<item>
									<para>
										<emphasis alert="nurse">For withdrawal symptoms in opioid-dependent patients; PE, vascular occlusion, abscesses, ulcerations</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11815">
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11820">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11825">
								<item>
									<label>•</label>
									<para>Respiratory dysfunction: respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;10/min</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11830">
								<item>
									<label>•</label>
									<para>Need for pain medication, physical dependence</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11835">
								<item>
									<label>•</label>
									<para>Safety measures: night-light, call bell within easy reach, assistance with ambulation, especially for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11840">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11844">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11850">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11854">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>That physical dependency may result when used for extended periods</para>
								</item>
								<item>
									<label>•</label>
									<para>That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia</para>
								</item>
								<item>
									<label>•</label>
									<para>How to use nasal product</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x11880">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Naloxone 0.4-2 mg IV, O<emphasis style="inf">2</emphasis>, IV fluids, vasopressors</para>
			</section>
		</monograph>
</alpha>
</drug_guide>